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Abstract: DNA is a unique biomolecule that carries genetic information. While DNA is widely consid-
ered to be double helical, important processes such as replication and transcription require single-stranded
DNA intermediates. Single-stranded DNA can form a variety of secondary structures, and one important
example formed by G-rich sequences is the G- quadruplex. Though these structures are kinetically and
thermodynamically stable in vitro, their existence and associated functions in vivo require additional eval-
uation. In particular, G- quadruplexes have been proposed to be attractive anti-cancer targets due to the
abundance of guanine-rich sequences in the promoter regions of many oncogenes such as c-Myc. Hurley
and co-workers have proposed that small molecules capable of stabilizing G-quadruplexes in promoters
are capable of decreasing oncogene expression. This hypothesis, however, has only been evaluated using
small molecules that exhibit little or no G-quadruplex selectivity as compared to duplex DNA. Hence,
the potential role of G-quadruplex ligands in transcriptional regulation requires further study. In this
thesis, I report the utilization of cationic phthalocyanines for probing G-quadruplex structures and func-
tion in vivo. Ammonium and guanidium-modified phthalocyanines bind to G-quadruplex DNA in vitro
with exceptionally high affinity (Kd < 2 nM) and high selectivity (>1’000-fold) as compared to duplex
DNA. Upon G-quadruplex binding, guanidinium- modified phthalocyanines exhibit a dramatic increase
in fluorescence intensity. This property can be utilized in cell-based imaging studies, where fluorescent
staining is localized in perinuclear regions and lysozomes of living cells. In dead and fixed cells, however,
staining was observed in the nucleolus due to the association of these compounds with RNA. Since direct
observation of promoter (or telomeric) G-quadruplexes fluorescence staining was not feasible, the abil-
ities of cationic phthalocyanines to interact with putative G-quadruplexes in promoters was evaluated
by measuring their global impact on gene expression using microarray analyses. Ammonium-containing
phthalocyanines caused statistically significant changes of 2-fold or more (p < 0.001) in the mRNA tran-
scription of approximately 2’000 genes in B16F10 cells. Approximately 39% of these genes contain a
putative G-quadruplex- forming sequence within 1’000 nucleotides of the transcription start site. This
frequency does not deviate from the genome-wide % of promoters containing a puatative G-quadruplex
forming sequence. Taken together, these results do not support the presence of functional G- quadruplex
structures in promoter regions capable of regulating gene expression. According to microarray analyses,
guanidinium-modified phthalocyanines exhibited a very limited ability to impact global gene expression in
B16-F10 cells. One derivative, tetrakis- (diisopropyl-guanidino) zinc phthalocyanine “Zn-DIGP” consis-
tently affected the transcription of only a single gene, CXCL10. qRT-PCR experiments demonstrated that
Zn- DIGP-mediated overexpression of CXCL10 was both dose- and time- dependent, and ELISA experi-
ments revealed that Zn-DIGP caused a 20-fold increase in extracellular CXCL10 protein concentrations at
sub-toxic doses. Zn-DIGP is a competitive inhibitor of CXCL10- mediated CXCR-3 activation (IC50 = 4
M), and it inhibits downstream events such as CXCL10-dependent cell migration. Interestingly, Zn-DIGP
binds to the G protein-coupled receptor (GPCR) CXCR3 without activating the receptor, yet is able to
cause endocytosis and degradation of CXCR3. While there are few peptide antagonists known to cause
internalization of GPCRs, Zn-DIGP represents, to the best of our knowledge, the first small- molecule
GPCR antagonist shown to cause receptor internalization and degradation. This process is possibly
responsible for Zn-DIGP-mediated CXCL10 overexpression via dysregulation of an endogenous negative
feedback loop. CXCR3 antagonists are rapidly emerging as a new class of anti-cancer agents that can
inhibit metastasis. The potential anti-metastatic activities of Zn-DIGP were therefore evaluated by an as-
say that mimics the hematogenous spread of malignant melanoma in vivo. Zn-DIGP was found to be well
tolerated upon its intravenous injection into mice at 8 mg/kg and was capable of inhibiting the formation
of tumor colonies in the lungs of C57BL/6 mice injected with B16F10 cells. Our results therefore provide
additional evidence that CXCR3 antagonists are a new class of anti-metastatic agents. Unlike previously
reported CXCR3 antagonists, however, Zn-DIGP is also a promising sensitizer for photodynamic therapy
(PDT). Upon photoexcitation with red laser light (660 nm), Zn-DIGP exhibits a high quantum yield for
singlet oxygen formation ( 0.46) that results in potent phototoxicity (EC50 0.16 M) in cell cultures. Zn-
DIGP can therefore be developed as a multi-functional PDT agent, where light energy can be harnessed
for the treatment of primary surface tumors, while simultaneously inhibiting the formation of new tumor
colonies in vital organs by interfering with chemokine signaling. DNA ist ein einzigartiges Biomolekül,
welches genetische Informationen speichert. Obwohl DNA üblicherweise als doppelsträngig angenommen
wird, treten wichtige Prozesse wie Replikation und Transkription nur auf, wenn die DNA einzelsträngig
vorliegt. Basierend auf ihrer Sequenz kann einzelsträngige DNA eine Vielzahl von Sekundärstrukturen
annehmen, und eine wichige Sekundärstruktur wird G-Quadruplex genannt. Obgleich diese Strukturen
in vitro kinetisch und thermodynamisch stabil sind, ihre Existenz sowie dazugehörige Funktionen in
vivo benötigen weitere Nachweise. Insbesondere wurden G-Quadruplexe als attraktive Angriffspunkte
für Krebstherapien vorgeschlagen aufgrund der Fülle von Guanin- reichen Sequenzen in den Promotor-
regionen vieler Onkogene wie beispielsweise c-Myc. Hurley et al. berichteten, dass kleine Moleküle,
welche G-Quadruplex-Strukturen in Promotorregionen stabilisieren, die Expression von Onkogenen inhi-
bieren könnten. Diese Hypothese wurde jedoch nur mit kleinen Molekülen evaluiert, welche wenig oder
keine Selektivität für G-Quadruplexe gegenüber Duplex-DNA zeigten. Deshalb erfordert die potentielle
Rolle von G-Quadruplex-Liganden in der Transkriptionsregulation weitere Untersuchungen. In dieser
Arbeit berichte ich über die Nutzung kationischer Phthalocyanine für den Nachweis von G-Quadruplex-
Strukturen und Funktionen in vivo. Ammonium- und guanidinium- modifizierte Phthalocyanine binden
an G-Quadruplex-DNA in vitro mit ausserordentlich hoher Affinität (Kd < 2 nM) und Selektivität (>
1000fach) verglichen mit Duplex-DNA. Beim Binden an G-Quadruplex-Strukturen zeigen guanidinium-
modofozierte Phthalocynine einen dramatischen Anstieg der Fluoreszenzintensität. Diese Eigenschaft
wurde in Zell-basierten Experimenten genutzt, in denen Fluoreszenz in perinukleären Regionen und Lyso-
somen lebender Zellen lokalisiert war. In toten und fixierten Zellen jedoch wurde die fluoreszente Färbung
in Nukleoli beobachtet aufgrund der Assoziation dieser Verbindungen an RNA. Da eine direkte Beobach-
tung der Fluoreszenzfärbung von Promoter- oder Telomer-assoziierten G-Quadruplexen nicht möglich
war, die Fähigkeit der Verbindungen, mit mutmasslichen G- Quadruplex-Sequenzen in Promotoren zu
interagieren, wurde indirekt untersucht durch Messung ihres globalen Effekts auf Genexpression mithilfe
von Mikroarray-Analysen. Ammonium-modifizierte Phthalocyanine bewirkten statistisch signifikante
Veränderungen von zweifach oder mehr (p < 0.001) der mRNA-Transkription von über 2000 Genen in
B16F10-Zellen. Etwa 39 % dieser Gene enthielten mutmassliche G-Quadruplex-formende Sequenzen in-
nerhalb von 1000 Nukleotiden ausgehend von der Transkriptions-Startstelle. Dieser Wert weicht nicht
ab vom Genom-weiten Vorkommen von Promotoren mit G-reichen Sequenzen. Zusammenfassend geben
diese Ergebnisse keinen Hinweis auf das Vorkommen von funktionellen G-Quadruplex-Strukturen in den
Promoterregionen, welche die Genexpression regulieren können. Gemäss der Mikroarray-Analysen zeigten
guanidinium-modifizierte Phthalocyanine eine sehr beschränkte Fähigkeit, die globale Genexpression in
B16F10-Zellen zu beeinflussen. Ein Derivat, tetrakis-(diisopropyl-guanidino) zinc phthalocyanine „Zn-
DIGP” beeinflusste die Transkription nur eines einzigen Gens konstant, CXCL10. qRT-PCR-Experimente
zeigten, dass Zn-DIGP-vermittelte Überexpression von CXCL10 sowohl Dosis- als auch Zeit- abhängig
war, und ELISA-Experimente offenbarten, dass nicht-toxische Mengen von Zn- DIGP einen 20fachen
Anstieg der extrazellulären CXCL10-Proteinkonzentration in B16F10- Zellen bewirkten. Zn-DIGP ist
ein kompetitiver Inhibitor der CXCL10-vermittelten CXCR3- Aktivierung (IC50 = 4 mM), und es in-
hibiert nachfolgende Prozesse wie beispielsweise CXCL10-abhängige Zellmigration. Interessanterweise
bindet Zn-DIGP an den G-Protein- gekoppelten Rezeptor (GPCR) CXCR3, ohne diesen zu aktivieren,
doch es ist in der Lage, Endozytose und Abbau von CXCR3 zu bewirken. Während nur wenige Peptid-
Antagonisten bekannt sind, welche Internalisierung von GPCRs verursachen, repräsentiert Zn-DIGP nach
unserem besten Wissen den ersten GPCR-Antagonisten auf Grundlage eines kleinen Moleküls, welcher
Rezeptorinternalisierung und Abbau bewirkt. Dieser Vorgang ist möglicherweise verantwortlich für die
Überexpression von CXCL10 durch eine endogene negative Feedback-Schleife. CXCR3-Antagonisten
treten immer mehr als eine neue Klasse von Antikrebsmitteln hervor, welche Metastasenbildung verhin-
dern können. Die potentielle Metastasen-inhibierende Aktivität von Zn-DIGP wurde deshalb durch einen
Test evaluiert, bei welchem die hämatogene Ausbreitung von bösartigen Melanomen in vivo nachgeahmt
wird. Es zeigte sich, dass Zn-DIGP bei intravenöser Injektion in Mäusen (8 mg/kg) gut toleriert wurde,
und es war in der Lage, die Bildung von Tumoren in der Lunge von C57BL/6-Mäusen, welchen B16F10-
Zellen injiziert worden waren, zu verhindern. Unsere Ergebnisse bieten deshalb einen zusätzlichen Hin-
2
weis, dass CXCR3-Antagonisten eine neue Klasse von Antikrebsmitteln darstellen. Anders als frühere
CXCR3-Antagonisten ist Zn-DIGP jedoch auch ein vielversprechender Sensibilisator für photodynamis-
che Therapien (PDT). Der Anregung mit rotem Laserlicht (660 nm) folgend weist Zn-DIGP eine hohe
Quantenausbeute für die Generierung von Singlett-Sauerstoff auf (0.46), welcher eine potente Phototox-
izität (EC50 0.16 M) in Zellkultur zur Folge hat. Zn-DIGP kann deshalb zu einem multifunktionellen
PDT-Agens weiterentwickelt werden, welches mithilfe von Lichtenergie für die Behandlung von primären
Oberflächentumoren benutzt werden kann, während es gleichzeitig die Bildung von neuen Tumorkolonien
in lebenswichtigen Organen verhindert, indem es Chemokin-vermittelte Signalwege beeinflusst.
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Summary 
DNA is a unique biomolecule that carries genetic information. While DNA is widely 
considered to be double helical, important processes such as replication and transcription 
require single-stranded DNA intermediates. Single-stranded DNA can form a variety of 
secondary structures, and one important example formed by G-rich sequences is the G-
quadruplex. Though these structures are kinetically and thermodynamically stable in vitro, 
their existence and associated functions in vivo require additional evaluation. In particular, G-
quadruplexes have been proposed to be attractive anti-cancer targets due to the abundance of 
guanine-rich sequences in the promoter regions of many oncogenes such as c-Myc. Hurley 
and co-workers have proposed that small molecules capable of stabilizing G-quadruplexes in 
promoters are capable of decreasing oncogene expression. This hypothesis, however, has 
only been evaluated using small molecules that exhibit little or no G-quadruplex selectivity as 
compared to duplex DNA. Hence, the potential role of G-quadruplex ligands in 
transcriptional regulation requires further study.  
 
In this thesis, I report the utilization of cationic phthalocyanines for probing G-quadruplex 
structures and function in vivo. Ammonium and guanidium-modified phthalocyanines bind to 
G-quadruplex DNA in vitro with exceptionally high affinity (Kd < 2 nM) and high selectivity 
(>1’000-fold) as compared to duplex DNA. Upon G-quadruplex binding, guanidinium-
modified phthalocyanines exhibit a dramatic increase in fluorescence intensity. This property 
can be utilized in cell-based imaging studies, where fluorescent staining is localized in 
perinuclear regions and lysozomes of living cells. In dead and fixed cells, however, staining 
was observed in the nucleolus due to the association of these compounds with RNA. Since 
direct observation of promoter (or telomeric) G-quadruplexes fluorescence staining was not 
feasible, the abilities of cationic phthalocyanines to interact with putative G-quadruplexes in 
promoters was evaluated by measuring their global impact on gene expression using 
microarray analyses. Ammonium-containing phthalocyanines caused statistically significant 
changes of 2-fold or more (p < 0.001) in the mRNA transcription of approximately 2’000 
genes in B16F10 cells. Approximately 39% of these genes contain a putative G-quadruplex-
forming sequence within 1’000 nucleotides of the transcription start site. This frequency does 
not deviate from the genome-wide % of promoters containing a puatative G-quadruplex 
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forming sequence. Taken together, these results do not support the presence of functional G-
quadruplex structures in promoter regions capable of regulating gene expression.  
 
According to microarray analyses, guanidinium-modified phthalocyanines exhibited a very 
limited ability to impact global gene expression in B16-F10 cells. One derivative, tetrakis-
(diisopropyl-guanidino) zinc phthalocyanine “Zn-DIGP” consistently affected the 
transcription of only a single gene, CXCL10. qRT-PCR experiments demonstrated that Zn-
DIGP-mediated overexpression of CXCL10 was both dose- and time- dependent, and ELISA 
experiments revealed that Zn-DIGP caused a 20-fold increase in extracellular CXCL10 
protein concentrations at sub-toxic doses. Zn-DIGP is a competitive inhibitor of CXCL10-
mediated CXCR-3 activation (IC50 = 4 M), and it inhibits downstream events such as 
CXCL10-dependent cell migration. Interestingly, Zn-DIGP binds to the G protein-coupled 
receptor (GPCR) CXCR3 without activating the receptor, yet is able to cause endocytosis and 
degradation of CXCR3.  While there are few peptide antagonists known to cause 
internalization of GPCRs, Zn-DIGP represents, to the best of our knowledge, the first small-
molecule GPCR antagonist shown to cause receptor internalization and degradation. This 
process is possibly responsible for Zn-DIGP-mediated CXCL10 overexpression via 
dysregulation of an endogenous negative feedback loop.  
 
CXCR3 antagonists are rapidly emerging as a new class of anti-cancer agents that can inhibit 
metastasis. The potential anti-metastatic activities of Zn-DIGP were therefore evaluated by an 
assay that mimics the hematogenous spread of malignant melanoma in vivo. Zn-DIGP was 
found to be well tolerated upon its intravenous injection into mice at 8 mg/kg and was 
capable of inhibiting the formation of tumor colonies in the lungs of C57BL/6 mice injected 
with B16F10 cells. Our results therefore provide additional evidence that CXCR3 antagonists 
are a new class of anti-metastatic agents. Unlike previously reported CXCR3 antagonists, 
however, Zn-DIGP is also a promising sensitizer for photodynamic therapy (PDT). Upon 
photoexcitation with red laser light (660 nm), Zn-DIGP exhibits a high quantum yield for 
singlet oxygen formation (  0.46) that results in potent phototoxicity (EC50  0.16 M) in 
cell cultures. Zn-DIGP can therefore be developed as a multi-functional PDT agent, where 
light energy can be harnessed for the treatment of primary surface tumors, while 
simultaneously inhibiting the formation of new tumor colonies in vital organs by interfering 
with chemokine signaling. 
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Zusammenfassung 
 
DNA ist ein einzigartiges Biomolekül, welches genetische Informationen speichert. Obwohl 
DNA üblicherweise als doppelsträngig angenommen wird, treten wichtige Prozesse wie 
Replikation und Transkription nur auf, wenn die DNA einzelsträngig vorliegt. Basierend auf 
ihrer Sequenz kann einzelsträngige DNA eine Vielzahl von Sekundärstrukturen annehmen, 
und eine wichige Sekundärstruktur wird G-Quadruplex genannt. Obgleich diese Strukturen in 
vitro kinetisch und thermodynamisch stabil sind, ihre Existenz sowie dazugehörige 
Funktionen in vivo benötigen weitere Nachweise. Insbesondere wurden G-Quadruplexe als 
attraktive Angriffspunkte für Krebstherapien vorgeschlagen aufgrund der Fülle von Guanin-
reichen Sequenzen in den Promotorregionen vieler Onkogene wie beispielsweise c-Myc. 
Hurley et al. berichteten, dass kleine Moleküle, welche G-Quadruplex-Strukturen in 
Promotorregionen stabilisieren, die Expression von Onkogenen inhibieren könnten. Diese 
Hypothese wurde jedoch nur mit kleinen Molekülen evaluiert, welche wenig oder keine 
Selektivität für G-Quadruplexe gegenüber Duplex-DNA zeigten. Deshalb erfordert die 
potentielle Rolle von G-Quadruplex-Liganden in der Transkriptionsregulation weitere 
Untersuchungen. 
 
In dieser Arbeit berichte ich über die Nutzung kationischer Phthalocyanine für den Nachweis 
von G-Quadruplex-Strukturen und Funktionen in vivo. Ammonium- und guanidinium-
modifizierte Phthalocyanine binden an G-Quadruplex-DNA  in vitro mit ausserordentlich 
hoher Affinität (Kd < 2 nM) und Selektivität (> 1000fach) verglichen mit Duplex-DNA. Beim 
Binden an G-Quadruplex-Strukturen zeigen guanidinium-modofozierte Phthalocynine einen 
dramatischen Anstieg der Fluoreszenzintensität. Diese Eigenschaft wurde in Zell-basierten 
Experimenten genutzt, in denen Fluoreszenz in perinukleären Regionen und Lysosomen 
lebender Zellen lokalisiert war. In toten und fixierten Zellen jedoch wurde die fluoreszente 
Färbung in Nukleoli beobachtet aufgrund der Assoziation dieser Verbindungen an RNA. Da 
eine direkte Beobachtung der Fluoreszenzfärbung von Promoter- oder Telomer-assoziierten 
G-Quadruplexen nicht möglich war, die Fähigkeit der Verbindungen, mit mutmasslichen G-
Quadruplex-Sequenzen in Promotoren zu interagieren, wurde indirekt untersucht durch 
Messung ihres globalen Effekts auf Genexpression mithilfe von Mikroarray-Analysen. 
Ammonium-modifizierte Phthalocyanine bewirkten statistisch signifikante Veränderungen 
von zweifach oder mehr (p < 0.001) der mRNA-Transkription von über 2000 Genen in 
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B16F10-Zellen. Etwa 39 % dieser Gene enthielten mutmassliche G-Quadruplex-formende 
Sequenzen innerhalb von 1000 Nukleotiden ausgehend von der Transkriptions-Startstelle. 
Dieser Wert weicht nicht ab vom Genom-weiten Vorkommen von Promotoren mit G-reichen 
Sequenzen. Zusammenfassend geben diese Ergebnisse keinen Hinweis auf das Vorkommen 
von funktionellen G-Quadruplex-Strukturen in den Promoterregionen, welche die 
Genexpression regulieren können. 
 
Gemäss der Mikroarray-Analysen zeigten guanidinium-modifizierte Phthalocyanine eine sehr 
beschränkte Fähigkeit, die globale Genexpression in B16F10-Zellen zu beeinflussen. Ein 
Derivat, tetrakis-(diisopropyl-guanidino) zinc phthalocyanine „Zn-DIGP” beeinflusste die 
Transkription nur eines einzigen Gens konstant, CXCL10. qRT-PCR-Experimente zeigten, 
dass Zn-DIGP-vermittelte Überexpression von CXCL10 sowohl Dosis- als auch Zeit-
abhängig war, und ELISA-Experimente offenbarten, dass nicht-toxische Mengen von Zn-
DIGP einen 20fachen Anstieg der extrazellulären CXCL10-Proteinkonzentration in B16F10-
Zellen bewirkten. Zn-DIGP ist ein kompetitiver Inhibitor der CXCL10-vermittelten CXCR3-
Aktivierung (IC50 = 4 mM), und es inhibiert nachfolgende Prozesse wie beispielsweise 
CXCL10-abhängige Zellmigration. Interessanterweise bindet Zn-DIGP an den G-Protein-
gekoppelten Rezeptor (GPCR) CXCR3, ohne diesen zu aktivieren, doch es ist in der Lage, 
Endozytose und Abbau von CXCR3 zu bewirken. Während nur wenige Peptid-Antagonisten 
bekannt sind, welche Internalisierung von GPCRs verursachen, repräsentiert Zn-DIGP nach 
unserem besten Wissen den ersten GPCR-Antagonisten auf Grundlage eines kleinen 
Moleküls, welcher Rezeptorinternalisierung und Abbau bewirkt. Dieser Vorgang ist 
möglicherweise verantwortlich für die Überexpression von CXCL10 durch eine endogene 
negative Feedback-Schleife. 
 
CXCR3-Antagonisten treten immer mehr als eine neue Klasse von Antikrebsmitteln hervor, 
welche Metastasenbildung verhindern können. Die potentielle Metastasen-inhibierende 
Aktivität von Zn-DIGP wurde deshalb durch einen Test evaluiert, bei welchem die 
hämatogene Ausbreitung von bösartigen Melanomen in vivo nachgeahmt wird. Es zeigte sich, 
dass Zn-DIGP bei intravenöser Injektion in Mäusen (8 mg/kg) gut toleriert wurde, und es war 
in der Lage, die Bildung von Tumoren in der Lunge von C57BL/6-Mäusen, welchen 
B16F10-Zellen injiziert worden waren, zu verhindern. Unsere Ergebnisse bieten deshalb 
einen zusätzlichen Hinweis, dass CXCR3-Antagonisten eine neue Klasse von 
Antikrebsmitteln darstellen. Anders als frühere CXCR3-Antagonisten ist Zn-DIGP jedoch 
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auch ein vielversprechender Sensibilisator für photodynamische Therapien (PDT). Der 
Anregung mit rotem Laserlicht (660 nm) folgend weist Zn-DIGP eine hohe Quantenausbeute 
für die Generierung von Singlett-Sauerstoff auf (  0.46), welcher eine potente 
Phototoxizität (EC50  0.16 M) in Zellkultur zur Folge hat. Zn-DIGP kann deshalb zu einem 
multifunktionellen PDT-Agens weiterentwickelt werden, welches mithilfe von Lichtenergie 
für die Behandlung von primären Oberflächentumoren benutzt werden kann, während es 
gleichzeitig die Bildung von neuen Tumorkolonien in lebenswichtigen Organen verhindert, 
indem es Chemokin-vermittelte Signalwege beeinflusst. 
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Chapter 1. Introduction 
Nucleic acids are an important class of biomolecules that play diverse roles in functioning of 
living cells. The central dogma of biology states that deoxyribonucleic acids (DNA) are 
transcribed into ribonucleic acids (RNA) which encode for proteins.
[1]
 Ever since Freidrich 
Miescher reported the isolation and elemental analysis of mysterious “nuclein” from nuclei of 
white blood cells, research on the structural and functional aspects of DNA has been rapidly 
mounting.
[2]
 In 1953, Watson and Crick proposed the duplex model for „B‟ form of DNA 
where two strands of DNA run anti-parallel to form a double helical structure consisting of a 
major groove and minor groove. This duplex is stabilized by hydrogen bonding and base 
stacking interactions between guanine-cytosine and adenine-thymine residues (Figure 1.1).
[3]
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Figure 1.1. Nucleobases with A) Watson-Crick and B) non-canonical base-pairing 
interactions. 
It is widely believed that the „B‟ form of double helical structure is the (one and only) 
biologically relevant structure of DNA. The most important functions of DNA such as 
replication and transcription, however, require the presence of single stranded templates. 
These processes overcome the large kinetic barriers of duplex disassociation, providing the 
opportunity for non-duplex DNA structure to form in living cells.  Some examples of non-
canonical DNA structures that have been characterized in vitro include hairpin loop,
[4]
 
triplex,
[5]
 i-motif 
[6]
 and G-quadruplex.
[7]
 (Figure 1.2) 
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Figure 1.2. Secondary structures of single stranded DNA. A) Hairpin loop; B) Triplex; C) G-
quadruplex; D) i-motif. 
1.1. G-quadruplex DNA 
In 1910, Bang reported that concentrated solutions of guanylic acid self-associate to form 
gels.
[8]
 Using fiber diffraction studies, Gellert and coworkers concluded that polymers of 
guanosine can fold into a tetrameric arrangement of guanine bases that interact via Hoogsteen 
hydrogen bonding and metal ion binding.
[9]
 As shown in Figure 1.3, the four guanine bases 
form square – coplanar arrangements that utilize the hydrogen atoms of N1 and N2 to bond 
with O6 and O7 of adjacent guanine to provide eight hydrogen bonds per G-tetrad. Structures 
containing two or more G-tetrads constitute a special family of secondary structures called G-
quadruplexes. 
 
 
 
 
 
 
 
Figure 1.3. Structure of A) intramolecular G-quadruplex and B) G-tetrad. 
1.1.1. Types of G-quadruplexes 
G-quadruplexes can be formed from a single guanine-rich sequence (intra-molecular) or two 
or more strands (inter-molecular). These structures can be classified as parallel or anti-
parallel based on the directionality of the phosphodiester backbones (Figure 1.4). Based on 
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the length and connecting nucleotides,[10, 11] the topology can be classified by diagonal, 
lateral, propeller[12, 13] or double-chain reversal.[13]  
 
Figure 1.4. Schematic representation of different topologies of G-quadruplex structures. 
1.1.2. Stabilizing factors 
Stabilizing factors important for duplex DNA such as base-stacking, hydrogen bonding, 
hydration and electrostatic interactions are also important to G-quadruplex stability. A unique 
feature of G-quadruplexes is the arrangement of O6 atoms of guanine. Assembly of guanine 
tetrads orients the O6 of each guanine residue towards the central cavity of the G-quadruplex 
core. Arnott and coworkers first suggested that the negatively charged central core is 
stabilized by cation co-ordination.[14] The selection of a suitable cation based on its size and 
charge determines the overall stability of G-quadruplex structures. The general trend for 
preference of cationic alkali metals is K+ > Na+ > Rb+ > NH4+ > Cs+ > Li+. Apart from these 
fundamental properties, loop length and sequence also determine the overall stability and 
topology of G-quadruplex structures. [15] The stability of G-quadruplexes generally increases 
until the loop reaches 5 nucleotides in length, longer loops typically do not have any 
additional influence on stability.[16] Among the nucleotides present in the loop, thymines  
tends to increase the G-quadruplex stability,[11]  whereas adenine can cause destabilization.[17, 
18] 
Chapter 1  13 
 
1.1.3. Equilibrium between duplex and G-quadruplex 
Interestingly, for every G-rich DNA sequence that is known to be capable of forming a G-
quadruplex structure, its complementary C-rich sequence has been found to be capable of 
folding into an i-motif structure in vitro.
[19-25]
 G-C rich DNA sequences can therefore exist as 
a mixture of G-quadruplex / i-motif and canonical duplex DNA (Figure 1.5).
[26]
 The large 
kinetic barriers for duplex dissociation that are a prerequisite to establishing this equilibrium 
can be overcome by transcription and replication processes, as well as single-stranded DNA 
binding proteins,
[27]
 chaperones,
[28, 29]
 small-molecule binding,
[30]
 partial 
dehydration/molecular crowding,
[31]
 and/or negative supercoiling in vivo.
[32-34]
 In aqueous 
buffer, G-quadruplex structures are typically very resistant to thermal denaturation (Tm > 70 
°C),
[35]
 while the vast majority of i-motif structures exhibit only marginal thermodynamic 
stabilities at neutral pH (Tm < 10 °C).
[19-25]
 G-quadruplex structures have therefore served as 
the primary target for probes designed to detect this type of conformational equilibrium in 
vivo. 
 
Figure 1.5. Equilibrium between G-quadruplex and duplex DNA. 
1.2. Locations of G-rich sequences in the genome 
Prokaryotic and eukaryotic genomes were identified to be rich in putative G-quadruplex 
sequences (PQS). 
[36-38]
 Bioinformatic analysis by Huppert and Balasubramanian showed that 
more than 376‟000 PQS are present in the human genome.[39] Their enrichment was identified 
to be non-random and correlate with functional regions of the genome. A high frequency of 
PQS were found in the telomeres and the promoter regions of eukaryotic genes. 
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1.2.1. Telomeres 
Telomeres are special DNA-protein complexes the end of chromosomes of all vertebrates. 
Telomeres consist of non-coding DNA, typically 8-10 kb long with single stranded 3` 
overhang up to 200 bp that is protected by special protein complexes called shelterin. The 
shelterin complex is composed of single-stranded and double-stranded DNA, DNA binding 
proteins (TRF1, TRF2), a single-strand DNA binding protein (Pot1), and Rap1, TPP, and 
TIN2 that bind via protein-protein interactions. The shelterin proteins prevent the DNA from 
being recognized as double stranded beaks and therefore protect the chromosome. During 
each round of replication, telomeres get shortened by RNA-primed DNA synthesis. This „end 
replication‟ problem can be overcome by expression of telomerase. Telomerase is a reverse 
transcriptase that carries its own RNA template that can be used to extend 3` end of the 
telomere. Telomerase is overexpressed in cancer cells allowing for their immortality, 
however the telomerase activity is tightly regulated in normal cells allowing gradual telomere 
shortening with each cell division. A second method for telomere extension that occurs in 
certain tumor cells that do not overexpress telomerases is recombination-mediated process 
called Alternative lengthening of telomere (ALT).
[40]
 
 
The 3` overhang of telomeric DNA consists of repetitive G-rich sequences. Some examples 
include Sachromyces cerevisiae: TG1-3,
[41]
 Oxytricha nova: TTTTGGGG,
[42]
 Arabidopsis 
thaliana: TTTAGGG
[43]
 and in mammals: TTAGGG.
[44]
 All of these sequences can form G-
quadruplex structures in vitro.
[45, 46]
 The first direct evidence for the presence of telomeric G-
quadruplexes in vivo was demonstrated using G-quadruplex specific antibodies in ciliates.
[47]
 
Further studies using RNA interference (RNAi) demonstrated that the telomere end binding 
proteins of ciliates – TEBPα and TEBPβ assist the formation of G-quadruplexes structures in 
vivo.
[48]
 The human telomeric G-quadruplex can fold into at least four different G-quadruplex 
conformation structures in vitro.
[49]
 Though their existence in eukaryotic cells is unproven, 
several indirect experiments supporting the formation of G-quadruplexes have been reported. 
For example, the shelterin protein „Pot 1‟ was reported to interact with single stranded 3` 
overhang and destabilize G-quadruplex structures.
[50]
 Recently, the ends of chromosomes 
were visualized in fixed human cells using a G-quadruplex specific antibody in fixed cells, 
suggesting the presence of G-quadruplexes at chromosomal ends.
[51]
 In yeast, mutation of G-
quadruplex stabilizing protein (EST1) causes telomere shortening suggesting a positive role 
of G-quadruplexes in telomere maintenance.
[52]
 In another study using yeast, G-quadruplexes 
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structures were found to inhibit exonuclease activities at telomeric ends in vitro. Together, 
these results suggest a positive role of G-quadruplex in maintaining telomere length and 
stability.[53] 
 
Given the ability of G-quadruplex folding to inhibit telomerase activity in vitro, it was 
proposed that small molecules that stabilize G-quadruplex structures could inhibit telomerase. 
Early studies demonstrated that the addition of a G-quadruplex specific binder, telemostatin 
to a cancer cells caused disassociation of telomere binding proteins from their sites and 
reduce cell proliferation.[54, 55]  Based on these results, small molecules that stabilize G-
quadruplex structures in the telomere and displace telomerase is considered as an possible 
anti-cancer strategy (Figure 1.6). Though several molecules were reported to inhibit the 
action of telomerase in vitro, subsequent studies showed that the telomerase inhibition was 
frequently a result of direct binding interactions with telomerase itself.[56] Hence, direct 
evidence for the therapeutic relevance of telomeric G-quadruplexes remain elusive. 
 
Figure 1.6. Possible role of G-quadruplex in telomerase inhibition.  
1.2.2. Nucleolus 
The nucleolus originates from nucleolar organizing regions (NOR) assembled from tandem 
rDNA genes that are present on different chromosomes.[57] Interestingly, rDNA has a C-rich 
template strand and G-rich non-template strand. Due to constitutive transcription of rDNA 
genes, the two strands are stabily disassociated into single-stranded DNA, providing 
opportunity for the G-rich strands to fold into G-quadruplex structures.[58, 59] 
 
Electron microscope studies in E.coli identified novel DNA structures (loops) being formed  
during rDNA transcription. These loops were proposed to have G-quadruplexes in the G-rich 
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strand and DNA/RNA hybrids in the complimentary strand.
[60]
 The formation of G-
quadruplex structures in the nucleolus of eukaryotic cells has been proposed to be mediated 
by nucleolin and various helicases. The high abundance of nucleolin in nucleolus, together 
with its high affinity for G-quadruplex structures (Kd = 1 nM) in vitro, implies the presence of 
G-quadruplex structures in the nucleolus.
[58, 59]
 In contrast, WRN
[61]
 and BLM
[62]
 helicases 
were reported to unwind G-quadruplex structures in vitro. WRN is localized primarily in the 
nucleolus
[63]
 and serves to increase the rate of rDNA transcription.
[64]
 Together, these results 
provide a contradicting view of the importance of G-quadruplex unfolding for active 
transcription. 
 
A potent G-quadruplex binder, CX-3543, is known to localize in the nucleolus and it inhibits 
rRNA biogenesis.
[65]
 CX-3543 is the only drug-like G-quadruplex binder that reached Phase 
2 clinical trials. However, due to bioavailability problems, CX-3543 failed Phase 2 clinical 
trials, and its proposed cellular target of rDNA has never been fully validated as a drug target.  
1.2.3. Recombination sites 
Class-switch recombination is a highly regulated, essential process that alters the genomic 
structure of the heavy chains of immunoglobulin. Recombination occurs at the 
immunoglobulin switch regions (S regions) which comprise repeats from 2-10 kb in length. 
This repeat region contains a G-rich sequence that has the ability to form G-quadruplex 
structures in vitro. Upon transcription of the S region, atomic force microscope (AFM) 
images identified large loops consisting of G-quadruplex and a DNA/RNA hybrid.
[66, 67]
 The 
protein MutSα binds to a G-quadruplex from the S-region (Kd = 1 nM) and it promotes a 
“synapsis step” which is essential for class switching.[68] The importance of G-quadruplex 
structures as recombination elements was clearly demonstrated in Neisseria gonorrhoeae. 
Neisseria gonorrhoeae is a pathogen that expresses antigenic variation in its pili. The 
antigenic variation is a result of recombination. The removal of 16 bp G-rich sequence shuts 
down antigenic variation, suggesting the importance of this sequence. Circular dichroism 
studies showed that this G-rich sequence can fold into a G-quadruplex structure in vitro. 
Mutations of this sequence that destabilize the G-quadruplex structure cause recombination 
failure. Furthermore, the addition of a G-quadruplex-specific binder, pyridostatin, inhibited 
antigenic variation, further confirming the utilization of a G-quadruplex structure in the 
recombination sites.
[69]
 This study demonstrated the importance of G-quadruplex in 
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prokaryotes. However, such direct demonstration of functional G-quadruplex structures in 
mammalian cells remains elusive. 
1.2.4. Promoter regions of oncogenes 
Bioinformatics-based searches for G3+N1-7G3+N1-7G3+N1-7G3+ identified strong enrichment of 
this PQS in promoters, 5‟-UTRs and 3‟-UTRs of human genes. 42.7% of 19‟628 
characterized genes contain at least one PQS less than 1000 nucleotides from the 
transcription start site.
[70]
 In addition, the density of PQSs was very high near transcription 
start sites, possibly as a result of evolutionary pressure. 12% of the 5`-UTR,
[70]
 15% of 3`-
UTR
[70]
 and 16% of the first 100 nucleotides of first introns
[71]
 also exhibited a high 
frequency of PQSs. Though not all the PQSs are validated experimentally, the strong 
enrichment of PQSs in gene regulatory regions raises the possibility of functional G-
quadruplex structures functional in gene regulation.
[72]
 
 
Initial evidence for G-quadruplex dynamics in regulating gene expression was reported in the 
β-globulin gene.[73, 74] Since then, many oncogenes such as c-Kit,[75] PDGF,[76] VEGF,[30] 
RetB
[77]
 were reported to have PQSs in their promoter region that can form G-quadruplexes 
in vitro. c-Myc is a proto-oncogene that contains a G-quadruplex forming motif in a nuclease 
hypersensitive element located 130 nucleotides upstream of transcription start site. This 
sequence can form a propeller-type parallel G-quadruplex in vitro.
[78]
 Mutation studies of the 
guanines in this Myc PQS demonstrated that the disruption of G-quadruplex stability could 
increase gene expression, suggesting that the G-quadruplex inhibits transcription.
[72]
 
Consistent with this model, proteins that either induce (nucleolin) or resolve (NM23-H2) G-
quadruplex were found to repress and activate c-Myc transcription, respectively.
[59]
 
[79, 80]
 
Given these results, Prof. Hurley has proposed that a structure-selective stabilization of G-
quadruplexes by small molecules can also regulate gene expression. Since then, several G-
quadruplex ligands such as TmPyP4,
[10]
 quindoline,
[81]
 and actinomycin
[82]
 have been shown 
to inhibit c-Myc transcription. 
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Figure 1.7. Possible role of G-quadruplex in gene regulation. 
Genome-wide microarray analyses of S.cerevisiae that had been treated with the G-
quadruplex-selective ligand N-methylmesoporphyrin (NMM) demonstrated increased 
transcription of genes having a PQS in the promoter, and decreased transcription of rDNA-
associated genes.[83] In contrast, deletion of Sgs1p helicase (unwinds G-quadruplexes in vitro) 
caused downregulation of genes containing a PQS in their promoter, implying that G-
quadruplexes inhibit transcription.[83] Furthermore, a genome wide analysis of TmPyP4-
treated cancer cells demonstrate that 60% of the affected genes contained at least one PQS in 
the promoter. However, a toxic dose of 100 μM of TmPyP4 was used in these 
experiments.[84] 
 
In 2000, Hanahan and Weinberg proposed six crucial events in the malignancy process, 
namely self-sufficiency in growth signals, decreased sensitive to normal growth signals, 
evasion of apoptosis, angiogenesis, unlimited replication and metastasis.[85] Given the vast 
abundance of PQSs in the human genome, there is at least one gene involved in each of these 
processes that possess G-quadruplex forming sequence in the promoter region. These genes 
include Myc and Kras for self sufficiency, RB1 for insensitivity, BCL2 for apoptosis evasion, 
VEGF for angiogenesis, TERT for unlimited replication and PDGF for metastasis.[79] This 
highlights the potentially broad importance of G-quadruplex in cancer (Figure 1.8). Targeting 
of promoter G-quadruplexes with small molecules is therefore a potentially attractive anti-
cancer strategy that can impact many different malignancy processes at once. 
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Figure 1.8. G-quadruplexes proposed to be involved in different stages of malignancy.
[79]
 
 
1.3. Targeting G-quadruplexes with small molecules 
Despite the growing indirect evidence supporting the presence of G-quadruplexes in 
mammalian cells, direct evidence is still lacking. The development of structure-selective 
fluorescent probes is an attractive strategy for identifying G-quadruplexes inside the cells. 
Targeting G-quadruplex in vivo with small molecules is a challenging task due to the 
dynamic nature of these structures and their limited abundance as compared to duplex DNA.  
 
Ever since Zahler and coworkers demonstrated G-quadruplex mediated telomerase 
inhibition,
[86]
 G-quadruplex ligands have been gaining notoriety as potential anti-cancer 
agents.
[87-93]
 Many different scaffolds have been tested for their ability to bind G-quadruplex 
DNA.
[92, 94]
 G-quadruplexes can bind to small molecules via end-stacking interactions on G-
tetrad and/or binding to the groove regions (Figure 1.9). Binding selectivity between various 
G-quadruplex structures can be accomplished by developing molecules that interact 
selectively with the loop regions. Though several reviews have classified the G-quadruplex 
probes from different perspectives,
[88, 91]
 here we will present a review of fluorescent small 
molecules as potential G-quadruplex probes. 
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Figure 1.9. Possible binding sites of small molecules on G-quadruplexes. Red and blue 
represent end stacking and groove binding, respectively. 
1.3.1. Fluorescent Probes 
Fluorescent probes provide powerful and direct means for studying the folding and 
localization of biological macromolecules in living cells and whole animals. Fluorescent 
probes capable of structure-specific reporting of G-quadruplex structures in vivo will provide 
tools for basic biological research and the exploration of G-quadruplex DNA as a potential 
drug target. 
 
Intercalating agents: Classic intercalating agents such as 9-aminoacridine and ethidium 
bromide bind to DNA via intercalation into layers of nucleobases.
[95]
 This type of binding 
mode is not normally observed in G-quadruplex-ligand complexes.
[91, 96, 97]
 A true 
intercalation mode for G-quadruplex-small molecule binding has only been reported for 
synthetic “G4-DNA wires” under non-physiological conditions that lack sodium and 
potassium ions.
[98-100]
 The large, solvent-exposed surface areas of G-tetrads provide good 
receptors for aromatic cations to stack onto (Figure 1).
[91, 96, 97]
 While classic intercalating 
agents can bind to G-quadruplexes via this “end-stacking” mode, they typically exhibit low 
G-quadruplex affinity and selectivity,
[101, 102]
 and their fluorescence is readily quenched by 
guanine residues.
[103, 104]
  
 
Anthraquinones (AQ) :  Anthraquinones (1) were among the first molecules reported to 
interact with parallel G-quadruplexes via end-stacking interactions.
[105]
 Several derivatives of 
1,5-diamidoanthraquinones and 2,6-diamidoanthroquinones were also analysed for 
cytotoxicity and telomerase inhibition. 2,6-derivatives such as 2 have shown remarkable 
cytotoxicity and IC50 values for telomerase inhibition.
[106]
 Since benzimidazole and 
anthraquinone derivatives were reported to be telomerase inhibitors, Huang and coworkers 
fused the imidazole ring and anthraquinone rings to obtain improved IC50 values for 
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telomerase inhibition. These studies suggested that by extending a planar aromatic surface 
improved telomerase inhibition could be achieved.
[107]
 The anthraquinone moieties were 
further derivatized at different positions (2,6-, 2,7-, 1,8- and 1,5-) with protonatable amino 
acids (Lys, Arg) and hydrophobic spacers to increase selectivity of the scaffold for G-
quadruplex over duplex.
[108]
 The binding affinity for one of the anthraquinone derivatives 
4,11-bis[(2-[acetamido]amino)ethyl)amino]anthrax[2,3-b]thiopene-5,10-dioone (3) (Figure 
1.10) to anti-parallel telomeric DNA was measured in the micromolar range with an 100-fold 
selectivity for G-quadruplex over duplex DNA. Interestingly, these molecules were reported 
to cause destabilization of G-quadruplex structures.
[109]
 Subsequent studies demonstrated that 
inhibition of telomerase was due to direct binding interactions with telomerase rather than G-
quaduplex DNA. Though these molecules are fluorescent, no fluorescent based studies were 
performed with G-quadruplex DNA. 
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Figure 1.10. G-quadruplex ligands: Anthraquinone derivatives. 
Quindoline: Anthraquinone derivatives (Figure 1.11) were reported to be better telomerase 
inhibitors than quindolines due to the presence of protonated side chains.
[110]
 The solution 
structure of G-quadruplex-quindoline complex indicated that the binding is driven by end-
stacking and electrostatic interactions.
[111]
 The inclusion of an electron donating group at the 
11 position of quindoline enhanced the electron density of N-5 nitrogen, resulting in 
protonation at physiological pH. Accordingly, substituted quindoline derivatives (6) were 
shown to bind induce G-quadruplex structures and inhibit telomerase in low micromolar 
range.
[112-114]
 Quindoline derivative 2J (5) (Figure 1.11) was also reported decrease down 
regulation of transcription of c-Myc
[81]
 and bcl-2 genes
[115]
 by stabilizing G-quadruplex 
structures. However, further studies by Boddupally and coworkers suggested that quindoline-
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mediated c-myc regulation was not due to the stabilization of G-quaduplexes, but via some 
other and unknown mechanism.
[116]
 No fluorescence-based studies were reported for these 
quindoline derivatives. 
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Figure 1.11. G-quadruplex ligands: quindoline derivatives. 
 
Quinacridine: Crescent shaped quinacridine molecules (Boq1 (8)) were reported to bind to 
anti-parallel G-quadruplexes with 10-fold selectively duplex DNA. Boq1 end-stacks on G-
tetrads and its cyclic framework disfavors intercalation into the double-stranded DNA.
[117]
 A 
platinum-quinacridine hybrid, Pt-MPQ (9) was reported to interact with quadruplex DNA via 
a dual binding mode, targeting preferentially guanines of G-tetrads, thereby giving the 
possibility of irreversibly trapping G-quadruplex conformations.
[118, 119]
 (Figure 1.12) The 
fluorescence properties associated with G-quadruplex binding were not reported for 
quinacridine based derivatives. 
 
Perylene: The polycyclic molecule PIPER (10) (Figure 1.13) containing a perylene scaffold 
was reported to be an effective telomerase inhibitor in the low µM range. In addition, PIPER 
was also reported to induce G-quadruplex folding from duplex DNA of the c-Myc 
promoter.
[120]
 NMR structures reveal that depending on the type of sequence, PIPER binds to 
G-quadruplex structures with variable stoichiometries.
[121]
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Figure 1.12. G-quadruplex ligands: quinacridine derivatives. 
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Figure 1.13. Structure of PIPER. 
Berberines: Berberines (11) are natural alkaloids derived from Chinese herbs. Berberine 
moieties were reported to intercalate preferentially in intermolecular G-quadruplexes as 
compared to intermolecular G-quadruplexes.
[122]
 UV-visible absorbance titrations revealed 
that G-quadruplex binding of berberine causes red shift (10-12 nm) and hypochromatic (34-
40%) changes in absorbance.
[123]
 9-N-substituted berberine (12) was shown to bind c-Myc G-
quadruplex DNA and down-regulate c-Myc expression
[124]
 whereas a derivative of 9-O 
substituted berberine (13) showed improved binding affinity for telomeric DNA, and 
telomerase inhibition (Figure 1.14).
[125]
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Figure 1.14. G-quadruplex ligands: berberine derivatives. 
Acridine derivatives: Acridine derivatives such as proflavine, acridine orange and 9-
aminoacridine (14) bind to duplex DNA with modest affinity (Kd  1 – 100 μM),
[126, 127]
 and 
exhibit very little structure selectivity.
[128]
 Interestingly, acriflavine and proflavine have 
recently been reported to act as templates for the formation of G-quadruplex structures from 
cyclic diguanylate, but the resulting complexes exhibit quenched fluorescence.
[129] 
 
Neidle and coworkers synthesized and evaluated a series of 3,6,9-trisubstituted acridines (15) 
for telomerase inhibition.
[130]
 One particular derivative, BRACO-19, binds to G-quadruplex 
with Kd of 32 nM and to duplex DNA with Kd of 1 μM.
[131]
 A co-crystal structure with a 
bimolecular human telomeric G-quadruplex revealed that BRACO-19 asymmetrically stacks 
on G-tetrads, resulting in π-π overlap with two guanine bases (Figure 1).[132] Unfortunately, 
no fluorescence properties have been reported for BRACO-19.  
 
Eritja and coworkers prepared oligomers of acridine (16) via solid phase synthesis and 
reported modest G-quadruplex affinities ranging from 0.16 – 22 μM that depend on the type 
of G-quadruplex used.
[133]
 Contrary to the fluorescence quenching typically reported for 
acridines,
[103, 104, 129]
 small increases in fluorescence intensity for the acridine oligomers (16) 
were observed at 440 nm upon addition of G-quadruplex DNA.
[133]
 The reported increases 
were probably a result of decreased acridine-acridine self quenching when the samples were 
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excited at 360 nm,
[126]
 or from DNA-acridine energy transfer when the samples were excited 
252 nm. 
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Figure 1.15. Intercalating agents : acridine and ethidium bromide 
 
Figure 1.16. Crystal structure of BRACO-19 (15) bound to a human telomeric G-quadruplex 
(PDB accession code 3CE5).
[132]
 
 
Ethidium derivatives: Depending on the exact sequence used, ethidium bromide (17) binds to 
duplex DNA with a broad range of different affinities (Kd = 0.3 – 130 μM).
[134, 135]
 
Fluorescence and calorimetric studies indicate that ethidium bromide exhibits similar binding 
affinities for G-quadruplex and duplex DNA,
[102]
 while equilibrium dialysis experiments 
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suggested a large preference for duplex DNA.
[115]
 The differences between the methods are 
likely a result of differences in stoichiometry that are typically not accounted for in affinity 
assessments. Interestingly, upon binding Poly d(G) - Poly d(C) ethidium‟s fluorescence is 
almost entirely quenched,
[84]
 while binding d(GC) - Poly d(GC) and AT-rich duplexes results 
in a 30-fold enhancement in fluorescence.
[136]
 For short oligonucleotides having similar 
compositions, the fluorescence enhancements observed for ethidium are highly dependent on 
DNA conformation, where: G-quadruplex < triplex < duplex.
[137] 
Taken together, these 
properties make ethidium bromide a very poor probe for G-quadruplex DNA. 
 
To improve upon the G-quadruplex affinity and specificity of ethidium, Mergny and co-
workers prepared four known derivatives and discovered that ethidium derivative (18) bound 
to anti-parallel intramolecular G-quadruplexes with Kd values ranging from 90 – 120 nM.
[138]
 
This represents an approximate 10-fold selectivity as compared to duplex DNA (Kd = 1.1 
μM).[138] Interestingly, the quantum yield of the ethidium derivative (18) increased from 0.04 
to 0.2 upon G-quadruplex binding, and DNA-to-probe energy transfer reactions were also 
observed – consistent with the presence of stacking interactions between compound 18 and 
guanine residues. Experiments conducted in D2O suggested that the fluorescence 
enhancements were a result of dye desolvation upon DNA binding.
[138]
 Unfortunately, no 
staining of whole cells has been reported for ethidium derivative (18), possibly due to poor 
cellular uptake. Indeed, other dicationic ethidium derivatives, like propidium iodide (19), are 
known to be impermeable to cellular membranes and therefore used to selectively stain DNA 
of dead cells. 
1.3.1.1. Cationic macrocycles 
The large, nearly planar surface areas of G-tetrads provide good receptors for macrocyclic 
fluorophores having similar molecular dimensions.
[45, 91, 96, 97, 139, 140]
 Compounds that stack 
onto the terminal G-tetrads of G-quadruplex structures typically exhibit 1:1 or 2:1 ligand:G-
quadruplex binding stochiometries with Kd values ranging in the low nM to low μM range. 
These compounds can be grouped into basic categories according to their charges: cationic, 
anionic, and neutral macrocycles.  
 
TmPyP4: The cationic porphyrin tetra-(N-methyl-4-pyridyl)porphine or “TMPyP4” (20) is 
probably the most widely-studied G-quadruplex ligand to date.
[141-148]
 Early studies 
demonstrated that telomerase inhibition by TMPyP4 is relatively insensitive to the identity of 
Chapter 1  27 
 
the metal ion coordinated within TMPyP4, but is highly dependent on the substituents at the 
meso positions.
[142]
 Extensive substitution of the meso positions with groups other than 
pyridinium failed to generate compounds with improved inhibitory activities, but the 
resulting structure-activity relationships suggested that base stacking and charge-charge 
interactions are important for porphyrin-DNA binding.
[142]
 Some caution must be exercised 
when interpreting such inhibitory data, however, since the reported trends in telomerase 
inhibition do not necessarily correlate with the G-quadruplex binding affinities of small 
molecules.
[149]
  
N
N
N
N
NNH
N HN
N
N
N
N
3,4-TMPyPz (21)
N
N
H
N
H
N
 TMPyP4 (20)
N N
N N
  (mixture of regioisomers)  
Figure 1.17. Cationic macrocycles: TMPyP4, 3,4-TMPyPz. 
X-ray crystallography and NMR studies demonstrated that TMPyP4 (20) can bind to G-
quadruplex DNA at many different sites, including the terminal G-tetrads,
[143]
 as well as the 
loops, grooves, and phosphodiester backbone (Figure 2).
[144]
 TMPyP4 binds to duplex, 
triplex, G-quadruplex, single-stranded, and bulk genomic DNA with similar affinities (Kd   
200 nM),
[128, 145]
 and is therefore not a structure-specific ligand. Upon addition to whole cells, 
the uniform nuclear localization of TMPyP4 suggests preferential staining of duplex 
DNA.
[146, 150] 
 
TmPyP4 is a modestly fluorescent compound in water (Ф = 0.04),[151] but is quenched upon 
G-quadruplex binding by photon-induced electron transfer from guanine residues.
[147, 152]
 
TMPyP4 can, however, exhibit a 2-fold higher quantum yield (Ф = 0.08) when it is bound to 
AT-rich duplex DNA.
[148, 152]
 This photophysical selectivity for duplex DNA can be partially 
overcome by monitoring energy transfer reactions from G-quadruplexes to TMPyP4 resulting 
from photoexcitation of the DNA at 260 nm.
[98]
 At the present time, however, this type of 
approach is not compatible with cellular imaging experiments, due to the practical limitations 
of photoexcitation and autofluoresence in the UV range. 
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Figure 1.18. Crystal structure of TmPyP4 (20) bound to a human telomeric G-quadruplex 
(PDB accession code 2HRI).
[144]
 
 
Tetramethylpyridiniumporphyrazines: According to computational modeling, 
phthalocyanines have especially good shape complementarity with stacked G-tetrads that 
constitute G-quadruplex DNA.
[153, 154]
 Tetrapyridino porphyrazines are aza analogues of 
phthalocyanines where the four benzene units in the macrocycle are replaced by pyridine 
moieties.  Balasubramanian and coworkers reported that tetramethylpyridiniumporphyrazine 
“3,4-TMPyPz” (21) binds to G-quadruplex DNA with Kd values ranging from 170 – 200 nM, 
while exhibiting 30-fold lower affinity to duplex DNA.
[139]
 While 3,4-TMPyPz (21) is a 
weakly fluorescent compound, its fluorescence is quenched by both G-quadruplex and duplex 
DNA, and is therefore not suitable as a G-quadruplex fluorescent probe.
[155]
 
1.3.1.2. Anionic macrocyclic G-quadruplex ligands 
NMM: N-methyl mesoporphyrin (NMM) (22) is commercially available as a mixture of four 
N-methyl-pyrrole regioisomers. N-Alkylation causes a large distortion of the porphyrin 
macrocycle from planarity,
[156]
 thereby decreasing self-association and increasing water 
solubility. NMM is a transition-state analog for iron insertion and potent inhibitor of 
ferrochelatase.
[157]
 During the development of NMM-specific DNA aptamers as 
deoxyribozymes,
[158]
 Sen and co-workers isolated NMM aptamers capable of adopting G-
quadruplex structures that bind to NMM with good affinity (Kd = 0.5 – 1.0 μM).
[159]
 These 
results provided the first reported examples of structure-selective G-quadruplex-ligand 
binding interactions.
[159]
 Subsequent studies using equilibrium dialysis demonstrated that 
NMM is highly specific for G-quadruplexes as compared to other common DNA 
structures,
[101]
 but NMM generally exhibits low-to-modest G-quadruplex affinity (Kd   10 
μM) and is selective for the parallel form of the human telomeric G-quadruplex.[160] NMM 
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also exhibits relatively weak fluorescence emissions that are enhanced 2 to 10-fold upon G-
quadruplex binding.
[148, 161]
 No reports about use of NMM as a fluorescent probe in cells are 
currently available, but strong protein-NMM binding interactions may dominate its cellular 
localization and bioavailability.
[157, 161]
 Despite these potential limitations, the addition of 
NMM to single-celled organisms can impact functions associated G-quadruplex-forming 
DNA sequences such as telomere capping in cdc13-deficient Saccharomyces cerevisiae,
[53]
 
and recombination in Neisseria gonorrhoeae.
[69] 
 
Protoporphyrin IX (PPIX): Due to its potent inhibition of ferrochelatase,
[157]
 the addition of 
NMM (22) to living cells causes the accumulation of protoporphyrin IX (PPIX, 23).
[162]
 PPIX 
is a ubiquitous heme precursor that is reported to be a G-quadruplex-selective fluorescent 
probe in vitro.
[163]
 In DMSO, PPIX exists as a monomer with a good quantum yield for 
fluorescence (Ф = 0.16), while in water, self quenching is observed due to the formation 
PPIX micelles.
[164]
 Fluorescence enhancements can therefore be observed upon addition of 
biomolecules that bind to and solubilize PPIX.
[165]
 The addition of G-quadruplex DNA to 
PPIX results in a 16-fold increase in fluorescence.
 [163]
 According to these changes, PPIX was 
reported to selectively bind parallel G-quadruplex DNA with good affinity (Kd  30 – 120 
nM), while exhibiting much lower affinities for duplex and anti-parallel G-quadruplex DNA 
(Kd > 50 μM).
 [163]
 According to FRET-based melting assays, however, little or no thermal 
stabilization of the parallel human telomeric G-quadruplex was observed by PPIX when 
applied at 1 μM.[160] While the basis of these conflicting reports is not entirely clear, early 
studies using DNAzyme aptamers also support only modest binding interactions between 
PPIX and G-quadruplexes (KM = 12.3 μM) in the presence of detergents (Triton X-100) and 
DMSO as co-solvents.
[158]
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Figure 1.19. Anionic macrocycles: NMM and PPIX. 
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The complex interplay between NMM, PPIX, and endogenous heme biosynthetic pathways 
may limit the usefulness of  these compounds as fluorescent probes in vivo, but the potential 
ability of PPIX to bind G-quadruplexes involved in the regulation of tetrapyrrole biosynthesis 
presents an intriguing possibility for the hypothetical existence of a “deoxyriboswitch” in 
early evolution. Given the potential abilities of NMM and PPIX to bind to genomic G-
quadruplexes that impact transcriptional control,
[11]
 one can imagine a negative feedback loop 
where PPIX accumulation causes transcriptional deactivation of the same genes responsible 
for its biosynthesis. While similar regulatory mechanisms might be present in the insulin-
linked polymorphic region (ILPR),
[166]
 it is not clear how differential gene expression in 
diverse tissue types could be efficiently regulated by simple DNA – metabolite binding 
interactions in higher animals. A similar argument could explain why direct metabolite-RNA 
regulatory interactions or “riboswitches” are a common feature in bacteria, fungi and plants, 
[167]
 yet are very rare or possibly absent in mammals.
 [168] 
1.3.3.3. Neutral macrocyclic G-quadruplex ligands 
Telomestatin and L1BOD-7OTD: Telomestatin (SOT-095) (24) is natural product isolated 
from Streptomyces anulatus
 
that binds to various G-quadruplexes with high affinity (Kd  30 
nM).
[169, 170]
 Telomestatin also exhibits good selectivity for intra- versus inter-molecular G-
quadruplex structures,
[171]
 and it exhibits a 70-fold lower affinity for duplex DNA.
[171]
 
Synthetic analogs of telomestatin containing six or seven oxazole units have also been shown 
to exhibit good G-quadruplex affinity and selectivity,
[172-174]
 but, like for the natural product, 
they also lack inherent fluorescence properties.
[175]
 Nagasawa and coworkers therefore 
synthesized a macrocyclic heptazole (L1BOD-7OTD) containing a BODIPY fluorophore 
(25).
[175]
 This conjugate exhibits excellent G-quadruplex affinity (Kd  0.2 – 80 nM) and 
specificity in vitro, as well as sensitive G-quadruplex detection in native gels.
[175]
 In an 
attempt to stain G-quadruplexes in cells, 0.5 μM of L1BOD-7OTD was incubated with HeLa 
cells for 18 hours, followed by fixation and permeabilization of the cells. Fluorescence was 
observed mostly in the nuclei and nucleoli of cells.
[175]
 While this staining may reveal the 
presence of rDNA G-quadruplexes,
[58]
 caution must again be exercised when interpreting 
these data, because common fixation and permeabilization methods can cause DNA 
conformational changes and redistribution of DNA ligands within cells.
[53, [176]
 To date, no 
live-cell imaging has been reported for this promising probe. 
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Figure 1.20. Neutral macrocycles: L1BOD-7OTD and Telomestatin.  
Luminescent metal complexes: Transition metal complexes encompass a large family of G-
quadruplex ligands,
[177]
 with the attractive potential for time-resolved phosphorescent 
imaging.
[178]
 In some cases, metal ions restrict a multidentate metal ligand into a co-planar 
conformation capable of end-stacking onto G-tetrads. For example, Vilar and co-workers 
reported a Nickel salphen complex (26) with 50-fold selectivity for G-quadruplexes as 
compared to duplex DNA, but no luminescence properties were reported for this complex.
[179]
 
Inspired by these results, Che and co-workers prepared a series of platinum-coordinated 
salphens and observed that one derivative, “Pt L3” (27) binds to c-Myc G-quadruplex with a 
Kd of 10 μM and exhibits a 10-fold lower affinity for duplex DNA.
[166,[180]
 This complex 
exhibits a low quantum yield for photoluminescence (Ф = 0.01) that increases approximately 
8-fold upon DNA binding. Although the exact mechanism for this increase remains 
unknown,
[180]
 relatively long lifetimes ( = 1.40 – 4.60 μs) indicate the presence of emissive 
triplet excited state(s).Che and coworkers synthesized a series of platinum (II) complexes 
containing a 2,6-bis-(benzimidazol-2-yl)pyridine (bzimpy) ligand.
[181]
 These compounds 
exhibit a 10-fold or larger selectivity for binding G-quadruplex as compared to duplex DNA. 
One particular derivative “Pt-bzimpy” (28) exhibited a 38-fold increase in luminescence upon 
G-quadruplex binding, but only a 4-fold increase upon saturation with calf thymus DNA. Pt-
bzimpy exhibited very mild cytotoxicity, but no cellular staining experiments were reported 
for this complex. 
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Figure 1.21. Luminescent metal complexes 
Ma and coworkers synthesized a series of Pt complexes and found that a platinum-
dipyridophenazine complex “Pt-Dppz” (29) exhibited a 293-fold increase in 
photoluminescence upon G-quadruplex binding.
[182]
 The authors suggested that decreased 
water-mediated quenching of an emissive Pt→π* metal-to-ligand charge transfer was 
responsible for the fluorescence enhancement. Pt-Dppz exhibited good G-quadruplex affinity 
(Kd = 0.1 μM), and good G-quadruplex selectivity according to equilibrium dialysis and gel 
staining experiments. The limited water solubility of Pt-Dppz, however, required the addition 
of 5% DMF as a co-solvent in these experiments. Pt-Dppz was reported to exhibit modest 
cytotoxicity, but no cellular staining experiments were reported for this complex.  
 
Octahedral ruthenium complexes containing intercalating moieties constitute a large family 
of DNA binders with interesting photophysical and electrochemical properties.
[183]
 Shi and 
coworkers recently reported that Ru(phen)2dppz (30) exhibits a 5-fold higher luminescence 
when bound to G-quadruplex versus i-motif DNA.
[184]
 The same authors reported that the 
same complex containing bipyridine instead of phenanthroline ligands, Ru(bpy)2dppz could 
differentially bind variable G-quadruplex topologies.
[185]
 Mao and Ji synthesized two new 
tetracationic metal complexes 31A and 31B each containing two tppz ligands coordinated to 
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ruthenium. 31A and 31B bind to G-quadruplex DNA with a Kd of ~0.01 μM. Upon binding to 
G-quadruplex DNA, luminescence increased approximately 5- and 8-fold for 31A and 31B, 
respectively.
[186]
 However, no cell based studies were reported for any of these ruthenium 
complexes. 
 
The poor membrane permeability of metal complexes can greatly limit their cellular 
uptake.
[178]
 While cationic metal complexes derived from porphyrins and phthalocyanines can 
provide exceptions to this rule,
[187]
 octahedral ruthenium complexes typically exhibit poor 
uptake.
[183]
 In 2009, Thomas and coworkers reported a dinuclear ruthenium complex 
containing a bridging tetrapyridophenazine ligand “tpphz” (32) selectively stains the nuclei of 
MCF-7 cells upon addition to live cells at 500 μM.[188] Experiments using endocyctosis 
inhibitors suggested that entry of these complexes into cells occurred via a non-endocytotic 
route. In vitro studies demonstrated that 32 binds to quadruplexes with affinities (Kd  0.23 
μM) very similar to duplex DNA (Kd  0.32 μM).
[189]
 The photoluminescent properties of 32 
are highly sensitive to folded state of the DNA. Upon G-quadruplex binding, a 150-fold 
increase in luminescence was observed, while the addition of duplex DNA resulted in only a 
50-fold increase.
[190]
 The enhancements in luminescence were ascribed to the shielding of 
nitrogen atom of phenazine rings of 32 from water molecules. Most importantly, cells stained 
with 32 exhibited multiple emission profiles thought to originate from different DNA 
structures. Intense, uniform nuclear staining at 680 nm was attributed to duplex DNA, while 
punctate staining within the nucleus emitting at 630 nm was suggested to represent 
alternative DNA structures like the G-quadruplexes.
[188]
 The emission profiles collected from 
the nuclei of stained cells did not exactly match those of standard samples prepared and 
analyzed in vitro.
[190]
 Given the abilities of dinuclear ruthenium complexes to mediate direct 
photocleavage of DNA,
[191]
 it is possible that the intra-nuclear targets of these interesting 
dinuclear complexes (20) can be further investigated using photocleavage and DNA 
sequencing.
 [192]  
 
Pyrene-based derivatives: Pyrene exhibits bright fluorescence in water ( = 0.69, ε = 35‟000 
cm
-1
M
-1
) that is quenched by molecular oxygen.
[193]
 In 1999, Ren and Chaires evaluated 
pyrene methylamine (33) for its nucleic acid selectivity using competition dialysis, having the 
expectation that the large planar surface of pyrene would selectively bind triplex and/or G-
quadruplex polymers.
[101]
 Surprisingly, a preference for poly(dAdT) duplex DNA was 
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discovered and subsequently confirmed using fluorescence titration experiments.
[101]
 The 
reversal of self-quenching upon DNA binding is an important mode of fluorescence 
enhancement for many of the fluorescent probes highlighted here (ex. acridine orange, DIGP, 
PPIX, etc).
[126, 153, 163, 194]
 In contrast, pyrene-pyrene self association gives rise to emissive 
excimers that emit photons at ~480 nm. Pyrene excimer formation can provide a means to 
differentiate between alternative DNA conformations. For example, Yoon and co-workers 
synthesized an imidazolium pyrene derivative “JY-1” (34) that generates excimer emissions 
in the presence of d(G)3 but not duplex DNA. The apparent affinity for d(G)3 was only 
modest (Kd  2 μM) and no cell-based studies have been reported,
[195]
 but NMR and CD 
experiments suggested that JY-1 is able to induce G-quadruplex folding from single strands 
by binding interactions in the groove regions of the DNA.
[195]
 This preference for groove 
binding may explain pyrene‟s selectivity for poly(dAdT) duplex DNA.[128]  
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Figure 1.22. Pyrene-containing derivatives. 
Classic groove binders: The quantum yields of unfused aromatic polycyclic dyes like DAPI, 
Hoechst 33258, and cyanines depend strongly on the rotational motions between the unfused 
aryl groups. Upon photoexcitation, the free dyes typically exhibit rapid non-radiative 
relaxation via internal rotational diffusion. Upon DNA binding, the loss of these rotary 
motions causes a dramatic increase in quantum yield.
[196]
 This same mechanism may account 
for the fluorescence enhancements reported for many other unfused aromatic compounds 
upon DNA binding.    
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Figure 1.23. “Classic” minor groove binders: Hoeschst 33258 and DAPI. 
Minor groove DNA binders are typically cationic, crescent shaped molecules. For example, 
Hoechst 33258 (35) is a commonly used cell-permeable probe that binds selectively to AT 
rich duplex DNA with Kd values ranging from 10 – 100 nM.
[197]
 Although Hoechst 33258 
exhibits useful fluorescence properties, it exhibits no G-quadruplex selectivity, with Kd 
values ranging from 0.1 – 1 μM.[198, 199] Other classic groove binders such as Distamycin, 
Netropsin, and DAPI (36) also exhibit selectivity for A/T-rich duplexes and lower affinities 
for G-quadruplex DNA.
[101, 200, 201] 
 
Cyanines: In 1996, Shafer and coworkers reported that the carbocyanine dye “DODC” (37) 
binds to a dimeric hairpin G-quadruplex in vitro.
[202]
 The binding affinity (Kd  1 μM) and 
selectivity were only modest (5-fold versus duplex DNA), but this interaction resulted in 
unique spectrophotometric signatures present in the dye-G-quadruplex complex which were 
absent for duplex and single-stranded DNA. Most notably, efficient DNA to DODC energy 
transfer reactions allowed for the detection of hairpin G-quadruplex structures in the presence 
of excess single strands and Watson-Crick duplexes. The resulting energy transfer emissions 
from DODC, however, were limited by its fluorescence quenching by the hairpin G-
quadruplex.
[202]
 To improve upon these properties, Tang and coworkers synthesized the 
cyanine derivative “ETC” (38) that exhibits a 70-fold fluorescence enhancement upon 
addition of parallel G-quadruplexes.
[194]
 The mechanism for fluorescence enhancement was 
reported to be liberation of fluorescent monomers from non-fluorescent “J”-type aggregates. 
While no affinities or selectivity ratios were reported, no detectable fluorescence 
enhancements were observed upon addition of duplex DNA to ETC.   
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Kotlyar and coworkers screened a collection of known DNA-binding cyanine dyes to identify 
candidates that could exhibit structure-specific fluorescence properties.
[99]
 The trimethine 
cyanine derivative “Cyan 2” (39) bound to G-quadruplex “wires” with high affinity that was 
accompanied by large increases in fluorescence intensity when the titrations were conducted 
in the absence of potassium ions.
[99]
 In the presence of potassium ions, however, no increases 
in fluorescence intensity were observed. The authors suggested that Cyan 2 is able to 
intercalate into ion-G-wires in the absence of potassium ions. In the presence of potassium 
ions, however, Cyan 2 is thought to favor an external, groove binding mode.
[99]
 Similar 
results have also been reported for TMPyP4 (7),
[100]
 and thiazole orange (40).
[100]
 
 
In the presence of sodium and potassium ions, the common fluorescent stain “thiazole 
orange” (40) exhibits similar affinity for G-quadruplex and duplex DNA (0.3 – 3.0 μM).[203, 
204]
 DNA binding is accompanied by a very large (100 to 1000-fold) increase in quantum 
yield (Ф = 0.1 – 0.4) for 40.[203] To improve G-quadruplex selectivity of thiazole orange 
while maintaining its useful fluorescence properties, Teulade-Fichou and co-workers 
synthesized a “hybrid” derivative “PDC-M-TO” (41). This compound contains a highly 
selective pyridocarboxamide G-quadruplex ligand fused to thiazole orange.
[205]
 PDC-M-TO 
exhibits excellent selectivity and gives much larger fluorescence enhancements upon binding 
G-quadruplexes as compared to duplex DNA. PDC-M-TO can be used to selectively stain G-
quadruplexes in gels, but no cell-based data have been reported for this promising probe. 
Following a similar strategy, Wong and coworkers fused a natural product 
benzofuroquinolinium moiety with thiazole orange to give a “Benzofuroquinolonium-
benzathiazole hybrid” (42).[206] This compound also exhibited very impressive G-quadruplex 
selectivity and fluorescence enhancements as compared to duplex DNA. When applied to 
fixed cells, 42 gave intense staining of nucleoli. While the authors suggested that this staining 
may reveal the presence of rDNA G-quadruplexes,
[206]
 common cross-linking and fixation 
methods can cause a dramatic redistribution of DNA ligands within cells.
[176]
 Special caution 
must therefore be exercised when interpreting data collected using fixed cells. 
 
Due its bright fluorescence when bound to G-quadruplexes, thiazole orange can be used as an 
energy acceptor from a second, non-covalent fluorescent probe in close proximity. As a 
fluorescent donor, Teulaude-Fischou and co-workers used the macrocyclic bis(quinacridine) 
derivative BOQ1.
[207]
 G-quadruplex structures were found to be capable of simultaneously 
hosting both molecules, allowing FRET to occur between them.
[208]
 The addition of human 
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telomeric G-quadruplex to a mixture of dyes caused a 3-fold increase in thiazole orange 
fluorescence when BOQ1 was photoexcited. In contrast, no FRET was observed upon 
addition of duplex DNA. While this general strategy provides an attractive possibility for 
cellular imaging, no examples of such G-quadruplex FRET pairs have been reported in cell-
based experiments.  
 
A powerful two-step strategy to visualize G-quadruplex ligands bound to cellular DNA has 
recently been reported by Balasubramanian and co-workers.
[209]
 According to this approach, 
the highly selective G-quadruplex ligand “Pyridostatin” was modified with a terminal alkyne 
group. The resulting non-fluorescent conjugate (43) was added to fixed cells and 
subsequently visualized by copper-catalyzed azide-alkyne “click” reactions with fluorescent 
azides. The nuclear distribution of 43 was found to be contained within nucleoli and many 
other foci located throughout the nucleus. Interestingly, co-staining experiments with TRF1 
antibodies revealed that most of the 43-containing foci were not associated with telomeric 
ends. Co-localization was instead observed with a GFP fusion protein of the DNA helicase 
“Pif1.” This helicase is capable of binding to and resolving G-quadruplexes during DNA 
replication.
[210, 211]
  Inhibition of such helicase activities by Pyridostatin was proposed to 
cause DNA damage and cell cycle arrest through DNA-damage checkpoint activation. 
Indeed, chromatin immunoprecipitation sequencing analysis of the DNA damage marker γ-
H2AX revealed that pyridostatin was associated with clusters of DNA sequences having a 
high propensity for G-quadruplex formation. The DNA damage at these foci was proposed to 
result from both replication- and transcription-dependent processes.
[209]
 Taken together, these 
results provide convincing evidence that endogenous “G4 resolvase activities” are important 
aspects of genome maintenance in human cells, and illustrate how site-selective probes for G-
quadruplexes can be used to make fundamental biological discoveries. 
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Figure 1.24. Cyanine-based derivatives and related compounds. 
 
Triphenylmethane and tetraphenylethene dyes: Bhasikuttan and coworkers reported the 
well-known dye Malachite green (44) as a G-quadruplex fluorescent probe.
[212]
 Upon 
photoexcitation, unbound Malachite green exhibits rapid non-radiative relaxation via internal 
rotational diffusion. Upon DNA binding, the loss of these rotary motions causes a dramatic 
increase in quantum yield. Although its binding affinities to G-quadruplex and duplex DNA 
are very similar (Kd  2 – 35 μM), Malachite green exhibits up to a 100-fold increase in 
fluorescence upon addition of high concentrations (100 μM) of d(G2T)13G.
[212]
 Given the 
potential for aggregation-induced fluorescence of these compounds,
[213]
 it is unclear if this 
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100-fold increase was a result of DNA-dye aggregation or the formation of discrete 
complexes. 
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Figure 1.25. Triphenylmethane and tetraphenylethene derivatives. 
Kong and coworkers conducted a systematic comparison of Malachite green (44) and Crystal 
violet (45) for G-quadruplex selectivity and fluorescence enhancements.
[214]
 The authors 
demonstrated that the fluorescence intensity of Crystal violet was consistently higher in the 
presence of diverse G-quadruplexes (6-fold increase) as compared to single-stranded and 
duplex DNA (3-fold increase).
[214]
 Malachite green (44) was shown to give less consistent 
results than Crystal violet (45) in terms of its ability to differentiate G-quadruplex from 
duplex DNA structures. The reported binding affinity of Crystal violet for various G-
quadruplexes, single-stranded and duplex DNA were all very similar (Kd  20 – 40 μM), but 
the fluorescence intensities observed from anti-parallel G-quadruplexes were more intense 
than those from parallel G-quadruplex complexes.
[214]
 However, the maximal changes in 
Crystal violet fluorescence intensity (60 to 100-fold) were much smaller than those used to 
detect Malachite green fluorescence changes in cells (1‟000 to 18‟000-fold) by a protein-
based sensor.
[215]
 These results suggest that 44 and 45 will probably not provide a practical 
means to detect G-quadruplex structures in cellular environments.  
 
Reversal of self-quenching upon DNA binding is an important mode of fluorescence 
enhancement for many of the probes presented here. In contrast, 1,1,2,2-Tetrakis[4-(2-
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bromoethoxy)-phenyl]ethene “TTAPE” (46) exhibits aggregation-induced emission 
enhancements upon DNA binding.
[213]
 Unbound TTAPE in aqueous solutions is essentially 
non-luminescent due to intramolecular rotational diffusion, but the addition of organic 
solvents that cause a loss of TTAPE solubility or alternatively, cause increases in solvent 
viscosity result increased luminescence at 472 nm. TTAPE binds to G-rich single-stranded 
DNA to give 4-fold increases in emissions at 470 nm in a potassium-dependent manor. 
TTAPE binds to G-quadruplex DNA with a modest apparent affinity (Kd = 4 μM). The 
resulting aggregation present in these complexes was reversible, as the addition of the C-rich 
complementary DNA released non-emissive TTAPE due to the formation of duplex DNA.
 
[213]
 
 
Carbazoles: Dicationic carbazole derivatives are known to bind selectively to the minor 
groove of AT-rich duplex DNA.
[190,[216]
 Chang and his colleagues reported that a novel 
carbazole derivative: 3,6-bis(1-methyl-4-vinyl pyridinium) carbazole diiodide “BMVC” (47)  
exhibits large (10 to 100-fold) increases in fluorescence intensity upon binding G-quadruplex 
and duplex DNA.
[217]
 While its affinities to duplex and G-quadruplex DNAs are very similar, 
a shift in BMVC emission wavelength from 550 nm to 575 nm was observed in the case of 
the G-quadruplex binding.
[217]
 Interestingly, the addition of BMVC to metaphase spreads 
resulted in uniform chromosomal staining, but with slightly higher emissions at ~580 nm near 
the telomeric ends.
[218]
 To provide better signal-to-noise, two-photon excitation fluorescence 
lifetime imaging microscopy was conducted. This approach was aimed at utilizing the 
slightly longer fluorescence lifetime of BMVC when bound to G-quadruplexes (2.2 ns) as 
compared to duplexes (1.5 ns). The resulting time-resolved emissions from BMVC in 
metaphase spreads appeared, to some extent, localized at the ends of chromosomes.
[219]
 While 
the differences were interpreted in terms of G-quadruplex structures, the staining patterns 
have not yet been independently validated using orthogonal means such as co-localization 
with telomere binding proteins. 
 
In a related study, Teulade-Fichou and coworkers synthesized a small family of N-Phenyl 
carbazoles. One such derivative “Cbz-2Py” (48) exhibited bright fluorescence upon DNA 
binding (Ф  0.58, ε  22,000 cm-1M-1) as well as a very good two-photon absorption cross-
section (δ  200 GM), but similar binding affinities (Kd  1 μM) were observed for G-
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quadruplex and AT-rich duplex DNA.
[220]
 Two-photon imaging of Cbz-2Py (48) in fixed 
cells suggested uniform staining of double stranded DNA. 
N
NN
R = H, "BMVC" (47)             
R = Ph, "Cbz-2Py" (48)
R
 
Figure 1.26. Carbazole derivatives: BMVC and CBZ-2Py. 
1.4. Aims 
The existence of G-quadruplex DNA structures and their potential role(s) in normal 
mammalian biology remain unclear. To address these fundamental questions, powerful 
probes for characterizing conformational dynamics of nucleic acids in vivo are needed. 
Fluorescent probes capable of structure-specific binding reporting of G-quadruplexes in vivo 
will provide much needed tools for basic biological research and the continued exploration of 
G-quadruplex DNA as a potential drug target. The objective of this thesis is to evaluate the 
guanidinium- and ammonium-containing phthalocyanines for probing G-quadruplex 
structures that may be present in the promoter regions of mammalian genes. 
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Chapter 2. Cationic phthalocyanines as G-
quadruplex probes 
2.1. Introduction 
After being discovered as impurities in 1907,
[1]
 phthalocyanines (Pcs) have been widely 
utilized as materials in diverse fields. Pcs are heteroaromatic, symmetric molecules 
containing four isoindole units linked with nitrogen atoms. Due to their interesting 
photophysical properties, Pcs have range of applications as dyes, catalysts, chemical sensors 
and in data storage devices. In vivo applications of phthalocyanines include tattoo inks and as 
photosensitizers in photodynamic therapy.
[2]
 Though Pcs are structurally related to 
porphyrins, Pcs are strictly synthetic as they do not occur naturally. According to 
computational modeling, phthalocyanines have especially good shape complementarity with 
G-tetrads that constitute G-quadruplex DNA (Figure 2.1).
[3]
 We were interested in developing 
cationic phthalocyanines with guanidinium groups because the cellular uptake and 
DNA/RNA affinity is typically better for guanidinium-containing molecules than analogous 
molecules containing ammonium
[4, 5]
 We therefore synthesized a small family of 
guanidinium-containing phthalocyanines (Figure 2.2).
[2, 6]
 
 
 
 
 
 
Figure 2.1. Structure of G-tetrad present in the G-quadruplex DNA (A) and phthalocyanine 
scaffold (B). Overlay of G-tetrad and phthalocyanine, illustrating similarities in molecular 
dimensions (C). 
N
N
N
N
N
NN
N
Zn
R
R
R
R
N
N
N
O
N
N
N
N
N
O
N
N
N
N
N
O
N
N
N
N
N
O
N
N
R R
RR
H
H
H
H
HH
H
H
H
H
H H
G-tetrad DNA  Phthalocyanine
N
N
N
N
N
N
N
N
Zn
R
R
R
R
N
N
N
O
N
N
N
N
N
O
N
N
N
N
N
O
N
N
N
N
N
O
N
N
R R
RR
H
H
H
H
HH
H
H
H
H
H H
C) B) A) 
Chapter 2   50 
 
2.2. Results and Discussion 
2.2.1. Synthesis of guanidino phthalocyanines 
Tetrakis-(diisopropyl-guanidine) zinc phthalocyanine “Zn-DIGP” were synthesized according 
to Figure 2.2. Phthalic anhydride was reacted with zinc chloride and ammonium molybdate at 
185 ºC to give the Zinc-containing macrocycle (2) in 98% yield. 2 was then reduced by 
sodium sulfide to give 3. Tetraamino zinc phthalocyanine (3) was then heated with 
diisopropyl carbodiimide in the presence of pyridine-HCl at 120 ºC to yield a demetallated 
guanidinium-containing phthalocyanine (4) in 83% isolated yield. Heating 4 in the presence 
of zinc chloride provides zinc-diisopropyl guanidino phthalocyanines (5) in 79% isolated 
yield. 
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Figure 2.2. Synthesis and structures of guanidino zinc phthalocyanines 6 – 8.[13,15] Reagents 
and conditions: (a) zinc chloride (0.25 equiv), ammonium molybdate (0.1 mol %), 
nitrobenzene, 185 
o
C, 4 h, 98%; (b) sodium sulfide (12 eq), DMF, 60 
o
C, 1.5 h, 75%; (c) 
diisopropyl carbodiimide (20 – 50 equiv), pyridine/pyridinium-HCl, 120 oC, 20 h; (d) 
trifluoroacetic acid (TFA) / water (e) zinc chloride, sodium acetate / acetic acid, 120 
o
C, 1 – 4 
h; TFA / water.
[13,15] 
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2.2.2. Absorption spectra of Zn-DIGP and DIGP 
Zn-DIGP and DIGP exhibit intense bands in their absorption spectra. The strongest 
absorption band is the Q-band which originates from π-π* transitions. Zn-DIGP exhibits a 
single Q-band is in the range of 650-680 nm whereas DIGP shows a split Q-band in the same 
range due to the loss of molecular symmetry.
[7, 8]
 In the metal free derivative, two of the 
isoindole nitrogen carries hydrogen atoms and the other two are iminic type nitrogens that 
cause loss of molecular and therefore electronic symmetry. 
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Figure 2.3. Absorption spectra of Zn-DIGP and DIGP in DMSO. 
Both Zn-DIGP and DIGP exhibit excellent solubility and obeys beer’s law over the 
concentration of 0.3 – 1 μM in DMSO. The fluorescence quantum yield in DMSO was 
determined to be 0.28 and 0.25 for Zn-DIGP and DIGP respectively. In water, however, these 
compounds exhibit quenched fluorescence (Ф < 0.001) as a result of strong self-
association.
[9]
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Figure 2.4. (A) Excitation spectra (λem = 770 nm) and emission spectra (λex = 600 nm) of 
DIGP (B) Excitation spectra (λem = 750 nm) and emission spectra (λex = 600 nm) of Zn-DIGP 
in DMSO. 
2.2.3. Binding studies 
For DNA binding studies, G-quadruplex-forming sequences from the promoter region of c-
myc and human telomeric sequence (“Htelo”) were used. Both of these sequences are 
reported to form intramolecular G-quadruplexes in vitro.
[10-12]
 To evaluate G-quadruplex 
specificity, a mutated human telomeric sequence in which guanine was replaced by adenine 
(“Htelo-Mut”), as well as C-rich complement strands of c-Myc (“c-Myc-C”) and Htelo 
(“Htelo-C”) was used. According to circular dichroism, “Htelo-Mut” does not form a stable 
G-quadruplex structure. 
  
Name Sequence (5`-3`) 
c-Myc TGAGGGTGGGGAGGGTGGGGAA 
Htelo GTTA(GGGTTA)4GG 
Htelo-mut GTTA(GAGTTA)4GG 
Htelo-C CC(TAACCC)4TAAC 
c-Myc-C (C)4A(C)2TT(C)4A(C)3T(C)4A(C)3T(C)4 
Table 2.1. Sequences used in the binding studies. 
The stoichiometries of Zn-DIGP-G-quadruplex DNA binding were determined by monitoring 
the absorbance spectrum of 1 μM of Zn-DIGP upon addition of variable equivalents of c-
Myc, Htelo and Htelo-C DNA. With the addition of DNA, increase in the extinction 
coefficient at 690 nm was observed (Figure 2.5). The addition of 0.25 equivalents of c-Myc 
caused a 50% increase in the extinction coefficient. This suggests that two equivalents of Zn-
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DIGP bind to one equivalent c-Myc G-quadruplex. Similarly, Zn-DIGP was found to bind 
Htelo and Htelo-mut with stoichiometries of 1:1 and 4:1, respectively (Figure 2.5).  
 
 
Figure 2.5. Absorption spectra of 1 µM of Zn-DIGP upon titration with c-Myc (A), Htelo (B) 
and Htelo mutant (C). 
 
To evaluate the DNA affinity of Zn-DIGP, two types of binding assays were performed. The 
first assay monitors Zn-DIGP fluorescence upon addition of DNA. Upon binding DNA, Zn-
DIGP exhibits a large increase in fluorescence that can be monitored using excitation at 620 
nm and emission at 705 nm (Figure 2.6). The origin of this fluorescence enhancement is the 
reversal of Zn-DIGP self quenching in water by DNA binding (Figure 2.6).
[9]
 
 
Figure 2.6. Schematic of “turn-on” fluorescence of Zn-DIGP.[9] 
To measure DNA affinity, variable concentrations of nucleic acids were added to a fixed 
concentration (10 nM) of Zn-DIGP and fluorescence was monitored. As shown in Figure 2.7, 
a dramatic increase in Zn-DIGP fluorescence was observed upon adding nucleic acids to give 
highly fluorescent complexes (Ф = 0.06 ± 0.002). Figure 2.7 A) presents the data fitted with 
one phase exponential association and B) presents sigmoidal dose response curve fits. Zn-
DIGP binds to c-Myc and Htelo G-quadruplex structure at a very low concentration as 
compared to Htelo-Mut, c-Myc-C and tRNA mix. The trend of Zn-DIGP affinity was found 
to be c-Myc G-quadruplex > Htelo > Htelo-Mut > tRNA > calf thymus duplex DNA > c-
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Myc-C. By using 2:1 binding model, the analysis of these data revealed Kd of < 2nM to c-
Myc G-quadruplex. A limit must be reported since the probe concentration used for direct 
detection was higher than the apparent Kd values, and Zn-DIGP aggregation might cause an 
underestimated DNA binding affinity. Compared to other nucleic acids structures, such as 
calf thymus duplex DNA (CT-DNA) and tRNA, Zn-DIGP shows at least 1000-fold and 100-
fold G-quadruplex selectivity, respectively (Figure 2.7B).  
 
    
Figure 2.7. Fluorescence enhancement studies of 10 nM of Zn-DIGP upon addition of 
different nucleic acids. 
By means of fluorescence enhancement assays, it was not possible to test the selectivity of 
Zn-DIGP for G-quadruplex DNA in the presence of competitor DNA. To evaluate the 
selectivity of Zn-DIGP for G-quadruplex DNA in the presence of other nucleic acid 
structures, a fluorescence quenching assay was performed (Figure 2.8).  
 
 
Figure 2.8. Schematic of fluorescence quenching assays. 
The impressive G-quadruplex affinity and specificity of Zn-DIGP was confirmed by 
monitoring the fluorescence quenching of a 5'-fluorescein-labeled c-Myc DNA upon titration 
of Zn-DIGP in the presence or absence of a 1,000-fold nucleotide excess of CT-DNA (Figure 
2.9). The likely reason for fluorescence quenching was attributed to environmental changes 
of fluroescein upon binding of Zn-DIGP to c-Myc DNA. As a control, the known cationic 
A) B) 
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porphyrin Zn-TMPyP4 (20, Chapter 1) was also evaluated. Consistent with its promiscuous 
binding of nucleic acids,
[13]
 a 10-fold loss in the apparent binding affinity of Zn-TMPyP4 was 
observed in the presence of competitor CT-DNA (Figure 2.9A), while a high apparent 
affinity (Kd ≤ 2 nM) between Zn-DIGP and c-Myc was measured even in the presence of a 
1,000-fold excess of CT-DNA. The metal free derivative DIGP exhibited similar G-
quadruplex affinity but somewhat lower selectivity (Figure 2.9B). 
 
 
Figure 2.9. Fluorescence quenching of 10 nM solutions of the 5`-fluroescein-labeled c-Myc 
DNA (Ex: 495 nm, Em: 520 nm) with Zn-DIGP (A), Zn-TMPyP4 (A) or DIGP (B) in the 
presence of a 1000-fold excess of calf thymus DNA or 100-fold excess of tRNA.  
2.2.4. Cytotoxicity studies 
To determine a suitable concentration limit of Zn-DIGP and DIGP for cell-based studies, it is 
important to know the effective concentration at which 50% of treated cells die (EC50). EC50 
values for Zn-DIGP and DIGP were measured using resazurin reduction assays. Resazurin is 
a non-fluorescent dye which is reduced by mitochondrial enzymes to give fluorescent 
resofurin (Figure 2.10). The fluorescent resofurin can be quantified using an excitation and 
emission wavelength of 560 nm and 590 nm in spectrophotometer. 
 
N
O OO
O
N
O OO
.Na
+ .Na
[R]
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BLUE PINK  
Figure 2.10. Reduction of resazurin to resofurin by mitochondrial enzymes. 
Variable concentrations of Zn-DIGP and DIGP were titrated into B16F10, SKMEL-28, 
Macrophage or MCF-7 cell cultures. After incubation for 24 hours, resazurin was added and 
A) B) 
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incubated for an additional 2-3 hours. Measured fluorescence data was fit using a sigmoidal 
dose response curve to calculate EC50 values (Figure 2.11). A summary of EC50 values of Zn-
DIGP and DIGP for various cell lines is given in Table 2.2. 
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Figure 2.11. Cellular respiration of cell cultures treated with variable concentrations of Zn-
DIGP and DIGP for 24 hours. 
Cell lines Type Origin 
EC50 (µM) 
Zn-DIGP DIGP 
B16F10 Melanoma Mouse >80  41 ± 8 
SKMEL-28 Melanoma Human >80  39 ± 6 
MCF-7 Breast carcinoma Human >80 >20  
Macrophages Leukemia Human >80 >20  
Table 2.2. Summary of cytotoxicity values after Zn-DIGP- and DIGP- treatment in different 
cell lines for 24 hours.  
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It is possible that these molecules could exhibit genotoxicity and prevent cell divisions upon 
prolonged treatment; hence we decided to evaluate long-term cytotoxicity. For these studies, 
the seeding number of cells was reduced to 5’000 instead of 10’000. As shown in Figure 
2.12, the time-dependent inhibition of respiration is very similar. These results demonstrate 
that longer incubation periods of Zn-DIGP and DIGP have no significant effect of the EC50 
values for B16F10 cells. Microscopic examination of cells treated with 5 µM of Zn-DIGP did 
not show any change in morphology or growth rate even after 10 days. 
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Figure 2.12. Cellular respiration of B16F10 cells after treatment with Zn-DIGP (A) and DIGP 
(B) for 24-72 hours. 
2.2.5. Cellular localization 
Since Zn-DIGP and DIGP were not toxic in the low micromolar range, we decided to use 5 
µM to probe for G-quadruplex DNA in cells. SKMEL-28 cells were initially chosen because 
of their excellent morphology and easy handling. Utilizing its pro-fluorescent properties, Zn-
DIGP and DIGP can be added to cells and directly imaged using fluorescence microscopy. 
Initial studies with living SKMEL-28 cells reveal that Zn-DIGP stains the peri-nuclear 
regions of the living cells. DIGP exhibits weak fluorescence localized in cytoplasm and peri-
nuclear regions (Figure 2.13). These compounds were tested in different cell lines including 
Hela, SKMEL-28, B16F10 and SHSY5Y, and in all cases their uptake was observed with 
similar staining patterns in living cells (Figure 2.14). Unfortunately, Zn-DIGP did not stain in 
the nucleus of living cells making it difficult to probe for G-quadruplex structures. 
 
Based upon its localization in live cells, we speculated that Zn-DIGP can be endocytosed and 
trapped in lysozomes. To evaluate this possibility 60 nM of lysotracker was added to living 
cells followed by 5 μM of Zn-DIGP or DIGP. As shown in Figure 2.15, Zn-DIGP co-
A) B) 
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localizes with lysotracker demonstrating that Zn-DIGP is taken up in the lysozomes of living 
cells. Interestingly, live-cell fluorescence imaging of Zn-DIGP can cause changes in 
morphology and dye distribution during data collection due to its potent phototoxicity 
(Chapter 3).  
 
 
Figure 2.13. Live SKMEL-28 cells stained with 3 M of Zn-DIGP or DIGP for 3 hours. A) 
& D) Brightfield image. B) Zn-DIGP fluorescence (Ex = 620 nm, Em = 700 nm). E) DIGP 
fluorescence (Ex = 620 nm, Em = 700 nm). C) Composite image of A) – B). F) Composite 
image of D) -E). Scale bars represent 15 μm. 
One possibility for achieving better imaging results is to use fixed cells. Cell fixation is a 
popular method to identify the localization of probes while the cells are supposedly 
maintained in a static state. Although cellular dynamics are compromised, the precise 
localization of molecules can reveal cellular targets. Cells were therefore fixed using para-
formaldehyde (PFA) and then treated with DIGP or Zn-DIGP.  
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Figure 2.14. Wide-field fluorescence microscopy images of living A) HeLa, B) MCF7, C) 
SKMEL-28 cells treated with 3 µM of Zn-DIGP in PBS for 2 hours. D) SKMEL-28 cells 
treated with 10 µM of Zn-DIGP in supplemented RPMI media for 2 hours. 
 
 
 
Figure 2.15. Live cell images of SKMEL-28 cells treated with Zn-DIGP (A-D) or DIGP (E-
F). Initial incubation with 60 nM of lysotracker (Ex = 490 nm, Em = 520 nm) (C & G) for 90 
minutes and Zn-DIGP or DIGP (Ex = 620 nm, Em = 700 nm) (B & F) for 3 hours. A) and E) 
are bright-filed images. D) and H) provide overlays. Images taken in wide field microscope. 
Scale bars represent 30 μm. 
The addition of Zn-DIGP to fixed cells results in staining of perinuclear and nuclear regions. 
DIGP, in contrast, specifically localizes to the nucleus of fixed cells (Figure 2.16). Binding of 
DIGP to double stranded DNA in these cells is indicated by a competition experiments where 
the fixed cells were first treated with DIGP for 3 hours followed by addition of duplex 
specific dye Hoechst 33342. As shown in Figure 2.17, the addition of Hoechst 33342 causes 
relocalization of DIGP to the nucleolus and cytoplasm. Such relocalization was not observed 
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for Zn-DIGP (Figure 2.18). Consistent with in vitro binding assays (Figure 2.9), these results 
demonstrate that DIGP binds to cellular duplex DNA while Zn-DIGP does not. 
 
  
Figure 2.16. Fixed SKMEL-28 cells stained with 3 µM of DIGP or Zn-DIGP for 3 hours. A) 
& D) Bright field image. B) Zn-DIGP fluorescence (Ex = 620 nm, Em = 700 nm). E) DIGP 
fluorescence. C) Composite image of A) – B). F) Composite image of D) - E), Scale bars 
represent 30 μm. 
 
Figure 2.17. Fixed SKMEL-28 cells treated with 3 µM of DIGP for 3 hours before (A-C) and 
after addition of Hoechst 33342 (D-G). A) and D) Fluroescence of DIGP (Ex = 620 nm, Em 
= 700 nm); B) and E) Bright field-images F) Fluorescence of Hoechst 33342 (Ex = 360 nm, 
Em = 470 nm); C) and G) Composite images of bright-field and fluorescence. Scale bars 
represent 30 μm. 
Zn-DIGP has much lower dissociation constant for binding G-quadruplex (Kd < 2 nM) than 
the concentrations used for these cell-staining experiments (3 µM). Fixed cells were therefore 
treated with variable concentrations (3 µM, 300 nM and 30 nM)  of Zn-DIGP or DIGP and 
imaged using fluorescence microscopy. Consistent with initial studies, 3 µM of Zn-DIGP 
stains mostly the peri-nuclear region of fixed cells, but 300 nM caused staining of the 
nucleolus (Figure 2.19). Cells treated with 30 nM of Zn-DIGP exhibited weak fluorescent 
F
 
 D
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staining, similar in magnitude to the auto-fluorescence of SKMEL-28 cells. Consistent with 
in vitro binding assays (Figure 2.9), DIGP can bind weakly to duplex DNA. When treated 
with 3 µM and 300 nM of DIGP, nuclear staining was observed (Figure 2.19 D-E). Cells 
treated with 30 nM of DIGP, in contrast, exhibited irregular staining of the cell surface 
(Figure 2.19 F). 
 
 
Figure 2.18. Fixed SKMEL-28 cells treated with 3 µM of Zn-DIGP for 3 hours, before (A-C) 
and after addition of Hoechst 33342 (D-G). A) and D) Fluorescence of Zn-DIGP (Ex = 620 
nm, Em = 700 nm); B) and E) Bright field-images F) Fluorescence of Hoechst 33342 (Ex = 
360 nm, Em = 470 nm); C) and G) Composite images of bright-field and fluorescence. 
 
 
Figure 2.19. Wide-field fluorescence microscopy images of fixed SKMEL-28 cells treated 
with Zn-DIGP (3 µM (A), 300 nM (B), 30 nM (C)) or DIGP (3 µM (D), 300 nM (E), 30 nM 
(F)) for 3 hours. 
Chapter 2   62 
 
2.2.6. Microarray analyses 
As the cellular imaging studies did not provide direct evidence for the ability of Zn-DIGP or 
DIGP to specifically stain G-quadruplex DNA inside living cells, we used an indirect 
approach to test for the presence of G-quadruplexes in the promoter regions of genes. Prof. 
Hurley and coworkers previously reported that G-quadruplex sequences located in the 
promoter regions of oncogenes can be involved in gene regulation.
[12]
 To provide a relatively 
unbiased approach for identifying the Zn-DIGP’s ability to regulate global gene transcription, 
microarray analyses were performed. It was expected that the results from the microarray 
analyses could be correlated with the presence of putative G-quadruplexes in the promoter 
region of each gene.  
 
Microarray analysis is already recognized as a powerful technique to identify the impact of 
genotoxic compounds. As previously reported for cisplatin,
[14]
 experiments were conducted 
using B16F10 cells in media containing 2% fetal calf serum (FCS). mRNA was harvested 
from cells grown in the presence/absence of Zn-DIGP, DIGP, or cisplatin. Extracted mRNA 
was subjected cDNA synthesis using a Cy3- or Cy5- labeled primer (Table 2.3). The cDNA 
was then subjected to hybridization with Agilent whole-genome mouse arrays and 
fluorescence intensities were collected in a scanner. 
  
A summary of microarray results are shown in Figure 2.20. Each dot in these graphs 
represents a single gene. The dots in the region of the diagonal line are the genes that show 
no changes in expression levels. The genes above and below the diagonal line represent 
upregulated genes and downregulated genes, respectively. The number of genes that exhibit 
changes in gene expression of 2-fold or more relative to untreated samples is provided in 
Table 2.3. As reported previously, cisplatin treatment causes 2-fold changes in expression for 
more than 750 genes, whereas Zn-DIGP affected the expression of only 40 genes. A second 
trial using primers with inversion of the Cy3/Cy5 used in cDNA synthesis revealed only 24  
genes with 2-fold changes in expression upon Zn-DIGP addition. Among the two Zn-DIGP 
trials, only 2 genes were found to be consistent: Sqstm1 and CXCL10. Both of these genes 
lack G-quadruplex motifs in their promoter regions, 5`- and 3`-UTRs. In addition, database 
search for the presence of G-quadruplex forming motifs among all positive hits in both trials 
revealed no correlation between the presence of G-quadruplex forming sequences in the 
promoters and changes in gene expression. 
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Figure 2.20. Dot plots of microarray analysis after (A and B) Zn-DIGP-, (C) DIGP- and (D) 
cisplatin-treatment of B16F10 cells for 24 hours. 
 
Compounds Cy 3 Cy 5 Total Upregulated Downregulated 
Zn-DIGP -1 Untreated Zn-DIGP 52 42 10 
DIGP Untreated DIGP 24 14 10 
Cisplatin Cisplatin Untreated 743 230 513 
Zn-DIGP -2 Zn-DIGP Untreated 28 10 18 
Table 2.3. Summary of total number genes that show at least 2-fold changes in mRNA levels 
after treatment with Zn-DIGP, DIGP, or cisplatin in B16F10 cells. 
 
A) B) 
C) D) 
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2.2.6. qRT-PCR 
The results of microarray analyses were further evaluated by quantitative real time PCR 
(qRT-PCR). These studies confirmed that Zn-DIGP causes 2-fold overexpression of 
CXCL10, but no change in SQSTM1. 
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Figure 2.21. Relative mRNA expression levels of CXCL10 and SQSTM1 according to qRT-
PCR in B16F10 cells treated with DIGP or Zn-DIGP for 24 hours. 
Further qRT-PCR experiments revealed that Zn-DIGP-mediated changes of CXCL10 mRNA 
were both dose dependent and time dependent (Figure 2.22). The biological importance of 
this discovery is presented in Chapter 4. 
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Figure 2.22. Changes in relative CXCL10 mRNA abundance according to qRT PCR. A) Zn-
DIGP concentration-dependent changes after 24 hours of treatment. B) Time-dependent 
changes in mRNA abundance in the presence of 5 μM of Zn-DIGP. The results are with 
respect to untreated cells and normalized to two different housekeeping genes (β-actin and 
SDHA).  
Having confirmed the microarray “hit” of CXCL10 for Zn-DIGP treated cells, the 
conspicuous absence of “hits” for genes reported to have functional G-quadruplex sequence 
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(PQS) in their promoter regions was tested next. Changes in the expression of selected genes 
such as MMP-2, MTA-1, RB1, VEGF and c-Myc (Table 2.4) were evaluated using qRT-PCR 
upon addition of variable concentrations of Zn-DIGP to B16F10 cells.  
Table 2.4. Positions of putative G-quadruplex forming motifs and their sequences present in 
the promoter regions of different oncogenes. TSS: Transcription start site; TES: Transcription 
end site. 
As shown in Figure 2.23, 5 µM of Zn-DIGP caused only small increases in MMP-2, MTA-1 
and RB1 over expression of MMP-2, MTA-1, and RB-1. However, none of these changes 
were dose dependent. Since c-Myc is a well studied model system for G-quadruplex-
dependent transcriptional regulation,
[12]
 time dependent studies using various doses of Zn-
DIGP and DIGP were performed in B16F10 cells. Addition of 25 μM of DIGP to B16F10 for 
48 hours caused decreased c-Myc mRNA abundance. Since this concentration is close to the 
EC50 of DIGP (35 μM), we concluded the effect is probably G-quadruplex independent.
[12]
 
No Gene Gene 
location 
TSS TES Sequence ( 5`-3`) 
1. MMP-2 Promoter -68  GGGCGAGTAGGGGGGTGGGGCAGAG 
AGGGGCGGG 
  Promoter -40  CCCGAGTGCGCCCCCCGCCCCCAGCCCC 
  3`UTR  -1009 CCCAGGCGCCCCTTCCCCCTCCAAT 
CCCACCAACCC 
  3`UTR  -508 CCCGCTCAGCCCTCCCTGCCCCTCCC 
2. MTA-1 Promoter -257  GGGGCACAGGGAGGGATCACCAGGG 
  Promoter -90  
 
GGGAAGGGGCGCGCGGGCCGCG 
GGCGGCGCGGGG 
 
  Promoter -36  CCCGAGGCCCCTCCCCGCCGCCC 
  3`UTR  -389 CCCCCCGCCCCTCGCCCG 
CCCACACGGCCCCTTCCCAG 
CCAGCCCGCCGCCCGCCCC 
3. RB1 Promoter -530  CCCCACAGCTCCCTCCCTTCCTTTCCC 
4. VEGFA Promoter -388  CCCTCTCCCCACCCGTCCC 
  Promtoter -58  GGGGCGGGCCGGGGGCGGGGTCC 
CGGCGGGG 
  3`UTR  -413 CCCTCCCCGATCCCCTGGCTCCCC 
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Figure 2.23. Changes in mRNA abundance of selected oncogenes according to qRT-PCR 
upon addition of various concentrations of Zn-DIGP for 24 hours in B16F10 cells. 
To address the possibility of cell type-specific effects, dependency on cell lines, we decided 
to evaluate the ability of Zn-DIGP and DIGP to effect c-Myc gene expression in SKMEL-28 
cells. As shown in Figure 2.25, Zn-DIGP and DIGP did not cause any significant changes in 
the c-Myc mRNA levels as compared to untreated samples. 
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Figure 2.24. Relative levels of c-Myc mRNA according to qRT-PCR following addition of 
different concentrations of Zn-DIGP-/DIGP- to B16F10 cells for 2, 24 or 48 hours. 
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Figure 2.25. Relative levels of c-Myc mRNA according to qRT-PCR upon addition of Zn-
DIGP-/DIGP- to SKMEL-28 cells for 24 hours. 
2.3. Ammonium phthalocyanines  
In contrast to previously-reported studies using TmPyP4 (20, Chapter 1),
[15]
 Zn-DIGP and 
DIGP did not exhibit the ability to affect gene expression in a G-quadruplex-dependent 
fashion. However, the limited number of mRNA changes according to microarray analyses 
prevented any statistically-meaningful conclusion. Therefore, we decided to evaluate 
ammonium phthalocyanine derivatives (Figure 2.26). It has been previously reported that 
octa-ammonium phthalocyanines are G-quadruplex ligands (Kd = 120 nM).
[16]
 These 
compounds can cause a G-quadruplex conformational change from anti-parallel to parallel 
structures and can induce G-quadruplex folding in the absence of potassium ions.
[17]
 No cell-
based studies of the octa-ammonium phthalocyanines were reported. Recently, Duan and 
coworkers reported “Zn-APc” (9) and showed it binds with duplex DNA with moderate 
affinity (Ka =1.33 x 10
5 
M
-1
).
[14]
 However, no evaluation of its potential ability to selectively 
bind to G-quadruplex DNA was reported. 
 
2.3.1. Synthesis 
Tetra(trimethylammonio)phthalocyanato zinc tetratrifluoroacetate (Zn-APc, 9) and tetra 
(trimethylammonio)phthalocyanato tetratrifluoroacetate (APc, 11) were synthesized as 
illustrated in Figure 2.26. Macrocycle 7 was synthesized by molybdenum catalyzed 
macrocyclization. It was then reduced using Na2S to give 8. Methylation of each amino group 
was achieved using excess of CH3I in DMF to give Zn-APc (9). This product was heated at 
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high temperature in pyridine HCl to give the metal-free product (11). Synthesis and 
purification of 9 and 11 were performed by Raul Pereira (Figure 2.26).  
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Figure 2.26. Synthetic route for the synthesis of zinc (Zn-APc) and zinc-free quaternary 
ammonium phthalocyanines (APc). Reagents and conditions: (a) zinc chloride (0.25 equiv), 
ammonium molybdate (0.1 mol %), nitrobenzene, 185 
o
C, 4 h, 98%; (b) sodium sulfide (12 
eq), DMF, 60 
o
C, 1.5 h, 75%; (c) pyridine/pyridinium-HCl, 120 
o
C, 17 h; (d and e) excess of 
methyl iodide, DMF, 25
 o
C, 51h  
2.3.2. Binding studies 
Fluorescence-quenching assays were performed as described in Section 2.2.3 with Zn-APc 
and APc. Zn-APc displayed high affinity for G-quadruplex DNA (Figure 2.27). The binding 
isotherm was identical in the presence or absence of a 1’000-fold excess calf thymus DNA, 
suggesting excellent specificity of Zn-APc to G-quadruplex DNA. The addition of tRNA 
caused a small reduction in apparent G-quadruplex affinity. The dissociation constants are 
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summarized in Table 2.5. Together with the similar results obtained for Zn-DIGP (Figure 
2.9), these data demonstrate that the substituents on the phthalocyanine scaffold do not have a 
dramatic influence on the G-quadruplex binding affinity or specificity in vitro.  
 
Interestingly, APc displayed a 5-fold higher affinity for G-quadruplex DNA than DIGP 
(Figure 2.9). In addition, a smaller loss in apparent binding affinity was observed for APc in 
the presence of competitor nucleic acids (Figure 2.27 B) as compared to DIGP (Figure 2.9). 
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Figure 2.27. Fluorescence quenching of 10 nM solution of the 5`-fluroescein labeled c-Myc 
DNA by Zn-APc and APc in the presence of 1’000-fold excess of calf thymus DNA or 100-
fold excess of tRNA. 
S.No Compound 
Kd (nM) 
c-Myc c-Myc + CT DNA c-Myc + tRNA 
1 Zn-APc < 2 < 2 21.3 ± 3 
2. APc < 2 27 ± 2 53 ± 5 
Table 2.5. Binding affinity and selectivity of Zn-APc and APc to c-Myc G-quadruplex in the 
presence of duplex DNA and tRNA. 
2.3.3. Cytotoxicity studies  
To identify suitable concentrations for cell-based studies, the toxicity of Zn-APc and APc 
was evaluated using resazurin-based cytotoxicity assays in B16F10 cells. The results 
demonstrate that Zn-APc and APc exhibited little or no toxicity upto 80 µM (Figure 2.28). 
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Figure 2.28. Cellular respiration of B16F10 cells upon treatment with Zn-APc and APc for 24 
hours. 
2.3.4. Cellular Localization 
Since Zn-APc and APc were not toxic in the low-micromolar range, their ability to probe G-
quadruplex DNA in cells was assayed using fluorescence microscopy. Similar to Zn-DIGP 
and DIGP, Zn-APc and APc were also pro-fluorescent and they could be simply added to  
cells and imaged directly. Depending on the concentration of the molecules and whether 
living or fixed cells were used, Zn-APc and APc show variable localization. In live cells,  Zn-
APc and APc did not reveal any detectable fluorescence in the cells (Figure 2.29 and Figure 
2.30). Brief exposure of light (few seconds) from the microscope cause increased 
fluorescence, and longer exposure times caused the cells to undergo morphological changes 
consistent with phototoxicity. The reasons of morphological changes could be due to the 
ability of Zn-APc and APc to behave as photosensitiers. 
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Figure 2.29. Imaging of live HeLa cells upon treatment with 3 µM of Zn-APc for 3 hours. A: 
Bright field images B: fluorescence images (Ex = 620 nm, Em = 700 nm). Images 1-3 
demonstrate the effects of increasing light exposure from the microscope. Scale bars 
represent 30 μm. 
 
Figure 2.30. Imaging of live HeLa cells upon treatment with 3 µM of APc for 3 hours. A: 
Bright field images B: fluorescence images (Ex = 620 nm, Em = 700 nm). Images 1-4 
demonstrate the effects of increasing light exposure from the microscope. Scale bars 
represent 30 μm. 
 
The ability of Zn-APc and APc to behave as fluorescent probe was then evaluated in fixed 
SKMEL-28 cells. Interestingly, the addition of 3 µM, 300 nM and 30 nM of Zn-APc results 
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in nucleolar staining, while the addition of 3 μM and 300 nM of APc causes nuclear staining. 
At 30 nM, APc causes nucleolar staining (Figure 2.31). 
 
Figure 2.31. Wide field microscopy images of fixed SKMEL-28 cells treated with Zn-APc (3 
µM (A), 300 nM (B), 30 nM (C)) or APc (3 µM (D), 300 nM (E), 30 nM (F)) for 3 hours. 
Images were collected using Ex = 620 nm, Em = 700 nm. 
2.3.5. DNAse/RNAse digestion 
Zn-APc was localized in nucleolus which is known to contain repetitive G-rich sequence.
[18]
 
In fixed cells, we speculated that Zn-APc may bind to G-quadruplex structures formed from 
the rDNA repeats. To test this hypothesis, fixed cells were subjected to DNAse and RNase 
treatment, followed by 30 nM of Zn-APc for 3 hours. As a control, the double stranded DNA 
specific dye Hoechst 33342 was also included. As expected, the DNase treated cells show 
diminished staining by Hoechst 33342 whereas RNase-treated cells still show strong nuclear 
staining by Hoechst 33342 (Figure 2.34; blue color). When Zn-APc was added to DNase 
treated cells, it was localized in nucleolus, similar to control cells. The addition of Zn-APc to 
RNAse-treated cells resulted in nuclear, not nucleolar, staining. These results suggest that Zn-
APc prefers to bind RNA contained within the nucleolus in fixed SKMEL-28 cells (Figure 
2.32). 
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Figure 2.32. DNase and RNase digestion of fixed SKMEL-28 cells followed by addition 20 
μM of Hoechst 33342 and 30 nM of Zn-APc for probing localization. Blue represents nucleus 
specific dye Hoechst 33342 (Ex = 360 nm, Em = 470 nm), Red represents Zn-APc (Ex = 620 
nm, Em = 700 nm). 
2.3.6. Microarray analyses 
To probe promoter G-quadruplexes using Zn-APc and APc, we conducted global gene RNA 
expression analysis in B16F10 cells treated with 5 μM of Zn-APc or APc for 24 hours in 
media containing 2% FCS. The mRNA was extracted from treated and untreated samples, 
and subjected to cDNA synthesis using labeled primers (Table 2.6). The labeled cDNA 
samples were then allowed to hybridize to whole genome mouse arrays from agilent, and the 
fluorescence intensities of Cy3 and Cy5 were recorded with a scanner. 
 
Cy 3 Cy 5 
Zn-APc-1 Untreated 1 
APc -1 Untreated 1 
Zn-APc-2 Untreated 2 
APc-2 Untreated 2 
Table 2.6. cDNA labels used in microarray analyses. 
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Figure 2.33. Microarray analyses of two different trials of Zn-APc (A1&A2) and APc 
(B1&B2) treated B16F10 cells. 
A summary of these microarray analyses is depicted in Figure 2.33. Each dot represents one 
gene and the diagonal line represents no changes in RNA expression between treated and 
untreated samples. The genes above and below the diagonal line indicate higher or lower 
RNA quantities as compared to untreated samples, respectively. The dots further from the 
diagonal indicate larger changes that were observed mostly for APc-treated samples (Figure 
2.33B). The number of genes that exhibited at least 2-fold changes in RNA expression upon 
addition of Zn-APc and APc addition are shown in Table 2.7. Only the genes that showed 
significant expression (p < 0.001) between both trials are included. 
 
 
 
 
B1) B2) 
A1) A2) 
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>2-fold Up-regulated Down-regulated Total 
Zn-APc 12 287 299 
APc 798 1302 2102 
Table 2.7. Results of microarray analyses summarizing the number of genes with 2-fold or 
larger changes in mRNA expression upon addition of Zn-APc or APc to B16F10 cells. 
 
Genes that exhibited 2-fold or larger changes in mRNA expression were analyzed for the 
presence of PQSs in their promoter regions, 5`-UTR, 3`-UTR using the quadparser database. 
This database contains information on whether a particular gene has PQS present in 
promoter, 5`UTR, or 3`UTR. The putative PQS consensus used for this analysis was G3+N1-
7G3+N1-7G3+N1-7G3+. The results demonstrate that almost 50% of the genes affected by Zn-
APc contain at least one G-quadruplex forming sequence either in promoter, 5`-UTR or 3`-
UTR. Some of the genes were uncharacterized and therefore not available in quadparser 
database (Table 2.8). 
 
  Location 
Number of putative G-quadruplexes 
Total Down-regulated Up-regulated 
Promoter 99 (39%) 96 3 
5`-UTR 12 (4.8%) 12 0 
3`-UTR 39 (15.7%) 35 4 
No G-quadruplex 127 (51%) 122 5 
Uncharacterized genes 51 48 3 
Table 2.8. The number of genes that contain G-quadruplex motifs that exhibit at least 2-fold 
changes in mRNA quantities upon addition of 5 μM of Zn-APc. 
The hits for the presence of at least one PQS in the promoter region were analyzed further. 
The PQS frequency near the promoter was plotted against the distance from transcription 
start site (up to 1’000 bp). As shown in Figure 2.34, the results demonstrate that a high 
frequency of G-quadruplex motifs were present within 200 bp of the transcription start site 
(TSS). A similar pattern was observed for all genes containing at least one PQS in the 
promoter.
[19]
 The enrichment of PQS proximal to TSSs could possibly indicate quadruplexes 
that functions as switches of transcription.
[12, 19]
 However, if this model was accurate, the 
addition of G-quadruplex binder should affect PQS-containing promoters more frequently 
than promoters lacking a PQS. This was not observed. Only 39% of the 299 genes affected by 
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Zn-APc addition contained at least one PQS near the promoter. This value significantly lower 
than the 42% of all genes that contain at least one PQS within 1’000 bp of the TSS. The 
results suggest that Zn-APc did not regulate gene expression according to the promoter PQS 
model previously proposed. 
[12, 19]
 
 
Next, PQS were searched in the 3’-UTR and 5’-UTR in Zn-APc targeted genes that showed 
2-fold changes. Unexpectedly, only 4% and 12.2% of the positive hits possessed PQS in 5`-
UTR and 3’-UTR respectively. These values are less than the 12% and 15.3% reported to be 
present in all genes. These results suggest that Zn-APc-targeted genes were independent of 
the presence of G-quadruplex sequence present in the promoter, 3`-UTR, or 5`-UTR. 
 
 
Figure 2.34. Graph showing the number of putative G-quadruplex motifs present in each of 
the 100 bp upstream of the transcription start site of 299 genes that exhibited 2-fold or larger 
changes in mRNA abundance upon addition of Zn-APc to B16F10 cells.   
As shown in Figure 2.33, the addition of APc caused much larger changes in mRNA 
expression in B16F10 cells than Zn-APc. These results are summarized in Table 2.9 - 2.11. 
To make the data analysis more feasible, genes with a 3-fold or larger changes in mRNA 
abundance were analyzed for the presence of PQSs in their promoter regions, 5`-UTR and 3`-
UTR using quadparser.   
 
Results in Table 2.10 illustrate that out of 667 total genes, only 477 were characterized. 
Among the characterized genes, 188 genes have at least one “promoter” PQS within 1’000 bp 
upstream of the TSS (39%). This frequency was again lower than the overall frequency of 
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PQS from the TSS of all genes in the mouse genome.
[20]
 A similar analysis of these 477 genes 
for PQS frequency in the 5`-UTR and 3`-UTR suggested that 5.6% and 13.4% of 
characterized genes affected by APc contain at least one PQS in 3`-UTR and 5`-UTR 
respectively. This frequency was again lower than the global frequency of all characterized 
genes containing at least one PQS in the promoter, 5`-UTR or 3`-UTR. Similar to Zn-APc, 
the results obtained with APc indicate that there is no correlation between the APc-targeted 
genes and PQS occurrence in the promoter, 3`-UTR, or 5`-UTR (Table 2.10). 
 
Number of genes Total Down-regulated Up-regulated 
        > 4-fold 172 102 70 
> 3-fold  667 417 250 
> 2-fold 2271 1404 867 
Table 2.9. The total number of genes affected by 5 μM of APc in B16F10 cells according to 
microarray analyses. 
 
Location 
Number of genes 
Total Down-regulated Up-regulated 
Characterized genes 477 303 174 
Promoter PQS 188 (39.4%) 134 54 
5`-UTR PQS 28 (5.6%) 20 8 
3`-UTR PQS 64 (13.3%) 11 53 
No PQS 247 (51%) 140 107 
Uncharacterized genes 190 114 76 
Table 2.10. The number of genes that contain putative G-quadruplex motifs in the promoter 
regions that exhibit at least 3-fold changes in mRNA abundance upon addition of 5 μM of 
APc. 
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Location 
Number of genes 
Total Down Up 
Characterized genes 125 77 48 
Intron PQS 66 (52%) 46 20 
Intron PQS – 1st 100 bp 22 (17.6%) 17 5 
No PQS 59 (47.2%) 31 28 
Uncharacterized genes 47 25 22 
Table 2.11. The number of genes that contain putative G-quadruplex motifs in the introns that 
exhibit at least 4-fold changes in mRNA abundance upon addition of 5 μM of APc. 
 
Previous studies have reported a 16% frequency of genes containing at least one PQS in the 
first 100 bp of the first intron. Maizels and coworkers proposed that G-quadruplex formation 
in these regions could potentially affect the completion of pre-mRNA transcription.
[21]
 We 
therefore analyzed the genes affected by APc addition for PQS sequences present in the first 
intron (Table 2.11). Approximately 18% of the genes possess at least one PQS, this frequency 
is very similar to the genomic average (16%). So the addition of APc did not have bias on 
intron specific G-quadruplex mediated gene expression.  
 
Among the APc affected genes, we speculated that the 39% of genes that possess a promoter 
PQS affected would be independent of 20% of genes that possess an intronic PQS. The genes 
that showed 4-fold changes in mRNA abundance were analyzed in this way. The genes that 
contain at least one promoter PQS, intronic and/or promoter PQS are represented by a Venn 
diagram. The results shown in Figure 2.35 demonstrate that no significant correlation was 
observed between APc targeted genes and their respective PQSs. 
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Figure 2.35. Venn diagram representing the number of genes affected by APc (> 4-fold) that 
have PQS in the promoter (Red), and first intron (Blue). Common genes are shown 
interjunction of two circles. 
2.4. Conclusion 
Zn-DIGP has favorable “turn-on” fluorescence properties. Zn-DIGP binds to G-quadruplex 
DNA with high affinity (Kd < 2 nM) and selectivity. DIGP is less selective than Zn-DIGP, as 
it binds to duplex DNA and tRNA. Zn-DIGP and DIGP are both capable of being taken up by 
living cells. Zn-DIGP was mostly localized in lysozomes of living cells, and in perinuclear 
regions of fixed cells. Microarray analyses were performed to identify the possible target 
genes of these compounds. Both Zn-DIGP and DIGP resulted in differential expression of 
only very few genes. Among which, only one gene: CXCL10 was consistently up regulated. 
No correlation was observed among the genes and putative G-quadruplex forming sequences 
in their promoters. The possible reasons for over expression of CXCL10 will be addressed in 
the Chapter 4. 
 
28 38 18 
11 21 25 13 7 7 
Total 
Down - regulation Up-regulation 
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Similar to Zn-DIGP and DIGP, Zn-APc and APc bind to G-quadruplex DNA with high 
affinity. They are also relatively non-toxic, cell permeable probes that localizes in peri-
nuclear regions of living cells. In fixed cells, APc and Zn-APc stain RNA in the nucleolus. 
Microarray analyses resulted in as many as 299 genes for Zn-APc and 2’000 genes for APc 
that gave 2-fold or larger changes in mRNA expression. However, no correlation between the 
mRNA quantities and the presence of G-quadruplex forming motifs in promoter, intron, 
5`UTR or 3`UTR was observed. 
 
None of the four phthalocyanine molecules therefore provide evidence for G-quadruplexes as 
a regulatory element for gene expression in mammalian cells. These results call into question 
previous studies that have proposed G-quadruplex structures as gene regulators of 
mammalian cells. 
2.5. Experimental Methods 
2.5.1. Binding assays 
DNA oligos (~30 M) were heated in a “TKE” buffer containing 50 mM Tris-HCl (pH 7.4) 
150 mM KCl, and 0.5 mM EDTA to 99 
o
C then slowly cooled to room temperature (over 
approximately 3 hrs) before use. tRNA Sigma Type X-SA was dissolved into TKE at room 
temperature and quantified using   = 9’640 cm-1 M ntd-1 (25 oC). Type I, highly polymerized 
calf thymus DNA was dissolved into TKE at 37 
oC overnight (12 hrs), centrifuged at 20’000 
x g, and the supernatant diluted 2X into TKE buffer. The solution was then sonicated for 2 
minutes in a TPC-15 bath sonicator from Telsonic Ultrasonics, and the solution quantified 
using   = 6’550 cm-1 M ntd-1 (25 oC). 
Oligo Name      Sequence     (cm-1M-1) (99 oC)   (cm-1M-1) (25 oC) 
c-Myc      TGAGGGTGGGGAGGGTGGGGAA     229’900          160’900 
Fl-cMyc        Flu-TGAGGGTGGGGAGGGTGGGGAA 262’400                   193’400 
Htelo                              GTTA(GGGTTA)4GG                   306’900                    276’200 
Htelo-mut                      GTTA(GAGTTA)4GG                     319’300                 287’400 
Htelo-C:                          CC(TAACCC)4TAAC                         -                          274’000 
c-Myc-long:   (G)4A(G)3T(G)4A(G)3T(G)4AA(G)2T(G)4       321’500                   257’200 
c-Myc-C:       (C)4A(C)2TT(C)4A(C)3T(C)4A(C)3T(C)4              -                           242’600 
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All titrations were conducted at room temperature in a “TKE” buffer containing 50 mM Tris-
HCl (pH 7.4), 150 mM KCl, and 0.5 mM EDTA. Absorbance and emission spectra were 
collected using a SpectraMax MP5 spectrophotometer in Greiner Bio-one UV-Star 96-well 
plates (final volume = 200 L). Fluorescence binding assays were conducted in Corning 384-
well black polystyrene assay plates with non-binding surfaces (final volume = 80 L). For 
absorbance and fluorescence enhancement experiments, a 2X solution of Zn-DIGP (2 M or 
20 nM) was added to the plate followed by one volume of DNA solution and mixed once by 
pipette. Plates were read multiple times to ensure equilibration was reached. Rapid 
equilibration of all binding interactions (after 30 minutes or less) was observed in all cases. 
For the fluorescence quenching experiments, color-free (natural) 1.7 mL polypropylene tubes 
(high clarity) obtained from Milian were used for making serial dilutions of each compound. 
An equal volume of Zn-DIGP and 20 nM solution of the fluorescein-containing DNA were 
mixed in a 384-well plate containing by pipetting exactly once. Measures had to be taken to 
circumvent some binding of Zn-DIGP to plastic tubes and pipette tips during their handling. 
This problem is most pronounced at concentrations below 100 nM and can be avoided by 
making two serial dilutions in the same plastic tubes. After incubating for one hour, the first 
dilutions were discarded and each tube kept for a second serial dilution. This pre-saturates 
each tube without increasing the concentration of Zn-DIGP. We have conducted this pre-
saturation up to four times, but the same results were obtained after a single pre-saturation. 
2.5.2. Cell Lines and Media 
Murine metastatic B16F10 melanoma cell line were cultured in Dulbecco’s modified Eagle’s 
medium (DMEM; Invitrogen, Carlsbad, CA, USA) supplemented with 10% or2% heat-
inactivated fetal calf serum (FCS) and 100 U/ml of penicillin (Sigma), 100 µg/ml of 
Streptomycin (Sigma). SK-Mel-28 cells were grown in Roswell Park Memorial Institute 
medium (RPMI) supplemented with 10% FCS, 2mM L-Glutamine, 100 U/ml of penicillin 
(Sigma), 100 µg/mL streptomycin (Sigma), and 1mM sodium pyruvate. All cell lines were 
grown in 5% CO2 at 37°C.  MCF-7 cells were grown in MEM media with 10% FCS, 2mM L-
Glutamine, 100 U/ml of penicillin (Sigma), 100 µg/mL streptomycin (Sigma), and 1mM 
sodium pyruvate. SHSY5Y were grown in DMEM with supplemented with 10% heat-
inactivated FCS and 100 U/ml of penicillin, 100 µg/ml of Streptomycin. 
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2.5.3. Cytotoxicity studies 
B16F10 or SKMEL-28 cells (10’000 cells) were seeded in 96 well plates and grown for 24 
hours prior to their incubation with variable concentrations of Zn-DIGP or DIGP for 
appropriate time (usually 24 hours). The cellular media were replaced with fresh media 
containing 86 µM resazurin (Sigma). Fluorescence was measured after 2-4 hours using M5 
spectrophotometer with excitation at 560 nm, emission at 590 nm, and a 570 nm cutoff filter. 
All samples were compared to untreated cells to calculate the % decrease in respiration - 
from which EC50 were calculated. 
2.5.4. Quantum Yields of Emission 
Quantum yields for photoluminescence were calculated according to: 
Ф =  Ф𝐑  ×  
𝐈
𝐈𝐑
 ×
𝐎𝐃𝐑
𝐎𝐃 ×
𝐧𝟐
𝐧𝐑
𝟐  
Where Ф = quantum yield; R = reference; I = area of emission; OD = optical density; n = 
refractive index of solvent. As a reference compound, Cy5 (Ф = 0.27) in PBS was used.[1] 
DIGP derivatives were diluted into DMSO to an optical density of 0.014 - 0.02 at a common 
wavelength of excitation (620 nm). Background-corrected emission spectra were integrated 
between 630 – 800 nm using a Spectramax M5 spectrophotometer.  
2.5.5. Microscopy 
B16F10 cells (~15’000) were seeded in Labtek 8 chambered plate (Nunc) in media 
containing 10% FCS. After overnight growth, media was replaced with fresh media 
containing 3μM Zn-DIGP and incubated for 24 hours. Images of the unfixed cells were taken 
in Leica LX wide field microscope before irradiation and 3 hours following irradiation. For 
fixation, 3% PFA was added for 15 minutes and washed thrice with PBS. Cells were then 
added with appropriate concentration of compound and imaged in either fluorescent or 
confocal microscope. 
2.5.6. Microarray Analyses 
B16F10 cells (~2 10
5
 cells) were seeded in T25 flasks and grown under standard 
conditions (see Cell Lines and Media section) for 24 hours. Zn-DIGP was added to a final 
concentration of 5 µM (0.1 % DMSO) in fresh media and the cells grown under standard 
conditions for 24 hours. The negative control contained only media and DMSO carrier. As a 
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positive control, 100 µM of cisplatin was used.
[22]
 mRNA was extracted from the isolated 
cells using a High Pure mRNA Isolation Kit (Roche) according to the manufacturer’s 
protocol. The quality of the isolated RNA was determined with a NanoDrop ND 1000 
(NanoDrop Technologies) and a Bioanalyzer 2100 (Agilent). Only samples having a 260 nm / 
280 nm ratio between 1.8 – 2.1, and a 28S/18S ratio of 1.5 – 2 were further processed. Total 
RNA samples (100 ng) were reverse-transcribed into ds cDNA. To assess sample quality, 
appropriate spike-in controls were included (Agilent). The cDNA were transcribed back into 
RNA in presence of Cy3 and Cy5-labeled primers using a Low Input Quick Amp labeling, 
two-color kit (Agilent). The labeled cRNA was purified using an RNeasy mini kit (Qiagen) 
and its quality and quantity was determined using NanoDrop ND 1000 and Bioanalyzer 2100. 
Only cRNA samples with a total cRNA yield higher than 1650 ng and a dye incorporation 
rate above 6 pmol/ μg were considered for hybridization. Cy3- / Cy5-labeled cRNA samples 
(825 ng each) were mixed with a Blocking Solution (Agilent) and fragmented to ~100-200 bp 
at 65°C with Fragmentation Buffer and resuspended in Hybridization Buffer using a Gene 
Expression Hybridization Kit (Agilent). cRNA Samples (50 μl) were hybridized to Agilent 
Mouse Whole Genome 4 x 44k arrays for 17h at 65°C. Arrays were then washed using 
Agilent GE Wash Buffers 1 and 2 (Agilent) according to the manufacturer’s instructions 
(Two-Color Microarray-Based Gene Expression Analysis Manual, www.agilent.com). An 
Agilent Microarray Scanner was used to measure the arrays. Raw data were processed using 
the Agilent Scan Control and the Agilent Feature Extraction Software Version 10. Quality 
control measures were considered before performing the statistical analysis. These included 
inspection of the array hybridization pattern (absence of scratches, bubbles, areas of non 
hybridization), proper grid alignment, performance of the spike-in controls (linear dynamic 
range over 5 orders of magnitude) and number of non-uniformity outliers (below 100 for all 
samples). 
2.5.7. qRT-PCR 
B16F10 cells (~ 2.5 × 105) were seeded in T25 flasks and grown for 24 hours under standard 
conditions (see Cell Lines and Media section). Zn-DIGP to a final concentration of 5 µM (0.1 
% DMSO) in fresh media was then added and the cells grown under standard conditions for 8 
– 24 hours. Appropriate carrier controls (DMSO only) were also included. mRNA was 
extracted from the isolated cells using a High Pure mRNA Isolation Kit (Roche) according to 
the manufacturer’s protocol. Fluorescence spectroscopy was used to confirm the absence of 
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Zn-DIGP in the isolated mRNA. mRNA was quantified using a NanoDrop 1000 (Implen). 0.6 
µg of mRNA was used for cDNA synthesis in reactions containing 2.5 µl of 10 x buffer 
(Applied Biosystems), 5.5 µl of MgCl2, 1.25 µl of random hexamer primers, 5 µl of dNTP’s, 
0.5µl of RNase inhibitor, 0.625 µl of reverse transcriptase (Applied Biosystems) and the total 
volume adjusted to 25 µl with deionized water.  The reactions were then heated at 42 °C for 1 
hour and deactivated at 95°C for 10 minutes. 0.75 µl of cDNA was used in real time PCR 
with 7.5 µl of PCR master mix (Applied biosystems), 0.75 µl of each primer (CXCL10 and 
β-actin or SDHA) and 6 µl of RNase free water. Experiments were conducted in triplicate 
and Ct values were determined using software from the 7900HT Fast RT-PCR (Applied 
Biosystems). Ct values were then converted to relative RNA abundance using the 2
-∆∆t 
method.
[23]
 
2.5.8. DNase/RNase digestion 
15`000 SKMEL-28 cells were seeded in Labtec 8 chambered well plate in media containing 
10% FCS. After washing once with PBS, cells were fixed with pure methanol for 1 minute at 
room temperature. Methanol is gently removed and 100µl of Triton X is added and incubated 
exactly for 2 minutes. After 2 minutes, Triton X was removed and the cells are washed twice 
with PBS. 1:1000 dilution of Hoeschst 333342 and 30 nM of Zn-APc are added in 2 separate 
wells for 3 hours. Cells are then washed with PBS. 100 μl of DNAse solution (Sigma D4263) 
and RNase solution (Roche 1119915) and PBS control are added to the cells and allowed to 
incubate for 2 hours. Cells were washed several times and imaged using Leica wide field 
fluorescence microscope.   
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CHAPTER 3. Guanidino phthalocyanines as 
photosensitizers 
3.1. Introduction: Cancer and its treatment 
Cancer is a disease characterized by uncontrolled division of abnormal cells. The 
proliferation of abnormal cells can cause a cluster of neoplastic cells (benign tumor). The 
tumor is considered to be malignant only if it gains the ability to invade the surrounding 
tissue and reach the blood stream by metastasis. This process might take several years before 
its symptoms are apparent. There are currently number of therapies available for cancer 
treatment such as surgery, chemotherapy, radiotherapy, immunotherapy and their 
combination. The choice of therapy is based on the type and stage of cancer.
[1]
 
3.1.1. Surgery 
Surgery is the frequently used approach to remove solid tumors. Removal of entire tumor 
mass prior to metastasis can completely eradicate the cancer. However, even a single 
remaining cancer cell can lead to tumor recurrence. If the tumor is metastasized, complete 
removal through surgery is not possible. Side effects such as anesthesia complications, 
infections and immune suppression are associated with surgery. In some cases, the removal 
of primary tumor was reported to promote metastasis itself.
[2]
 
3.1.2. Radiotherapy 
Damaging the genetic material of cells by ionizing radiation inhibits cellular replication in an 
oxygen-dependent manner. Though normal and cancer cells are both killed by radiation 
therapy, the treatment is given in low doses so that the normal cells can recover and grow 
normally. As the radiation focused on a particular region, the treatment is localized. 
Disadvantages of radiation therapy include skin burns, nausea and vomiting.
[3]
 
3.1.3. Chemotherapy 
Chemotherapy is the application of toxic substances to destroy cancer cells. Unlike surgery 
and radiation therapy, chemotherapy is systemic. Depending on the type of drug, its mode of 
action can include cell cycle inhibition, kinase inhibition or binding to DNA. Side effects 
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such as pain, diarrhea, nausea, hair loss and vomiting are typical. Another drawback 
associated with chemotherapy is prolonged treatment causes drug resistance in cancer cells.
[4]
 
3.2. Photodynamic therapy  
3.2.2. Mechanism  
Photodynamic therapy (PDT) utilizes the interaction of light with photosensitizers. Upon 
illumination, the sensitizer absorbs a photon which causes a promotion of one electron from 
ground state to an excited state. By internal conversion, the electron falls to the lowest 
vibration level of the excited singlet state. By intersystem crossing, the excited singlet state 
can be converted to a triplet state. At this stage, the electron can relax to the ground state by 
radiative phosphorescence. In PDT, the long life time of the excited triplet state allows 
sufficient time for the photosensitizer to mediate chemical reactions. Two types of toxicity 
are observed. Type I process involve a photosensitizer that reacts with biomolecules to 
generate addition products. In a Type II process, molecular triplet oxygen is converted to 
singlet oxygen and/or other reactive oxygen species (ROS) such as 
.
OH and H2O2. These 
reactive oxygen species can exhibit anti-tumor effects by direct killing of the cell, vascular 
damage or activation of immune response.
[5]
 Though both type I and type II process can 
contribute to the generation of reactive oxygen species, it is generally believed that type II is 
the most important pathway, and that 
1
O2 is the most important ROS generated.
[6]
 (Figure 3.1 
& Figure 3.2) 
3.2.3. Singlet Oxygen 
Molecular oxygen is one of the most important substances on earth. The electronic 
configuration of molecular oxygen is 1s
2
 2s
2
 2p
4
 and the electronic properties of molecular 
oxygen are determined by 6 electrons in p-molecular orbitals. After filling the first four 
electrons in the bonding orbital of p shell, the remaining two electrons can be filled into the 
anti-bonding orbitals by three possible ways. In triplet state, electrons occupy two different 
anti-bonding orbitals and in singlet state, both the electrons occupy a single anti-bonding 
orbital with opposite spins. In its ground state, molecular oxygen exists in a triplet state. 
(Figure 3.3) 
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Figure 3.1. Jabaloniski diagram representing possible events of an excitation. S0 : Electronic 
ground state; S1 and S2 : Electronic excited  singlet state; T1 : Triplet state; VR : Vibrational 
relaxation; IC : internal conversion; ISC : Intersystem crossing. 
 
 
Figure 3.2. Possible mechanisms of photosensitizers in photodynamic therapy. 
Unlike triplet oxygen, singlet oxygen can undergo reactions such as ene-, 1,2- and 1,4- 
cycloaddition reactions. In cells, singlet oxygen is reported to target biological membranes. 
Components of the cell membrane such as phospholipids, proteins and cholesterol can be 
readily oxidized by 1O2.[7-9]  The products can then break down into free radicals and initiate 
chain oxidation of other lipids. In proteins, the amino acids tyrosine, tryptophan, histidine, 
methionine, and cysteine are susceptible to oxidation by singlet oxygen. In DNA, guanine 
residues can be oxidized by singlet oxygen to generate 8-oxo guanine which triggers strand 
cleavage.[10] 
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Figure 3.3. Possibilities of electron occupation in p orbital of oxygen. 
The efficiency by which photosensitizers generate singlet oxygen is determined by the 
quantum yield of singlet oxygen formation which is defined as  
Ф =
 The  number  of  singlet  oxygen  generated
The  number  of  photons  absorbed
 
3.2.4. Photosensitizers: 
By utilizing light energy, photosensitizers can convert triplet oxygen into singlet oxygen and 
to mediate type II toxicity. An ideal photosensitizer should meet the following requirements 
to be effective in PDT.
[11]
 
 Water solublity 
 Selective uptake in cancerous cells 
 Minimum dark toxicity and maximum toxicity in the presence of light 
 Non-mutagenic and non-carcinogenic 
 Excitation wavelengths in the far red or IR to minimize tissue absorption of light 
 High quantum yield and long-lived triplet state 
 Rapid excretion from the body 
The first attempt to utilize photodynamic effects for the treatment of human tumors was 
performed by Tappenier and Jesionek in 1903.
[5]
 Inspite of the reported positive effects, 
further research in PDT was not reported again until 1972 when Diamond and co-workers 
demonstrated that the haemotoporphyrin, upon activated by white light, caused regression of 
an experimental glioma in rats.
[12]
 Doherty and coworkers reported that fluorescein activated 
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by a 488 nm laser and hematoporphyrin activated by red light, resulted in tumor reduction in 
mice.
[13]
 In 1974, Tomson reported that acridine orange, when activated by an argon laser, 
caused destruction of a mouse epithelial tumor.
[14]
 In the following year, Kelly and coworkers 
demonstrated that specific destruction of heterotransplant of human bladder carcinoma in 
mice could be obtained by local exposure to white light following hematoporphyrin 
injection.
[15]
 In 1978, Doherty and his coworkers clearly demonstrated that hematoporphyrin 
derivatives activated by red light resulted in complete or partial response in mouse malignant 
lesions.
[16]
 Since then, a large number of studies have been reported on photodynamic 
therapy. Recent research on PDT has been focused on 3 families of photosensitizers. 
[11]
 
(i) Porphyrin family 
a. Hematoporphyrin derivative (HpD) 
b. Benzoporphyrin derivative (BPD) 
c. 5-aminolevilinic acid (ALA) 
d. Texaphyrins 
(ii)  Chlorophyll family  
a. Cholins 
b. Purpurins 
c. Bacteriocholins 
(iii)  Dyes  
a. Phthalocyanine 
b. Naphthalacyanine 
 
An iron-free derivative of heme, haematoporphyrin derivative (HpD) was one of the first 
commercially available and clinically-utilized photosensitizers. In 1978, Dougherty and 
coworkers reported successful results on HpD mediated PDT treatment for many tumor types 
in humans. In 1995, Food and Drug administration approved Photofrin in USA after which 
other countries like Canada, Netherlands, France and Italy approved. However, HpD and its 
derivatives have two important disadvantages. First, they cause severe side effects in skin 
after PDT treatment. Secondly, they are prepared as a complex mixture instead of a single 
active component. Overcoming this disadvantage, several „second generation 
photosensitizers‟ have been synthesized. 5-aminolaevelic acid is a prodrug which is 
converted enzymatically to protoporphyrin IX (Figure 3.4). Protoporphyrin IX has a longer 
excitation wavelength than photofrin, and it gives better tissue depth penetration of 
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photoexcitation. ALA (Levulan) was approved in 1999 for the treatment of cancerous lesions. 
In 2001, the methyl ester of ALA (Metvix) was approved for the treatment of basal cell 
carcinoma and actinic keratosis. However, it must be emphasized that ALA treatments can be 
painful since high light energy and/or longer treatment times are typically required. Foscan is 
another commercially available photosensitizer belonging to the Chlorin group. Though it 
requires much lower doses than photofrin, the healing time for the side effects remain high. 
Purlytin is another chlorin derivative that has excellent properties as a photosensitizer but is 
poorly soluble in water. Another derivative of chlorin in clinical trial is e6 that is 
characterized to be effective on cutaneous lesions. However, the lack of tissue selectivity 
makes it clinically less important than compounds that exhibit selective uptake.
[11]
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Figure 3.4. Structure of Foscan, e6 Chlorin and Protoporphyrin IX 
3.2.5. Phthalocyanines 
The interest in phthalocyanines for use in PDT started in 1985.
[17]
 The main advantages of 
phthalocyanines over other photosensitizers are the increased absorption of far-red light, and 
low cytotoxicity in the dark. The presence of diamagnetic metal-center increases the 
phototoxicity of phthalocyanines due to long-lived triplet states and the axial substituents on 
the metal and side groups on the phthalocyanines can have role in solubility. The cellular 
uptake of phthalocyanines depends on polarity, lipophilicity, central metal ion, axial ligand, 
serum levels, charge state and delivery vehicles.
[18]
 The accumulation of phthalocyanines 
appears to be continuous process inside the cell, as the intracellular Pc levels can remain 
constant after 3 days. Pc accumulates mainly in cytoplasm and lysozomes. Depending on the 
charge state of Pc, relocation was observed upon exposure to light. Among the many Pc‟s 
reported to date, several derivatives such as Zn-Pc and Al-Pc are currently in different phases 
of clinical trials.
[18]
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3.3. Aims 
According to the fluorescence imaging reported in the previous chapter, Zn-DIGP can cause 
changes in morphology of cells during live-cell imaging. To explore this further, we decided 
to evaluate the ability of Zn-DIGP to behave as photosensitizer, and to evaluate its light-
dependent toxicity. To evaluate a possible role of G-quadruplex tarrgeting in the 
phototoxicity of Zn-DIGP and its ability to photocleave plasmid containing G-quadruplex 
forming sequence was evaluated. 
3.4. Results and discussion 
Phthalocyanines containing different metal ions including Cadmium, Cobalt, Copper, Iron, 
Mercury, Nickel, Palladium, Phodium, Tin, Zinc were synthesized by Dr. Jawad Alzeer 
(Figure 3.5).  
3.4.1. Absorbance spectra of M-DIGP 
The absorbance spectra of various metal containing DIGP‟s (M-DIGP) are shown in Figure 
3.6. The strongest absorption band is the Q-band which originates from π-π* transitions. M-
DIGP exhibits a single Q-band over the range of 650-680 nm whereas DIGP shows split Q-
band in same range due to the loss of molecular symmetry (Figure 3.6).
[19, 20]
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containing various metal ions “M”, and the reference compounds zinc phthalocyanine (ZnPc) 
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Figure 3.6. Absorption spectra of different metal-containing and metal-free DIGP derivatives 
in DMSO. 
3.4.2. Fluorescence Quantum yield 
DIGP derivatives containing Zinc, Cobalt, Palladium and Copper exhibit excellent solubility 
and obey Beer‟s law in DMSO over a concentration range of 0.3 – 5 µM. We therefore 
measured the quantum yields of these compounds for photon emission in DMSO. The known 
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compounds zinc phthalocyanine “Zn-Pc” and zinc phthalocyanine tetrasulfonic acid “Zn-
PcTSA” were included as references (Figure 3.5). The quantum yield of Zn-DIGP for 
luminescence ( = 0.28) was more than 100-fold higher than the other metal-containing 
DIGPs (Table 3.1). The relatively high quantum yield of Zn-DIGP allows for its direct 
visualization inside cells using fluorescence microscopy. 
 
 
 
 
 
 
 
 
Table 3.1. Luminescence quantum yields of various phthalocyanines. 
3.4.3. Microscopy 
Upon addition of Zn-DIGP to live B16F10 cells, strong staining of perinuclear organelles and 
trafficking vesicles by Zn-DIGP was observed. (Figure 3.7).
[21]
 Upon irradiation with 20 
joules of far-red light (660 nm), Zn-DIGP-treated cells exhibited large morphological 
changes and the loss of cellular respiration. Interestingly, a redistribution of Zn-DIGP from 
the perinuclear organelles of living cells to the nuclei of dead and dying cells was observed 
following irradiation (Figure 3.7). 
 
Compound Φ for emission 
DIGP 0.26 
Zn-DIGP 0.28 
Cu-DIGP < 0.001 
Co-DIGP < 0.001 
Pd-DIGP 0.002 
Zn-Pc 0.34 
Zn-PcTSA 0.29 
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Figure 3.7. Cellular uptake of Zn-DIGP into living B16F10 cells before (A-C) and after (D-F) 
a 90 second exposure to red laser light at 660 nm. (A) & (D) Brightfield image. (B) & (E) Zn-
DIGP fluorescence (Ex = 620 nm, Em = 700 nm). (C) Composite image of (A) – B). (F) 
Composite image of (D) – (E). Scale bars represent 30 µm. 
3.4.4. Phototoxicity 
Changes in the morphology of Zn-DIGP-treated cells upon illumination suggested 
phototoxicity. To quantify the changes in respiration, standard “Alamar Blue” assays were 
conducted. B16F10 cells were incubated with variable concentrations of DIGP, Co-DIGP, 
Cu-DIGP, Pd-DIGP, Rh-DIGP, Fe-DIGP, Cd-DIGP, Hg-DIGP, Sn-DIGP or Ni-DIGP and 
illuminated with red laser light for 90 seconds. After 3 hours, resazurin was added and its 
conversion into resofurin was quantitated to determine EC50 values. As an appropriate 
control, 0.1% DMSO was serially diluted and added to the cells and subjected to 
illumination. As shown in Figure 3.8, light did not have any effect on the respiration of 
DMSO-treated cells. 
 
Cells treated with Pd-DIGP and Zn-DIGP, exhibited light-mediated toxicity at very low 
concentrations, whereas other M-DIGP derivatives did not exhibit phototoxicity. The EC50 
values of different M-DIGP derivatives are summarized in Table 4.1. Consistent with 
microscopy results, Zn-DIGP-treated cells exhibited potent phototoxicity with an EC50 of 0.1 
μM. This value is roughly 1000-fold lower than samples without light activation. Similarly, 
Pd-DIGP also exhibited 25-fold lower EC50 values upon photoexciation as compared to non-
irradiated samples (Figure 3.9). 
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Figure 3.8. Cellular respiration after illumination of DMSO-treated B16F10 cells. 
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Figure 3.9. Phototoxicity of M-DIGP in B16F10 cells. Blue line indicates the viability (% of 
total metabolic activity versus untreated cells) of cell cultures incubated with M-DIGP and 
kept in the dark (-hγ) as compared to M-DIGP-treated cells irradiated with 20 joules of 660 
nm light (+hγ) (red). 
Compound EC50 (+ hγ) 
(μM) 
EC50 (-hγ) 
(μM) 
DIGP 32 ± 6 25 ± 5 
Cd-DIGP 7.5 77 
Co-DIGP >80 >80 
Cu-DIGP >80 >80 
Fe-DIGP 1.5 9.8 
Hg-DIGP 31 15 
Ni-DIGP 2.3 4.5 
Pd-DIGP 3 ± 0.14 >80 
Rh-DIGP >80 >80 
Sn-DIGP >80 >80 
Zn-DIGP 0.15 ± .08 >80 
ZnPc.TSA 2.5 ± 0.5 >80 
Table 3.2. Summary of effective concentration (EC50) values of M-DIGP derivatives in 
B16F10 cells. Cells treated with various M-DIGP derivatives were kept in the dark (-hγ) as 
compared to M-DIGP-treated B16F10 cells that were irradiated with 20 joules of 660 nm 
light (+hγ). 
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3.4.5. Singlet oxygen quantum yield 
To evaluate why such large differences in phototoxicity were observed for the different 
metal-containing DIGP derivatives, the quantum yield of singlet oxygen was determined for 
each compound by monitoring the time-dependent photobleaching of 1,3-diphenyl 
isobenzofuran (DPBF).
[22]
 Consistent with the relative trends in phototoxicity of each 
compound, the quantum yields for singlet oxygen formation followed the same trend: Zn > 
Pd >> Cu / Co /H2 (Figure 3.10). Differences between the various metals can be explained by 
the magnetic properties of each metal cation.
[23, 24]
 The paramagnetic ions (copper, cobalt) do 
not generate singlet oxygen whereas diamagnetic metals (zinc and palladium) generate 
singlet oxygen and hence exhibit potent phototoxicity. Since all three of the Zn-containing 
phthalocyanines exhibited similar quantum yields for singlet oxygen formation (Φ  0.4 – 
0.6), the large differences in phototoxicity between Zn-DIGP (EC50 = 0.16 µM) and Zn-
PcTSA (EC50 = 2.5 µM) are likely related to the favorable accumulation of Zn-DIGP in 
living cells.     
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Figure 3.10. Photobleaching of DPBF absorbance in the presence of different metal 
containing DIGPs (2 μM) and irradiation at 660 nm. 
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Table 3.3. Singlet oxygen quantum yield for various phthalocyanines. 
3.4.6. Photocleavage studies 
Zn-DIGP generates singlet oxygen upon photoactivation and it binds to G-quadruplex DNA 
with high affinity and selectivity in vitro. (Chapter 2). Since guanosine can be oxidized by 
singlet oxygen and subsequently cleaved, we speculated that Zn-DIGP could cause G-
quadruplex specific photoocleavage. This property could, in theory, allow for site-specific 
DNA cleavage studies to be conducted in cells. To test this possibility, 1 μM of Zn-DIGP was 
mixed with pBR322 plasmid and illuminated with  630 nm laser light for variable periods of 
time.  Figure 3.11 demonstrates that irradiation converts the plasmid from supercoiled form 
to relaxed (nicked) form. This effect was dependent on the duration of illumination. 
Appropriate control samples lacking Zn-DIGP or without irradiation did not cause any 
conversion. 
To evaluate the possibility of G-quadruplex-specific photocleavage, we decided to 
incorporate a G-quadruplex sequence from the c-Myc promoter into plasmid DNA and 
evaluate the concentration at which Zn-DIGP causes photocleavage. For this experiment, we 
decided to use plasmid DNA that remains unaffected by S1 endonuclease. S1 endonuclease is 
a restriction enzyme that cleaves single-stranded DNA. In the supercoiled closed form, 
plasmid DNA has the possibility for the forming single-stranded DNA and assisted secondary 
structures that can be cleaved by S1 endonuclease.
[25]
 Zn-DIGP could bind to such regions 
and trigger photocleavage. In order to evaluate G-quadruplex-specific photocleavage, we 
decided to use a plasmid that does not possess an endogenous S1 nuclease site. 
Compound 
Φ for 
1
O2 
DIGP 0.06 ± .008 
Zn-DIGP 0.51 ± .05 
Cu-DIGP 0.03 ± 0.006 
Co-DIGP < 0.01 
Pd-DIGP 0.41 ± .02 
ZnPc 0.61 
ZnPc.TS 0.50 ± .04 
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Figure 3.11. Photocleavege of plasmid pBR322 by Zn-DIGP and 660 nm light according to 
gel electrophoresis based on duration of illumination separated by agarose gel 
electrophoresis. Lane 1: native Plasmid pBR322; Lane 2: pBR322 + 1 μM of Zn-DIGP; Lane 
3: pBR322 + 30 seconds of illumination with 630 nm; Lane 4: pBR322 +1 μM of Zn-DIGP + 
30 seconds of illumination with 630 nm; Lane 5: pBR322 + 1 μM of Zn-DIGP + 45 seconds 
of illumination with 630 nm; Lane 6: pBR322 + 1 μM of Zn-DIGP + 60 seconds of 
illumination with 630 nm; Lane 7: pBR322 + 1 μM of Zn-DIGP + 90 seconds of illumination 
with 630 nm. 
 
We screened the available plasmids including pUC18, pHen1 and pET15B for S1 nuclease 
sensitivity. Figure 3.12 demonstrates that the pHen1 plasmid was not affected by S1 nuclease 
(Lanes 3 and 4), whereas other plasmids underwent significant changes due to S1 nuclease. 
To test the ability of Zn-DIGP to photocleave the pHen1 plasmid (no insert), we added 1 μM 
of Zn-DIGP to pHen1 and tested for the photocleavage. Surprisingly, no conversion to nicked 
DNA was observed, whereas the plasmid pET15B was converted from supercoiled to nicked 
form (Figure 3.13). These results indicate that pHen1 could be a useful vector for conducting 
G-quadruplex-specific photocleavage reactions. Myc-1, a sequence derived from c-Myc 
oncogene that is well known to form a G-quadruplex even in the context of duplex DNA,
[26]
 
was chosen for incorporation in pHen1. 
 
 
 
 
Nicked Plasmid 
Supercoiled Plasmid 
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Figure 3.12. Agarose gel electrophoresis of S1 nuclease-treated plasmids. Lane 1: pUC18; 
Lane 2: pUC18 + S1 nuclease; Lane 3: pHen1; Lane 4: pHen1 + S1 nuclease; Lane 5: 
pET15B; Lane 6: pET15B + S1 nuclease. 
Due to the restriction sites present in the pHen1 plasmid, we decided to amplify Myc-1 with 
primers containing BamH1 and EcoR1 restriction sites using the polymerase chain reaction 
(PCR). The PCR product was then digested with BamH1 and EcoR1. Similarly, pHen1 
(vector) plasmid was digested using these restriction enzymes. The restricted pHen1 plasmid 
was separated using agarose gel electrophoresis (Figure 3.14) and the band representing 
linear DNA was gel extracted. The restricted plasmid and PCR amplified Myc-1 sequence 
were ligated using DNA ligase. The ligated DNA was transformed into E.coli DH5α and 
selected in ampicillin containing media. The cloning was confirmed by selecting colonies 
from the plate and subjecting them to colony PCR amplification with the same primers (Table 
3.4). Many colonies showed the band of interest (60 bp) in the gel. (circles in Figure 3.15)  
1       2      3      4      5      6      7      8 
 
Figure 3.13. Photocleavage of pET15B and pHen1 plasmid by 1 μM of Zn-DIGP. Lane 1: 
1kb ladder; Lane 2: pET 15b; Lane 3: pET15b + 1 µM Zn-DIGP + 90 seconds of 660 nm 
laser. Lane 4: pHen1; Lane 5: pHen1 +  1 µM Zn-DIGP; Lane 6: pHen1 + 90 seconds of 660 
nm laser; Lane 7: pHen1 + 1 µM Zn-DIGP + 90 seconds of 660 nm light; Lane 8 :  BamH1 
restricted pHen1. 
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Name Sequence (5`-3`) 
Forward Primer AATTGGATCCGGGAGGGGCG 
Reverse Primer ATATGAATTCCTGAGTTCTCCTCC 
Myc-1 
GGGAGGGGCGCTTATGGGGAGGG 
TGGGGAGG 
GTGGGGAAGGTGGGGAGGAGACTCAG 
 
Table 3.4. Primers used to amplify G-quadruplex forming sequence “Myc-1” from c-Myc 
template.  
1          2           3         4 
 
Figure 3.14. Single digestion and double digestion of pHen1 plasmid using BamH1 and 
BamH1/EcoR1 analyzed by agarose gel electrophoresis. Lane 1: 1kb ladder; Lane 2 : native 
pHen1; lane 3 : BamH1 digested pHen1; Lane 4 : pHen1 digested with EcoR1 and BamH1. 
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Figure 3.15. Colony PCR of pHen1 transformed E.coli cells separated by a 2% agarose gel. 
Circled bands indicate the clones selected for further studies (Clones A, D, E, F) Lane 1: 1 kb 
ladder; Lane 2-12: Clones A-K; Lane 13: Negative control; Lane 14: PCR on native pHen1. 
Four colonies were selected and the cloning was confirmed by PCR (Figure 3.16). Clones A 
and E (Lanes 2 and 4 in Figure 3.15) were chosen to study further. As shown in Figure 3.17, 
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double digestion of clones A and E contained a 60 bp fragment which was not present in 
native plasmid. Sequencing the samples resulted in the presence of Myc-1 sequence in clone 
A and E. These results suggest that the c-Myc G-quadruplex forming sequence ”Myc-1” was 
incorporated into the pHen1 plasmid. 
1     2     3      4     5      6     7 
 
Figure 3.16. PCR of pHen1_clone A-D plasmids. Lane 1: 1kb ladder; Lane 2-5: PCR on 
clone A, D, E, F; Lane 6: PCR on native phen1; Lane 7: negative control. 
1    2      3     4     5    6      7 
 
Figure 3.17. Restriction digestion of phen1_cloneA plasmid. Lane 1: 1kb ladder; Lane 2: 
Native pHen1; Lane 3: pHen1_cloneA; Lane 4: pHen1_cloneE; lane 5: Double digestion – 
EcoR1 and BamH1 on Native pHen1; Lane 6: Double digestion – EcoR1 and BamH1 on 
pHen1_A; Lane 7: Double digestion – EcoR1 and BamH1 on pHen1_cloneE. 
 
In order to test for Zn-DIGP-mediated photocleavage, both pHen1 and pHen1_clone A were 
subjected to varying concentrations of Zn-DIGP and illuminated for 90 seconds of 660 nm 
light. In both cases (Figure 3.18; Figure 3.19), concentration-dependent conversion of 
supercoiled form to nicked form was observed. However, we anticipated selective cleavage 
of the c-Myc containing pHen1 (Phen1_cloneA). Unfortunately, the concentration at which 
Zn-DIGP caused photocleavage were similar for both pHen1 and pHen1_Clone A. Therefore, 
no G-quadruplex-specific photocleavage could be confirmed. Strangely, in the lanes of 
plasmid irradiated with 10 μM of Zn-DIGP, no plasmid was seen. A possible reason for this 
could be complete destruction of the plasmid due to the presence of high concentration of Zn-
DIGP.  
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Figure 3.18. Photocleavage of pHen1 plasmid treated various concentration of Zn-DIGP and 
illuminated with light of 660 nm for 90 seconds. Bands were resolved using agarose gel 
electrophoresis. Lane 1: Native pHen1; Lane 2: pHen1 + 10 µM Zn-DIGP + irradiation; Lane 
3: pHen1 + 5 µM Zn-DIGP + irradiation; Lane 4: pHen1 + 2 µM Zn-DIGP + 90 seconds + 
irradiation; Lane 5: pHen1 + 1 µM Zn-DIGP + irradiation; Lane 6: pHen1 + 0.5 µM Zn-
DIGP + irradiation; Lane 7: pHen1 + 0.25 µM Zn-DIGP + 90 seconds light; Lane 8: pHen1 + 
0.125 µM Zn-DIGP + irradiation. 
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Figure 3.19. Photocleavage of pHen1_cloneA plasmid treated various concentration of Zn-
DIGP and illuminated with light of 660 nm for 90 seconds. Bands were resolved using 
agarose gel electrophoresis. Lane 1: Native pHen1; Lane 2: pHen1 + 10 µM Zn-DIGP + 
irradiation; Lane 3: pHen1 + 5 µM Zn-DIGP + irradiation; Lane 4: pHen1 + 2 µM Zn-DIGP 
+ 90 seconds + irradiation; Lane 5: pHen1 + 1 µM Zn-DIGP + irradiation; Lane 6: pHen1 + 
0.5 µM Zn-DIGP + irradiation; Lane 7: pHen1 + 0.25 µM Zn-DIGP + 90 seconds light; Lane 
8 : pHen1 + 0.125 µM Zn-DIGP + irradiation. 
3.5. Conclusion 
Among the different M-DIGP derivatives tested, Zn-DIGP and Pd-DIGP exhibited high 
quantum yields for generating singlet oxygen and phototoxicity to treated cells when 
illuminated with red light. In addition, Zn-DIGP exhibited relocalization from perinuclear 
organelles to the nucleus upon irradiation. Though this molecule has high affinity for G-
quadruplex DNA in vitro, no G-quadruplex-specific photocleavage was observed in our c-
Myc plasmid construct. 
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3.6. Experimental Methods 
3.6.1. Cytotoxicity and Phototoxicity Studies 
B16F10 or SKMel28 cells (10‟000 cells) were seeded in 96 well plates and grown for 24 
hours prior to their incubation with variable concentrations of M-DIGP derivatives for 24 
hours. Individual wells were then photoexcited with a 250 mW diode laser (containing a 
beam spreader to diameter of 1 cm) at 660 nm for 90 seconds. After 3 hours of incubation in 
the dark at 37 ºC incubator, the cellular media were replaced with fresh media containing 86 
µM resazurin (Sigma). The fluorescence was measured after 2-4 hours using M5 
spectrophotometer with excitation at 560 nm, emission at 590 nm, and a 570 nm cutoff filter. 
All samples were compared to untreated cells to calculate the % decrease in respiration - 
from which EC50 values were calculated. 
3.6.2. Microscopy 
B16F10 cells (~15‟000) were seeded in Labtek 8 chambered plate (Nunc) in media 
containing 10% FCS. After overnight growth, media was replaced with fresh media 
containing 3 μM Zn-DIGP and incubated for 24 hours. Individual wells were then 
photoexcited with a 250 mW diode laser (containing a beam spreader to diameter = 1 cm) at 
660 nm for 90 seconds. Images of the unfixed cells were taken in Leica LX wide field 
microscope before irradiation and 3 hours following irradiation. 
3.6.3. Singlet oxygen quantum yield 
Quantum yields for singlet oxygen generation were determined from the time-dependent loss 
of 1,3-diphenylisobenzofuran (DPBF) (Sigma) according to published procedures.
[22]
 Briefly, 
DPBF (50 µM) and a photosensitizing agent were prepared in DMSO so that the optical 
density at 660 nm = 0.1. The decrease in DPBF absorbance was monitored at 417 nm as a 
function of irradiation time at 660 nm using a 250 mW diode laser (containing a beam 
spreader to diameter = 1 cm). All measurements were carried out in quartz cuvette at room 
temperature. Singlet oxygen quantum yield was calculated from the following:
[27]
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where Ф represents the quantum yield and m represents the slope of DPBF bleaching due to 
of sample (S) and reference (R) with irradiation time and A represents absorbance of sample 
(S) and reference (R) at 660 nm.
[28]
  Quantum yields were calculated with respect to ZnPc as 
a standard (Ф = 0.61).[28, 29] The absorbance of the samples at 660 nm (OD = 0.1) did not 
change over the course of the experiments.  
 
3.6.4. Photocleavage experiments 
Plasmid DNA (350-500 ng) was mixed with 1 μM of Zn-DIGP in TKE buffer and photo 
illuminated with 90 seconds with a 660nm laser (20 joules). Depending on the type of 
experiment, the concentration of Zn-DIGP and duration of illumination was varied. After 
photo illumination, the samples were loaded with DNA dye (Sigma) and separated on a 1.8% 
agarose gel. 
3.6.5. Agarose Gel electrophoresis 
1.2 g of agarose was dissolved in 60 ml of Tris-acetate EDTA (TAE) buffer (40mM Tris, 
1mM EDTA, pH: 8 adjusted with acetic acid) and heated in a microwave for 2 minutes. After 
mild cool down, ethidium bromide (final concentration: 0.5 μg/ml) was carefully added and 
poured on the gel cast and the combs were placed. Upon solidification, gel was transferred to 
tank filled with TAE buffer and the samples were loaded. An electric field was then applied 
(50 volt for 30 minutes) and the gel was imaged with a transilluminator. 
3.6.6. S1 nuclease treatment 
The components in the Table 3.5 were mixed and incubated for 30 minutes at 37 ºC. S1-
nuclease treated samples were added with 6X gel loading dye and separated with a 1.8% 
agarose gel. 
 
S.No Components Volume (μl) 
1 DNA (500 ng) 4.75 
2 S1 nuclease (50U) 0.5 
3 5X reaction buffer 4 
4 ddH2O 10.25 
Table 3.5. Components of S1 endonuclease digestion 
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3.6.7. Cloning 
Primer Sequence (5`-3`) 
Forward Primer AATTGGATCCGGGAGGGGCG 
Reverse Primer ATATGAATTCCTGAGTTCTCCTCC 
Table 3.6. Primers used for amplification 
The sequence of Myc-1 sequence (5‟-GGGAGGGGCGCTTATGGGGAGGGTGGGGAGG 
GTGGGGAAGGTGGGGAGGAGACTCAG-3‟) was ordered from Sigma. Primers 
containing the restriction site of BamH1 and EcoR1 were obtained from Microsynth. The 
mixture containing the components of PCR reaction was prepared as shown in Table 3.7. 
Components Volume (μl) 
Forward Primer (10 μM) 1 
Reverse primer (10 μM) 1 
10X buffer 5 
dNTPs (2.5 mM) 4 
Taq polymerase 0.5 
Template 0.5 
ddH2O 25 
Table 3.7. PCR components used for amplification of Myc. 
Samples were added and PCR was performed with the following program. 
 
Temperature 95 ºC 95 ºC 55 ºC 72 ºC 72 ºC 4 ºC 
Duration 5 mins 15 seconds 15 seconds 15 seconds 5 mins end 
 
 
Table 3.8. PCR program used for PCR amplification of Myc 
PCR samples were analyzed by gel electrophoresis (1.8% agarose gel). Appropriate negative 
controls without the template DNA were included. 
 
 
 
 
 
40 cycles 
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S.No Components Volume (μl) 
1 PCR of Myc (22.5 ng/μl) 18.5 
2 BamH1 1 
3 EcoR1 0.5 
4 2X tango buffer 5 
5 ddH2O - 
Table 3.9. Components of restriction digestion of the insert. 
 
S.No Components Volume (μl) 
1 pHen1 DNA (155 ng/μl) 5 
2 BamH1 1 
3 EcoR1 0.5 
4 2X tango buffer 4 
5 ddH2O 9.5 
Table 3.10. Components of restriction digestion of pHen1. 
Components were mixed in sterile vial and incubated for 1 hour at 37 ºC. Restricted samples 
were added with 6X gel loading dye and separated with a 1.8% agarose gel. Insert and vector 
DNA were extracted from the gel using a gel extraction kit. (Sigma) 
 
S.No Components Volume (μl) 
1 Insert (20 ng/μl) 3 
2 Vector (15 ng/μl) 2 
3 10X buffer 2 
4 DNA ligase 1 
5 ddH2O 12 
Table 3.11. Components of ligation. 
Ligation components were added according to Table 3.11. Samples were then left at room 
temperature for 1 hour. The samples were then added to 100 μl of competent cells and kept 
on ice for 10 minutes. Meanwhile, a heating block was set to 42 ºC. The vials were kept at 42 
ºC exactly for 45 seconds and transferred to ice. Fresh 1 ml of Luria Broth (LB) media was 
added and incubated at 37 ºC for 1 hour. The transformed cells were plated in LB media 
containing ampicillin. Plates were incubated at 37 ºC overnight. 
Transformed colonies were checked for the presence of plasmid by prescreening colonies by 
PCR. PCR mixtures according to the table 3.12 were prepared and each colony from the plate 
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was picked by a sterile tip and added to the vials. After PCR, the samples were analyzed on 
2% agarose gel. 
Components Volume (μl) 
Forward Primer (10 μM) 1 
Reverse primer (10 μM) 1 
10X buffer 5 
dNTPs (2.5 mM) 4 
Taq polymerase 0.5 
Template 0.5 
ddH2O 25 
Table 3.12. PCR components for performing colony PCR. 
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CHAPTER 4. Guanidino phthalocyanines as 
CXCR3 antagonists 
4.1. Introduction 
4.1.1. Chemokines 
Mammals have two types of fundamental immune functions, the “innate immune system” 
that consists of monocytes, granulocytes, macrophages, and natural killer cells, and “the 
adaptive immune system” that consists of T cells and B cells. The communication between 
these different cell types is largely mediated by chemokines and cytokines. 
 
Chemokines are small (8-10 kDa), extracellular proteins which act as signaling molecules 
between immune cells. They can be functionally classified into homeostatic chemokines and 
inflammatory chemokines. Homeostatic chemokines are constitutively expressed for 
maintaining tissue homeostasis, and perform variety of functions such as directing 
lymphocytes to lymphoid organs and immuno surveillance. In contrast, inflammatory 
chemokines are not constitutively expressed, but are induced upon external stimuli and 
recruit lymphocytes for triggering inflammation or wound healing. There are more than 40 
chemokine ligands and 19 receptors identified to date.[1-4]  
 
4.1.1.1. Structure and functions 
According to the presence of cysteine (C) residues at the N-terminus, chemokines can be 
classified into C, C-C, C-X-C, C-X3-C where X is any amino acid. C-X-C group of 
chemokines can be further classified according to the presence of a Glu-Leu-Arg (ELR) motif 
that can be angiogenic (ELR +), or angiostatic (ELR -) when absent. The cysteine residues 
are known to be important for mediating interactions with receptors.[2, 4] 
 
Chemokine receptors are G-protein coupled receptors that contain 7-transmembrane 
polypeptide chains. Upon binding to the receptor, the chemokine initiates a conformational 
change in the receptor and activates it. This leads to an exchange of GDP to GTP in the G 
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protein which eventually dissociates to G-α and G-βγ subunits. These dissociated G proteins 
perform variety of downstream signaling events depending on the receptor and ligand type. 
Broadly, several physiological processes such as cell differentiation, angiogenesis, 
angiostasis, migration, invasion, immune surveillance and lymphocyte trafficking are all 
controlled by these chemokine-ligand interactions.[2] 
4.1.2. CXCR3-CXCL10  
According to the results from microarray analysis and qRT-PCR, Zn-DIGP causes highly 
selective overexpression of CXCL10 in treated cells. CXCL10 is a chemokine that binds to 
the receptor CXCR3. Other CXCR3 ligands include CXCL9 and CXCL11. The dissociation 
constant for murine CXCR3 and the ligands CXCL9, CXCL10 and CXCL11 are 11.65 ± 0.9 
nM, 1.35 ± 0.56 nM, and 1.41 ± 0.2 nM respectively.[5] 
 
4.1.2.1 Structure 
The CXCL10 gene encodes for a 10 kDa interferon-gamma inducible chemokine with a 21 
amino acid signal peptide that gets cleaved during the downstream events. The N-terminus of 
CXCL10 has one intervening amino acid between two cysteines, so it is classified as a 
“CXC” chemokine. Moreover, CXCL10 lacks an ELR motif, suggesting that it is angiostatic. 
An independent NMR study demonstrated that CXCL10 has series of loops and one turn of a 
3-10 helix at its N-terminus, followed by three antiparallel β strands packed against C-
terminal α helix. Disulfide bridges are formed between cysteines 9-36 and 11-53.[6] Though 
the NMR study was performed using a mutated CXCL10 that is monomeric, X-ray 
diffraction studies of wild type CXCL10 suggest that CXCL10 exists as a dimer or 
tetramer.[7] 
 
CXCR3 is a seven transmembrane G-protein coupled receptor containing 316 amino acids. 
The structure of the CXCR3 receptor is not fully characterized but CXCR3 is known to be 
expressed in different forms in different target cells. The classical receptor CXCR3-A is 
expressed in type 1-helper (Th1) T cells, cytotoxic CD8+ T cells, activated B cells and 
natural killer cells. CXCR3-A is activated by CXCL9, CXCL10 and CXCL11. A spliced 
variant CXCR3-B contains a longer N-terminal extracellular domain that mediates its 
angiostatic effects. CXCL4 is reported to bind specifically to CXCR3-B, but not to CXCR3-
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A.[8] Recently, a third CXCL3 variant having a truncated C-terminus that gives only 5 or 6 
transmembrane passes was reported to be selectively activated by CXCL11.[9] 
 
4.1.2.2. CXCR3-CXCL10 interaction 
The receptor binding and activation of CXCR3 occurs in two steps. In the first step, CXCL10 
binds to the N-terminus of the receptor and in the second step, the N-terminus of CXCL10 
binds to a second site of the receptor causing activation. Step 1 is mediated by a docking 
domain located between the first pair of conserved cysteines and the first β strand responsible 
for recognition. The amino acids responsible for docking include 20s loop (Arg 20, Arg 22), 
β1 strand (Ile 24) and the 40s loop (Lys 46 and Lys 47). Step 2 is mediated by a triggering 
domain which is the unstructured N-terminus (Arg 5, Arg 8) of CXCL10. Oligomerization of 
CXCL10 was found to be necessary for biological functions of CXCL10.[6, 7] Apart from 
CXCR3, CXCL10 is reported to bind to glycosoaminoglycans like heparin sulphate,[7] 
another possible target of Zn-DIGP.[10] 
 
Figure 4.1. Computer-generated model of CXCR3 (A) and NMR structure of CXCL10 (B). 
Blue and red colors represent cationic and anionic residues. 
4.1.2.3.  Downstream signaling 
Downstream signaling events of CXCR3 activation were studied in pericytes.[11] The binding 
of ligands to CXCR3 resulted in the activation of the Ras/ERK cascade by triggering 
components such as Ras, Raf-1 and MEK. The addition of CXCL10 caused increased 
phosphoinosital 3 kinase (PI3K) activity which further activates Akt kinase and PDK-1. 
Activation of CXCR3 also caused activation of Src kinases. Moreover, cross-talk between 
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ERK, Src and PI3K was observed since Src was reported to activate the ERK cascade. 
Combining the studies, Marra and coworkers proposed that activation of Src results in 
recruitment of Ras to trigger the ERK cascade. In parallel, activation of PI3K and Akt was 
also achieved, although the relation between this pathway and activation of Src remains 
unclear. These pathways mediate critical cellular functions such as cell proliferation, actin 
polymerization, cell invasion and migration.[11] 
 
 
Figure 4.2. CXCR3 activation pathway in pericytes leading to downstream signals such as 
chemo attraction, invasion, migration and proliferation.  
Following receptor activation, CXCR3 is degraded following its internalization. In T-
lymphocytes, CXCL11-mediated endocytosis was independent of the clatharin pathway or 
calveolae pathways. Cell surface replenishment of CXCR3 occurs by de novo synthesis and 
transport through the endoplasmic reticulum and Golgi.[12] Two distinct domains that 
contribute to CXCR3 internalization are its carboxy terminus and β-arrestin1 for CXCL9/10 
or a third intracellular loop for CXCL11.[13] 
4.1.2.4. Expression and Function 
CXCR3 is absent in naive T cells, but its expression is induced upon activation by dendritic 
cells. It remains highly expressed in type-1 helper (Th1)-type CD4+ T cells, effector CD8+ T 
cells, and innate-type T lymphocytes such as natural killer cells and monocytes. CXCL10 is 
secreted by activated T-lymphocytes, endothelial sites, monocytes, neutrophils and 
keritonocytes. The ligands CXCL9, CXCL10 and CXCL11 are thought to have similar 
functions in vivo. Among the differences in regulation, CXCL10 is induced by Interferon 
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(IFN) α/β/γ, whereas CXCL9 induction is restricted to IFN-γ. CXCL11 is induced by IFN-
γ/β.[14] 
 
The CXCL10 promoter contains a functional Interferon Stimulated Response Element (ISRE) 
and nuclear factor κβ1 binding site. Apart from signal induction by IFN- γ, CXCL10 is also 
induced by Toll-like receptors and RNA helices including RIG-1 and MID5 through 
activation of IFN-regulatory factor 3 and the release of IFN-α. Autocrine signaling between 
IFN-α and STAT1 activates the CXCL10 gene. CXCL10 is also reported to be induced by 
hypoxia reperfusion injury by NF-κβ activation.[14] 
 
The major functions associated with CXCL10-CXCR3 interactions are chemoattraction of 
immune cells to target sites, and mediation of angiostatic activities. During inflammation, 
IFN-γ produced by leukocytes induces the production of CXCR3 ligands in stromal cells, 
immune cells, and transformed tumor cells. In response, ligands recruit activated T-
lymphocytes that express CXCR3 through paracrine signaling and localize it to the target site. 
The chemokines also bind to CXCR3-B in endothelial cells and activate a p38 pathway that 
mediates angiostatic activities.[15]  
4.1.3.  In cancer 
Kawada and coworkers demonstrated that CXCR3 promotes colon cancer metastasis to 
lymph nodes. They constructed cells expressing CXCR3 (‘DLD1CXCR3’) and compared 
them to non-expressing control cells in nude mice. Both cell lines reached lymph nodes after 
2 weeks but, DLD1CXCR3 cells generated colonies that expanded more rapidly than control 
cells.[16] In another study, CXCR3 was detected in a variety of breast cancer cells such as 
MDA-MD-231, MCF-7 and T47D.[17] CXCR3 silencing inhibited lung colonization and 
spontaneous lung metastasis, but had no effect on locally growing tumors. These anti-
metastatic activities were compromised in natural killer (NK)-deficient cells, implying an 
importance of NK cells in inhibiting metastasis.[18] Clinical diagnoses suggested that >85% of 
cancer patients show moderate CXCR3 staining in breast cancer, and a significant correlation 
between CXCR3 expression and poor survival rate was observed. In lymphoma, CXCR3 was 
reported to be expressed in only certain subsets of lymphomas, in contrast to CXCR5 which 
is expressed by all types of B-cell lymphomas. Hence, Jones and coworkers proposed that 
CXCR3 could be a marker for B-cell chronic lymphocytic leukemia.[19] 
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The chemokine CXCL10 is reported to be involved in both tumor progression and inhibition. 
High levels of endogeneous CXCL10 expression were reported in Hodgkins lymphoma and 
nasopharyngeal carcinoma,[20] as well as breast cancer cell lines,[17] and renal carcinoma cell 
lines.[21] Moreover, CXCL10 promotes growth of thyroid cancer cells,[22] and invasion in 
colorectal cancer cells.[23] In colorectal cancer cells, Raitman and coworkers demonstrated 
that CXCL10 causes overexpression of matrix metallo proteinase 9 (MMP9) and induces cell 
migration.[23] Conversely, CXCL10 is also reported to inhibit cell proliferation of 
neuroblastoma,[24] and prostate cancer cell lines.[25] In hepatocellular carcinoma patients, a 
correlation between infiltrating lymphocytes and CXCL10 overexpression was observed.[26] 
In renal cell carcinoma, CXCL10 overexpression facilitated the inhibition of tumor 
regeneration.[27] Wendel and coworkers demonstrated that exogenous application of CXCL10 
to lymphoma increases NK cell accumulation and prolonged survival. Their results further 
indicated that CXCL10 expression has an important role for NK infiltration into tumors.[28] 
According to the angiostatic mechanism, Sdgari and coworkers showed that CXCL10 
overexpression in human lymphoma causes spontaneous tumor regression in immune-
compromised nude mice.[29]  
 
4.1.3.1. Role of CXCL10 and CXCR3 in melanoma 
Metastatic melanoma cells such as B16F10, B16F1, BLM and SK-Mel-28 were all reported 
to express CXCR3.[30, 31] Silencing of the CXCR3 gene in B16F10 cells resulted in reduced 
migration and invasion upon addition of CXCL9 or CXCL10. CXCR3-deficient B16F10 cells 
injected into a lymph node metastatic mouse model C57BL/6 demonstrated reduced lymph 
node metastasis as compared to wildtype B16F10 cells. Similarly, when CXCL9 and 
CXCL10 were injected with adjuvant into lymph nodes, wild type B16F10 cells caused larger 
metastatic colonies to form.[30] In another study, using the BLM melanoma cell line,  it was 
shown that CXCL9 activates the small GTPases RhoA and Rac1, inducing the reorganization 
of actin cytoskeleton to trigger cell chemotaxis.[31] In patients having cutaneous malignant 
melanoma, a positive correlation between CXCR3 expression with tumor thickness and 
progression was reported.[32] 
 
The chemokine CXCL10 has an inhibitory role in melanoma metastasis. When CXCL10 was 
genetically expressed in tumor cells, no significant impact in proliferation was observed but 
host-mediated anti-tumor effects were observed in vivo. The response was reported to be T 
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cell-dependent, and mediated by lymphocytes, neutrophils and monocytes.[33] When B16F1 
cells were transfected with an adenovirus vector expressing CXCL10, reduced melanoma 
invasion in vitro and reduced melanoma metastasis in vivo were observed. Furthermore, 
screening for 30 different chemokines in patients revealed that CXCL10 was overexpressed 
among patients in remission than progression. These results clearly demonstrated that 
increase in CXCL10 levels serve to reduce melanoma metastasis.[34] 
 
Results from our microarray analyses and qRT-PCR demonstrate that addition of Zn-DIGP to 
B16F10 cells causes increase in CXCL10 mRNA (Figure 2.21 and Figure 2.22). Enzyme 
linked immunosorbent assays (ELISA) were used to quantify the changes in CXCL10 
expression at the protein level (Figure 4.3). Depending upon the Zn-DIGP concentration and 
incubation time, as much as 20-fold upregulation of CXCL10 was observed. 
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Figure 4.3. Changes in extracellular CXCL10 concentrations according to ELISA. A) Zn-
DIGP concentration-dependent changes after 24 hours of treatment. B) Time-dependent 
changes in CXCL10 concentrations in the presence of 5 μM of Zn-DIGP. 
 
The possible reasons for CXCL10 overexpression upon addition of Zn-DIGP is subjected to 
further investigation here. According to previous reports,[35] co-expression of TNF-α and 
IFN-γ cause transcriptional activation of CXCL10. Hence, we evaluated the ability of Zn-
DIGP to impact TNF-α and IFN-γ expression. As shown in Figure 4.4, Zn-DIGP did not 
induce expression of these secreted cytokines. We therefore speculated that CXCL10 
overexpression might be related to the ability of Zn-DIGP to inhibit the CXCL10/CXCR3 
binding interaction. 
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Figure 4.4. Changes in protein concentration (CXCL10, IFN-γ, TNF-α) according to ELISA 
upon addition of 5 μM of Zn-DIGP to B16F10 cells for 24 hours. 
4.1.4. CXCR3 antagonists 
CXCR3 activation is well known to promote cancer metastasis, and this has motivated the 
development of suitable antagonists for CXCR3. One of the most promising antagonists 
reported to date is AMG-487 (1) (Figure 4.5). AMG-487 competitively binds to CXCR3 and 
displaces CXCL10 and CXCL11 with an IC50 of 8 nM and 8.2 nM, respectively. CXCL10- 
and CXCL9-mediated cell migration was also inhibited by AMG-487. The pharmacokinetic 
parameters of AMG-487 suggested moderate clearance after intravenous dosing in dogs, and 
AMG-487 was found to be orally available. A sub-cutaneous dose of 3 mg/kg of AMG-487 
showed similar migration inhibition results as using CXCR3-deficient cell lines.[36] Organ-
specific inhibition of metastatic colon carcinoma was also observed.[37] AMG-487 inhibits 
lung metastasis in vivo. Studies involving mice deficient in NK cells indicated a reduced anti-
metastatic activity, suggesting the possible involvement of natural killer cells in mediating 
metastasis inhibition.[38]  Unfortunately, AMG-487 did not exhibit any efficacy in phase II 
clinical trials among patients with psoriasis and rheumatoid arthritis and hence the trial was 
terminated.[39] 
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Figure 4.5. Structure of AMG-487. 
Compounds containing a piperdinyl scaffold have also been reported to be CXCR3 inhibitors 
(Figure 4.6). A series of 1-aryl-3-piperdine-4-yl urea (2) were found to be good inhibitors, 
but they have high log D values, low solubility in water, and therefore poor pharmacokinetics 
properties.[40] Replacing the urea with thiodiazole,[41] the central piperidine unit to exo-
tropanyl[41] or the benzyl urea with 2-amino quinoline[42] resulted in molecules that gave 
better pharmocodynamics, good potency, good solubility and bioavailability. 
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Figure 4.6. Structure of piperdinyl urea analogs.  
High-throughput screening identified a new lead compound containing 4-aryl-[1,4] diazepene 
ethyl urea as a CXCR3 inhibitor (4) (Figure 4.7). One such compound inhibited CXCL10-
mediated calcium flux with an IC50 as low as 20 nM and  CXCL10-mediated migration with 
an IC50 of 100 nM.[43] 
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Figure 4.7. Structure of a 4-aryl-[1,4] diazapene ethyl urea. 
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High-throughput screening using membrane filtration binding experiments identified a 
benzimidazole (5, Figure 4.8) as a weak inhibitor (IC50 = 3 μM) of CXCR3. Modifying the 
aliphatic substituent at the C4 position improved its potency, and it inhibited CXCR3 with 
IC50 of 80 nM.[44] Further lead optimization resulted in discovery of a new compound (6) 
binding to CXCR3 in the low nM range (20-50 nM).[45] The main disadvantage associated 
with these molecules was metabolic instablility upon exposure to mouse liver microsomes.[45]  
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Figure 4.8. Structures of benzimidazole analogs. 
A series of 3-disubstituted piperidine-2,6-diones analog of benzamitide (7, Figure 4.9) were 
tested for their ability to inhibit CXCL11-mediated cAMP production in CXCR3-transfected 
Chinese hamster cells. Apart from binding to CXCR3, this experiment revealed that one 
enantiomer of the racemic mixture was capable of binding to a muscarinic receptor. 
Substitutions of 3-piperidine ring with carbonyl functions was found to increase selectivity 
over the muscarinic receptor.[46] 
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Figure 4.9. Structure of a 3-disubstituted piperidine-2,6-dione. 
Leurs and coworkers reported another scaffold containing a guanidinium group “IPAG” to be 
a CXCR3 antagonist (8, Figure 4.10). IPAG gave moderate CXCR3 affinity with pKi of 5.4 
in the 125I-CXCL10 displacement assays.[47] 
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Figure 4.10. Structure of IPAG. 
B16F10 cells are known to express both CXCL10 and CXCR3.[48] The high-affinity 
interaction between CXCL10 and CXCR3 (Kd ≈ 0.2 nM) is mediated by arginine, lysine and 
isoleucine residues of CXCL10 that bind to an acidic patch on CXCR3.[6, 7] Interestingly, all 
of the CXCR3 antagonists highlighted here contain at least one basic functional group. These 
compounds can therefore be classified as hydrophobic cations. As hydrophobic cations, the 
similar physicochemical properties of CXCL10 and Zn-DIGP suggested that Zn-DIGP could 
mimic CXCL10 to competitively bind CXCR3. Hence, the affinity of Zn-DIGP to CXCR3 
was investigated. 
4.2. Results and Discussion 
4.2.1. CXCR3 binding studies: Radiolabeled ligand displacement assays 
Competitive displacement experiments using membrane-immobilized CXCR3 receptors and 
125I-labeled CXCL10 were conducted. Human cells Chem 1 overexpressing CXCR3 were 
membrane purified and immobilized on to filter plate coated with polyethyleneimine. The 
addition of 125I-labeled CXCL10 to these preparations results in selective binding of the 
immobilized CXCR3. The addition of variable concentrations of unlabeled CXCL10 or Zn-
DIGP causes displacement of 125I-labeled CXCL10 depending from the membrane. This loss 
of 125I labeled CXCL10 can be monitored using a scintillation counter (Figure 4.11). By 
plotting the sigmoidal dose response curve, IC50 and Ki can be determined. Ki values are 
summarized in Table 4.1. 
 
 
Figure 4.11. Schematic of radiolabeled ligand displacement assays. 
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Figure 4.12. Binding studies of Zn-DIGP to CXCR3 with/without prior incubation with Zn-
DIGP according to radiolabeled ligand displacement assay. 
As a control, unlabeled CXCL10 was titrated and the apparent Ki (0.57 ± 0.02 nM) matched 
previous reports.[49] Using this assay, Zn-DIGP was found to displace 125I-labelled CXCL10 
with an apparent Ki of 29 ± 1 μM (Figure 4.12). To evaluate any possible effect of the order 
addition, Zn-DIGP was incubated prior to 125I-CXCL10 addition. The pre-incubation step did 
not affect the Ki values. Hence, Zn-DIGP can reversibly bind to the CXCR3 receptor (Figure 
4.12). 
 
Compound IC50 Ki 
CXCL10 0.86 nM 0.57 nM 
ZnDIGP 44 μM 29 μM 
CXCL10 : 60 minutes pre-incubation 0.26 nM 0.18 nM 
ZnDIGP : 60 minutes pre-incubation 37 μM 25 μM 
Table 4.1. Results of radiolabeled ligand displacement assays. 
4.2.2. Agonist assays 
To evaluate the functional impact of Zn-DIGP - CXCR3 binding, agonist assays were 
performed in Chem 1 cells that over express CXCR3 by monitoring changes in intra-cellular 
calcium levels. Activation of CXCR3 by CXCL10 causes increases in intra-cellular calcium 
levels that can be monitored by the fluorescence of a Ca2+-specific dye “fluo-8”. The addition 
of Zn-DIGP did not increase in calcium levels even at a concentration of 1 mM which is 
approximately 40 times higher than Ki of Zn-DIGP for displacement of CXCL10 from 
CXCR3 (Figure 4.13). These results suggest that Zn-DIGP does not activate CXCR3. 
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Figure 4.13. Activation of receptor by CXCL10 and Zn-DIGP in CXCR3 expressing Chem 1 
cell line according to intra-cellular calcium levels. 
4.2.3. Antagonist assays 
To test the ability of Zn-DIGP to inhibit CXCL10-mediated activation of CXCR3, Zn-DIGP 
was incubated with CXCR3 expressing Chem 1 cells for 15 minutes followed by the addition 
of 13 nM CXCL10 (EC50 from agonist assays). Reduced calcium levels were observed in Zn-
DIGP treated samples (Figure 4.14). The IC50 of Zn-DIGP for CXCL10-CXCR3 inhibition 
was 3.8 ± 0.6 µM. Notably, the IC50  is approximately the same concentration used for most 
of the experiments (mice studies, microarray, qRT-PCR) reported here. Results from the 
ligand displacement assays and the agonist assays demonstrate that Zn-DIGP binds to 
CXCR3 and inhibits receptor activation. 
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Figure 4.14. Inhibition of the receptor activation in the Zn-DIGP-treated Chem1 cells 
according to changes in intra-cellular calcium levels. 
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4.2.4. Receptor Internalization assays 
The IC50 for CXCR3 inhibition is almost 8-fold lower than the Ki value observed for 
CXCL10 displacement (29 ± 1 μM).  This apparent conundrum can be explained by cell 
surface dynamics and receptor turnover. It is important to note that ligand displacement 
assays were performed using CXCR3 embedded on membranes whereas the calcium flux 
assays were performed using live cells. Since CXCL10 binding is known to initiate 
internalization of CXCR3 [12, 38, 50], we speculated that Zn-DIGP binding might also cause 
receptor internalization, albeit without receptor activation. To test this possibility, B16F10 
cells were treated with Zn-DIGP or CXCL10, and CXCR3 was visualized by 
immunofluorescence. In both the cases, a dramatic loss of CXCR3 staining was observed 
after 1-2 h of incubation (Figure 4.15). The localization of CXCR3 was also distinctly 
different in treated and untreated cells, where CXCR3 was distributed over the cell surface of 
control samples, whereas CXCL10 and Zn-DIGP treated cells exhibited perinuclear CXCR3 
accumulation consistent with receptor turnover (Figure 4.15). The differences between Zn-
DIGP IC50 value for CXCR3 inhibition (3.5 μM) and its CXCR3 affinity ligand displacement 
(Ki = 29 μM) can therefore be attributed to the ability of Zn-DIGP to bind CXCR3 without 
activation of the receptor, yet causing endocytosis and degradation of CXCR3.  
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Figure 4.15. Confocal microscopy images of B16F10 cells stained for CXCR3 following the 
addition of Zn-DIGP (5 μM) or CXCL10 (20 nM). Green staining represents the CXCR3 
specific antibody and blue staining represent nucleus specific Hoechst 33258. (A) – (C) are 
images taken at t = 0 of incubation, (D) – (F) are images taken after 1 hour following the 
addition of CXCL10 and Zn-DIGP. G-I represents images taken after 2 hours of media, 
CXCL10 and Zn-DIGP addition. In all cases, cells were fixed prior to imaging. Scale bars 
represent 30 µm. 
4.2.5. Migration assays 
Upon CXCL10-mediated activation of CXCR3, the spike in intracellular calcium levels is 
known to trigger actin polymerization and increased cellular migration.[30, 38] We therefore 
investigated CXCL10-activated cellular motility using scratch assays (Figure 4.16).[51] As a 
selectivity control, the chemotactic cytokine CCL21, that binds to receptor CCR7 and 
Epidermal growth factor (EGF) were also evaluated.[52] The changes in migration indices 
indicate specific inhibition of CXCL10-mediated cellular migration by Zn-DIGP (Figure 
4.17). 
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Figure 4.16. Bright field images of scratches made in monolayers of B16F10 cells. (A) – (B) 
images taken immediately after addition of CXCL10 in untreated and Zn-DIGP treated cells. 
(C) - (D) are images taken after 24h. Scale bars represent 50 mm.  
 
Figure 4.17. Inhibition of CXCL10-induced migration by Zn-DIGP in B16F10 cells 
according to scratch assays. 
 
Results from these migration results are summarized in Figure 4.17. The use of Zn-DIGP did 
not cause large changes in migration in samples containing media only. Addition of 20 nM 
CXCL10 caused a large increase in cell migration that is inhibited by Zn-DIGP. The data can 
be expressed quantitatively by calculating the “migration effect” which is the ratio of 
migration indices for Zn-DIGP-treated samples divided by the respective controls. The 
smaller the migration effect ratio, the greater the influence of Zn-DIGP has on inhibiting 
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migration. As shown in Table 4.2., the migration effect ratio is smallest for CXCL10. Smaller 
effects were observed for CCL21, EGF, media containing 10% FCS. 
 
S.No Condition 
Migration Index 
Migration effect 
Control Zn-DIGP 
1 Starvation medium 1.7 1.4 0.83 
2 20 nM CXCL10 2.5 1.5 0.56 
3 10% FCS 2.4 1.75 0.71 
4 20 nM CCL21 2 1.5 0.76 
5 20 nM EGF 2 1.4 0.67 
Table 4.2. Summary of migration indices according to scratch assays. 
 
To further evaluate these effects, we varied the concentration of CXCL10 (Figure 4.18). As 
expected, as the concentration of CXCL10 increased, the migration index was also increased. 
Zn-DIGP-treated cells, however, were not sensitive to increasing concentrations of CXCL10. 
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Figure 4.18. Scratch assay results where migration index is defined as the ratio of the area of 
scratch at 0h to 24h.  
 
 
 
 
 
Chapter 4                                                                                                                                129 
 
 
 
 
 
 
 
 
Table 4.3. Summary of migration effects with increasing concentration of CXCL10 according 
to scratch assays. 
 
4.2.6. Invasion assays 
CXCL10-CXCR3 activation is reported to activate invasion. According to a matrigel-based 
invasion assay, cells treated with CXCL10 and Zn-DIGP showed approximately 2-fold 
decreases in invasion index as compared to cells treated only with CXCL10. In the case of 
CCL21- activated invasion, little, if any inhibition by Zn-DIGP was observed (Figure 4.19).  
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Figure 4.19. Results from Matrigel-based invasion assays using 20 nM of CXCL10 or CCL21 
as the chemoattractant. 
Condition 
Migration Index 
Migration effect 
Control Zn-DIGP 
Starvation medium 1.5 1.3 0.781 
2 nM CXCL10 2 1.45 0.72 
20 nM CXCL10 2.1 1.4 0.65 
50 nM CXCL10 2.6 1.8 0.67 
100 nM CXCL10 3.9 1.7 0.44 
20 nM CCL21 2.2 1.85 0.83 
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4.2.7. In vivo studies 
As CXCR3 antagonism and CXCL10 overexpression are both known to inhibit melanoma 
metastases in vivo, we decided to evaluate the anti-metastatic activities of Zn-DIGP using a 
well-known assay that mimics the hematogenous spread of malignant melanoma in vivo. In 
this assay, C57BL/6 mice were intravenously injected into the tail vein with B16F10 cells. 
After 20 days, the animals were sacrificed and the number of lung metastases determined by 
visual inspection.
[53, 54]
 Control animals receiving untreated cells or cells treated with the 
carrier-only (sodium trifluoroacetate in DMSO) contained 38 ± 8 (average ± standard 
deviation) lung metastases on day 20. When the B16F10 cells were pre-treated 5 M of Zn-
DIGP (Type A) in cell cultures for 16 hours prior to their injection, an almost complete 
inhibition of lung metastases was observed with only a single animal of six containing four 
small tumors on day 20. The other five animals were tumor-free (Figure 4.20). In a more 
stringent experimental design (type B), a solution of Zn-DIGP was injected into the animals 
directly at 8 mg / kg on day two, following the injection of untreated B16F10 cells into the 
same animals on day one. All animals treated this way reacted well to the injection, showed 
no signs of subsequent stress, and survived the duration of the experiment to day 20. In this 
experiment, the intravenous application of Zn-DIGP caused an approximate 50% reduction in 
the number and size of lung metastases on day 20. (Figure 4.20) 
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Figure 4.20. In vivo effects of Zn-DIGP (A) and DIGP (B) on melanoma tumor growth. 
Vertical bars represent the mean number and standard error of tumor colonies present in 
lungs on day 20. *** and ** represent p < 0.001 and p < 0.01 respectively. 
 
 
A) B) 
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4.3. Conclusion 
CXCL10 overexpression caused by Zn-DIGP in B16F10 appears to be independent of both 
G-quadruplex structures or overexpression of IFN-γ or TNF-α. Zn-DIGP competitively binds 
to CXCR3 with a Ki of 29 µM, a value approximately 7-fold higher than its IC50 value for 
CXCR3 - CXCL10 inhibition (IC50 = 4 μM). The differences between these values can be 
explained by the ability of Zn-DIGP to bind CXCR3 without activation of the receptor, yet 
causing endocytosis and degradation of CXCR3. There are few peptide antagonists known to 
cause internalization of GPCRs.[55, 56] However, to the best of our knowledge, this is the first 
example of a small molecule GPCR antagonist that has been shown to cause receptor 
internalization and degradation.[57] Zn-DIGP-mediated overexpression of CXCL10 and 
antagonism of CXCR3 adds indirect evidence for the presence of an endogenous feedback 
loop between CXCR3 and CXCL10 expression. 
 
Since CXCR3 antagonism is an attractive anti-cancer target, Zn-DIGP was evaluated for its 
anti-metastasis activity in vivo. Zn-DIGP was found to be well tolerated upon its intravenous 
injection into mice at 8 mg/kg and was capable of inhibiting the formation of tumor colonies 
in the lungs of C57BL/6 mice injected with B16F10 cells. This study opened up new avenues 
for phthalocyanine scaffolds as new antagonists for GPCR’s, in particular CXCR3. 
 
We have demonstrated that Zn-DIGP exhibits excellent properties as a PDT agent (Chapter 
3) as well as an ability to inhibit formation of tumor colonies in the lungs of C57BL/6 mice 
injected with B16F10 cells. To the best of our knowledge, Zn-DIGP provides the first 
example of a preclinical candidate possessing both of these properties. 
4.4. Experimental Methods 
4.4.1. ELISA 
B16F10 cells (~2.5 × 105) were seeded in T25 flasks and grown for 24 hours under standard 
conditions (see Cell Lines and Media section). Zn-DIGP to a final concentration of 5 µM (0.1 
% DMSO) in fresh media was then added and the cells grown under standard conditions for 8 
– 48 hours. Appropriate carrier controls (DMSO only) were also included. 5 ml of cell media 
was concentrated to 750 µl by a biological concentrator (Milipore UFC800324).  Murine 
IFN-γ and TNF-α was quantified by ELISA previously described.[53, 54] Briefly, 0.5 μg/ml of 
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IFN-γ or TNF-α capture antibody was coated on each well of 96 well Maxisorp plates (Nunc, 
Cophenagen, Denmark) and incubated overnight at room temperature. After washing with 
wash buffer (PBS containing 0.05% Tween 20), nonspecific binding was blocked by 1% 
BSA in PBS for 1 hour. Plates were again washed thrice after which control and Zn-DIGP 
treated samples were added. Standard samples were prepared by half log dilutions of 
recombinant IFN-γ and TNF-α (Peprotech). Plates were incubated for 2 hours and washed 
three times with wash buffer (PBS containing 0.05% Tween-20). 0.25μg/ml of murine IFN-γ 
and TNF-α specific antibody (polyclonal, developed from rabbit) was then added in diluent 
(PBS containing 0.1% BSA and 0.05% Tween-20) and incubated for 2 hours at room 
temperature and washed three times with wash buffer. Avidin-conjugated peroxidase was 
then added and incubated for 30 minutes. After washing the plated three times with wash 
buffer, 100μl of 2,2'-azino-bis(3-ethylbenzothiazoline-6-sulphonic acid) (Sigma) was added 
and the plates incubated for 5 minutes at room temperature for color development. The 
absorbance of each sample was read at 405 nm using Spectramax M5 spectrophotometer. 
4.4.2. [125I] CXCL10 displacement assays 
Zn-DIGP was dissolved in DMSO at a concentration of 100 mM and serial dilutions were 
conducted in DMSO. 60-fold dilutions were then made into an equilibrium binding buffer 
(water supplemented with 50 mM HEPES, 5 mM MgCl2, 1 mM CaCl2, 0.2% BSA at pH 7.4) 
to concentrations that were four-fold higher than the final assay concentration. CXCL10 and 
Zn-DIGP was mixed 1:1 (v/v) with [125I]-CXCL10 to a final concentration of 0.1 nM and 
added to CXCR3 membranes (Millipore) prepared in assay buffer at 1 unit/well. The assay 
plate was incubated at room temperature for 120 minutes. Prior to CXCL10 capture, the FC 
filter plate (Millipore) was pre-coated with 0.3% Polyethyleneimine (PEI) for one hour. 
Following capture, the FC filter plate was washed three times (50 mM HEPES, pH 7.4, 500 
mM NaCl, and 0.1% BSA). The filtration plate was allowed to dry and 50 μL per well of 
scintillation fluid was added and counted on a Perkin Elmer (Wallac) 1450 Microbeta TriLux 
liquid scintillation counter. Ki values were calculated based on the Cheng-Prusoff equation; 
Ki = IC50/[1 + ([L]/Kd), where IC50 is the half maximal inhibition concentration, [L] is the 
CXCL10 ligand concentration (0.1 nM), Kd is the measured equilibrium dissociation constant 
(0.2 nM) of the CXCL10 / CXCR3 binding interaction.  
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4.4.3. Ca2+ flux assays 
CXCR3 expressing Chem1 cells (~ 50,000) were seeded in 96 well plates and incubated at 
room temperature for 30 minutes before transferring to 37 ºC incubator for overnight 
incubation. GPCR Profiler Assay Buffer (Hanks Balanced Salt Solution containing 20 mM 
HEPES and 2.5 mM Probenecid; pH = 7.4) and loading buffer (Assay buffer + 5 mM Fluo-8 
dye) were prepared. Fresh cells were then washed once with GPCR profiler assay buffer and 
incubated with loading buffer for 1.5 hours. Meanwhile, Zn-DIGP was dissolved in DMSO at 
a concentration of 100 mM and serial dilutions were conducted in DMSO. 1000-fold 
dilutions were made into Millipore’s GPCR Profiler Assay Buffer to concentrations that were 
three-fold higher than the final assay concentration. Vehicle only and positive controls were 
prepared in the same way. Wells containing cells were prepared in Millipore’s GPCR Profiler 
Assay Buffer. The CXCR3 agonist assays were conducted using a FLIPRTETRA instrument 
where Zn-DIGP, vehicle controls, and reference agonist (CXCL10) were added to the assay 
plates containing Chem1 cells that overexpress CXCR3, and a fluorescence baseline was 
established in Millipore’s GPCR Profiler Assay Buffer. Upon completion of the agonist 
assay, the assay plate was removed from the FLIPRTETRA instrument and incubated at 25 °C 
for seven minutes.  
4.4.4. Antagonist Assay 
The antagonist assay was conducted using the same assay plate that was used for the agonist 
assay. The antagonist assay was also conducted on a FLIPRTETRA instrument for duration of 
180 seconds and was used to assess Zn-DIGP’s ability to inhibit CXCR3. Using EC50 of 
CXCL10 determined by the agonist assay, all pre-incubated Zn-DIGP wells were challenged 
with EC50 concentration of CXCL10 after establishment of a fluorescence baseline. All assay 
plate data were subjected to appropriate baseline corrections. Maximum fluorescence values 
were then exported and data processed to calculate percentage activation, percentage 
inhibition (relative to EC80 and vehicle control values), and additional statistical values (Z’, 
percentage variation between replicate data values) to assess the quality of each plate. All 
dose response curves were generated using GraphPad Prism. The curves were fit by utilizing 
“Sigmoidal Dose Response (Variable Slope)” equation where the bottom parameter was fixed 
to “0.” Where appropriate, the top parameter was fixed to “100” to better predict potency 
values when a curve was not fully generated by the concentrations assayed. 
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4.4.5. Receptor Internalization assays 
B16F10 cells (~ 70`000) were seeded in 24 well plates containing cover slips in 10% FCS 
containing media. After 4 hours, 10% FCS containing media was replaced with 0% FCS 
containing media. After overnight incubation, the used media was replaced with fresh 0% 
FCS containing media and left for 30 minutes. After 30 minutes, 0% FCS media containing 
20 nM of CXCL10 or 5 μM Zn-DIGP were added and incubated for 0 minutes, 1 hour or 2 
hours. Cells were then washed twice with 1 ml of PBS,  fixed with 3% PFA for 15 minutes 
and washed twice again with PBS. Cover slips were stained with CXCR3 primary antibody 
(1:400 dilution in PBS containing 0.1% BSA) (Abcam) and incubated at room temperature 
for 1 hour and washed twice with PBS. Fluoroscein labeled secondary antibody (Abcam) 
staining was performed with 1:500 dilution in PBS containing 0.1% BSA and incubated for 1 
hour at room temperature. In order to visualize the nucleus, a 1:1000 dilution of 10 mg/ml 
Hoechst 33258 in PBS was applied for 15 minutes at room temperature. Cells were then 
washed with PBS 5 times and subjected to imaging by SP2 confocal microscope. 
4.4.6. Migration assays 
B16F10 cells (~ 75000) were seeded in 24 well plates for approximately 4 hours. The media 
was then replaced with starvation medium (0% FCS) in the presence or absence of 5µM Zn-
DIGP and incubated overnight. Used media were then replaced by PBS and a scratch was 
made with sterile pipette tip and the detached cells were removed. Starvation media 
containing variable concentrations of CXCL10 or CXCL10 + 5 µM of Zn-DIGP was added 
to the cells. Bright field images with 4x objective were taken immediately after the scratch 
and after 24 hours of incubation. The area of scratch was calculated using Image J software. 
The migration index is defined as the ratio of the area of scratch made at time 0 h to the area 
of scratch at 24 hours. 
4.4.7. Invasion assays 
4 x 105 B16F10 cells were seeded in T25 flasks. Once the cells adhered, cells were replaced 
with 10% FCS media with presence or absence of 5 µM Zn-DIGP. After overnight 
incubation, 20,000 cells were taken in 0% FCS medium containing 0.1% BSA with or 
without Zn-DIGP in the upper compartment of invasion chamber. The lower compartment is 
filled with 20 nM CXCL10 or CCL21 and sometimes 5 µM Zn-DIGP. After 10 hours, cells 
in the upper compartment were removed using cotton swab. Cells that invaded through the 
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membrane remain attached on the other side of the membrane. Those cells were washed, 
fixed, stained with nucleus specific dye Hoechst and counted. 
4.4.8. Animal Studies 
C57BL/6 mice were bred in the animal facility of the Institute of Medical Virology, 
University of Zurich, and used at 6-8 weeks of age. All experiments were conducted 
according to the Guide for the Care and Use of Laboratory Animals. Zn-DIGP 
(trifluoroacetate salt) was diluted into DMSO at a concentration of 10 mM (15.5 mg/mL). 
Alternatively, as a control vehicle, 40 mM solutions of sodium trifluoroacetate were prepared 
in DMSO. Zn-DIGP and control vehicles were diluted 10-fold to make 1 mM and 4 mM 
solutions, respectively, in DMEM + 10% FCS and sterile filtered immediately prior to their 
application onto cells or injection into mice. In the first series of experiments (type A), 
B16F10 cell cultures were incubated with 5 µM of Zn-DIGP or 20 µM sodium 
trifluoroacetate under standard conditions described above for 16 hours. The cells were then 
trypsinized and washed twice with PBS and diluted to 2 x 105 cells in a total volume of 200 
µl. The formation of pulmonary metastases was established by intravenous injection of Zn-
DIGP-treated or control cells into the tail vein of C57BL/6 mice. Twenty days later, the 
animals were sacrificed and numbers of lung metastases were examined by visual inspection 
of lungs.[58] 
In a second series of experiments (type B), 2 x 105 cells of B16F10 cells, in 200 µl of PBS 
were injected into the tail vein of C57BL/6 mice. After one day of growth, the mice were 
then injected with 100 µL of 1 or 4 mM solutions of Zn-DIGP or sodium trifluoroacetate 
carrier (prepared in DMEM + 10% FCS as described above). Twenty days later the animals 
were sacrificed and numbers of metastases were examined by visual inspection of lungs.[8, 9] 
The results for untreated animals were the same as those receiving the carrier only. The 
results are shown as numbers of metastases in individual mice. Bars represent relative 
numbers of metastases +/- standard errors from two independent experiments. 
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